



San Francisco

Spring Group Meeting

APRIL 30 - MAY 2, 2026

Welcome to SWOG's Spring 2026 Meeting!

We're excited to welcome you to our first SWOG meeting as group chairs, and we're eager to engage with, and learn from, all of SWOG's members.

The one session we urge you, above all others, not to miss is Friday's plenary, "A Dialogue with Members" (2 – 4 pm PT, in-person and online). It's the platform we'll use to honor SWOG's outgoing leaders, introduce our incoming leadership slate, and outline our vision for how best to extend and build on SWOG's success in the coming years.

For the latter half of plenary, we'll shift to a town hall-style forum to discuss SWOG's future with SWOG's members. What would you like to see the group do that we're not doing? What should the group be doing more of? Bring your questions, your concerns, your ideas! Or email them to us ahead of time at meetings@swog.org.

A core theme of the meeting will be celebrating the legacy of Dr. Charles D. Blanke, SWOG group chair emeritus. As part of that celebration, we invite you to contribute to a book of member messages we can present to him as an informal – and we hope fun and meaningful – chronicle of his time and impact as SWOG chair.

Look for the book near the meeting registration table, and please take a moment to compose a message, recount a favorite memory, or just write a simple "thank you." You'll have another chance to sign at the group reception Friday evening, where – to help inspire you – we'll also have a display of memorable photos from Dr. Blanke's tenure. If you won't attend in person but would still like to add your message to the book, simply email it to meetings@swog.org.

We hope you have a productive, enjoyable meeting!



Dawn L. Hershman, MD, MS
SWOG Group Chair



Primo "Lucky" N. Lara, Jr., MD
SWOG Group Chair

Group Meeting Index

Chair's Welcome Message	2
Schedule of Events	4-6
Plenary Session	7
Top Accruals & Top Performing Sites	8-9
Meeting Supporters & Exhibitors	10
Funding & Career Development Opportunities	11
Take Action Symposium	12 & 32
Clinical Trials Partnership (CTP) Update Forum	13
Vice Chair's Council on Representation Lecture	14
Jeri & Noboru Oishi Symposium	15
Give to Support SWOG's Work	16
Frank & Linda Meyskens Annual Endowed Lectureship	17
Robert B. Livingston Translational Cancer Lecture	17
S2504 & S2506 Joint Kickoff	19-20
S2433 Kickoff	21
S2424CD Kickoff	22
Nicholas J. Vogelzang, MD, GU Symposium	23
SWOG Committees	25
Adolescent and Young Adult Committee	26
Advanced Practice Provider & Nurse Scientist Committee	27
Clinical Trials Training Course	28
Pharmaceutical Sciences & Drug Information Joint Meeting	29
SWOG Latin America Initiative Symposium	30
ORP Site Operations	31
Transplant & Cell Therapies Committee	33
VA Committee	34
Committee Agendas and Accrual Reports	
Barlogie-Salmon Myeloma Committee	35-38
Breast Committee	39-45
Cancer Control & Prevention Committee Leadership	46
Cancer Care Delivery Committee	47-48
Early Therapeutics & Rare Cancers Committee	59-62
Gastrointestinal Committee	63-72
Genitourinary Committee	73-85
Immunotherapeutics Committee	86-87
Leukemia Committee	88-94
Lung Committee	95-104
Lymphoma Committee	105-110
Melanoma Committee	111-113
Palliative Care Committee	49-50
Prevention, Screening, and Surveillance Committee	51-52
Radiation Oncology Committee	114
Symptom Management and Survivorship Committee	53-58
SWOG Publications	115-124
Future Meeting Dates	124

SWOG 2026 Spring Programs

Atrium Level | *Bay Level* | *Street Level* | *Pacific Concourse Level*

SPRING PROGRAM-AT-A-GLANCE

REGISTRATION & INFORMATION DESK: GRAND BALLROOM FOYER, STREET LEVEL

WEDNESDAY: 3:00 PM - 6:00 PM

THURSDAY-FRIDAY: 6:30 AM - 5:00 PM

SATURDAY: 6:30 AM - 12:00 PM

HOPE FOUNDATION INFORMATION DESK: GRAND BALLROOM FOYER, STREET LEVEL

THURSDAY-FRIDAY: 8:00 AM - 5:00 PM

SATURDAY: 8:00 AM - 11:00 AM



EXHIBITS

GRAND BALLROOM FOYER,
STREET LEVEL

THURSDAY-FRIDAY:
8:00 AM - 5:00 PM

◀ GO TO THE MEETING APP ONLINE
swog.org/meetingappS26

MEETING ROOM/LEVEL

WEDNESDAY, APRIL 29, 2026



4:00 PM–6:00 PM	Quality Initiative Meeting (Closed Business Meeting)	SEACLIFF C
4:30 PM–6:00 PM	Hope Foundation Board Meeting (Board Members Only)	PACIFIC D
6:00 PM–8:30 PM	NCORP Research Base Executive Committee (Committee Members Only)	PACIFIC JK

THURSDAY, APRIL 30, 2026

7:00 AM–7:20 AM	Clinical Trials Training Course Check In	GRAND BALLROOM FOYER
-----------------	--	----------------------

7:20 AM–12:00 PM	Clinical Trials Training Course	GRAND BALLROOM A
7:30 AM–8:30 AM	Vice Chair Council on Representation Lecture	PACIFIC HI
8:00 AM–10:00 AM	Palliative Care Committee	BAYVIEW ROOM
9:00 AM–11:00 AM	Early Therapeutics & Rare Cancers Committee	SEACLIFF AB
10:30 AM–12:30 PM	Cancer Care Delivery Committee	BAYVIEW ROOM
12:30 PM–2:00 PM	Site Operations	GARDEN ROOM
1:00 PM–2:00 PM	S2424CD Kick-Off Meeting	SEACLIFF AB
1:00 PM–3:00 PM	Leukemia Working Group (Working Group Members Only)	WATERFRONT AB
2:00 PM–3:30 PM	SWOG Tissue Banking Meeting (Closed Business Meeting)	PACIFIC JK
2:00 PM–4:00 PM	Sarcoma Working Group of the Early Therapeutics Committee	PACIFIC F
2:00 PM–4:00 PM	Symptom Management & Survivorship Committee	BAYVIEW ROOM
2:00 PM–5:00 PM	CRA Clinical Trials Training Course Practicum	GRAND BALLROOM B
2:30 PM–4:00 PM	Professional Review Committee (Closed Business Meeting)	PACIFIC D
2:30 PM–4:30 PM	Take Action Symposium	GRAND BALLROOM A
3:00 PM–4:30 PM	Transplant & Cell Therapies Committee	GARDEN ROOM
3:00 PM–5:00 PM	Radiation Oncology Committee	SEACLIFF AB
4:30 PM–6:00 PM	VA Committee	PACIFIC HI
4:30 PM–6:30 PM	Prevention, Screening, & Surveillance Committee	BAYVIEW ROOM

SWOG 2026 Spring Programs

Atrium Level | *Bay Level* | *Street Level* | *Pacific Concourse Level*

5:00 PM–6:00 PM	Conflict Management Committee (Closed Business Meeting)	PACIFIC F	8:00 AM–11:30 AM	Breast Committee & TM Working Group (Working Group Members Only)	SEACLIFF AB
5:15 PM–7:15 PM	Leukemia Committee	GARDEN ROOM	8:30 AM–10:30 AM	Immunotherapeutics Committee	SEACLIFF CD
5:30 PM–6:30 PM	Clinical Trials Partnerships Update Forum	GRAND BALLROOM A	8:45 AM–9:45 AM	Lung-MAP Administrative Meeting (Committee Members Only)	PACIFIC JK
6:00 PM–7:30 PM	Early Therapeutics & Rare Cancers Committee Working Group Dinner Retreat (Invitation Only)	PACIFIC D	8:45 AM–12:15 PM	GI Committee & TM Working Group (Working Group Members Only)	GARDEN ROOM
7:00 PM–9:00 PM	Breast Committee Social (Invitation Only)	UPPER ATRIUM	9:00 AM–11:00 AM	Myeloma Working Group (Committee Members Only)	WATERFRONT AB
FRIDAY, MAY 1, 2026					
7:00 AM–8:00 AM	NCORP/MU-NCORP Site PI Meeting	GARDEN ROOM	9:00 AM–11:00 AM	Pharmaceutical Sciences Committee & Drug Information Subcommittee	PACIFIC D
7:00 AM–8:00 AM	Clinical Trials Partnerships Scientific Advisory Board (Closed Business Meeting)	PACIFIC G	11:00 AM–12:30 PM	ORP Open Forum	PACIFIC L-0
7:00 AM–8:30 AM	Imaging Committee (Committee Members Only)	PACIFIC D	11:30 AM–1:30 PM	Lung Working Group (Working Group Members Only)	SEACLIFF CD
7:00 AM–8:30 AM	Lung-MAP Site Coordinators Meeting (Committee Members Only)	PACIFIC JK	11:30 AM–1:30 PM	Advanced Practice Providers & Nurse Scientists Committee	WATERFRONT AB
7:00 AM–11:00 AM	GU Working Group (Committee Members Only)	GRAND BALLROOM BC	11:30 AM–1:30 PM	Advocates Committee (Committee Members Only)	PACIFIC JK
7:30 AM–8:00 AM	Jeri & Noboru Oishi Symposium Check-In	BAYVIEW A FOYER	11:45 AM–1:45 PM	Surgery Committee	PACIFIC HI
7:30 AM–10:30 AM	SWOG Data & Safety Monitoring Committee (Closed Business Mtng)	PACIFIC F	12:00 PM–1:30 PM	SWOG Latin America Initiative Symposium	BAYVIEW ROOM
8:00 AM–10:30 AM	Jeri & Noboru Oishi Symposium	BAYVIEW ROOM	12:30 PM–1:30 PM	S2504/S2506 Joint Kick-Off Meeting	SEACLIFF AB
			12:45 PM–1:45 PM	S2433 Kick-Off Meeting	GARDEN ROOM
			1:00 PM–2:00 PM	Plenary Reception (Light Hors D'oeuvres)	GRAND BALLROOM FOYER
			2:00 PM–4:00 PM	Plenary Session	GRAND BALLROOM
			4:15 PM–5:15 PM	Lung Community Engagement Subcommittee (Committee Members Only)	PACIFIC D

SWOG 2026 Spring Programs

Atrium Level | *Bay Level* | *Street Level* | *Pacific Concourse Level*

SPRING PROGRAM-AT-A-GLANCE

4:15 PM–5:45 PM	Adolescent & Young Adult (AYA) Committee	WATERFRONT AB	8:00 AM–10:00 AM	Mentoring APPs (Invitation Only)	PACIFIC D
4:15 PM–6:15 PM	Nicholas J. Vogelzang, MD GU Symposium	BAYVIEW ROOM	9:00 AM–10:30 AM	Quality Assurance Committee (Committee Members Only)	PACIFIC F
4:15 PM–6:15 PM	Lung Radiation/Surgery Subcommittee (Committee Members Only)	PACIFIC JK	9:15 AM–11:15 AM	GU Committee	GRAND BALLROOM A
4:30 PM–6:30 PM	GI Committee	GARDEN ROOM	9:15 AM–11:15 AM	Melanoma Working Group (Working Group Members Only)	PACIFIC HI
4:30 PM–6:30 PM	Barlogie-Salmon Myeloma Committee	PACIFIC HI	9:30 AM–11:30 AM	Lymphoma Working Group (Working Group Members Only)	PACIFIC JK
4:30 PM–6:30 PM	Breast Committee	SEACLIFF B-D	9:30 AM–12:30 PM	Lung Committee	GARDEN ROOM
6:45 PM–8:30 PM	Group Reception	ATRIUM	11:30 AM–1:30 PM	Melanoma Committee	GRAND BALLROOM B
SATURDAY, MAY 2, 2026					
7:00 AM–7:45 AM	Board of Governors (Board Members Only)	GRAND BALLROOM B	11:45 AM–1:45 PM	Lymphoma Committee	GRAND BALLROOM A
8:00 AM–9:00 AM	Committee Chairs (Committee Chairs Only)	GRAND BALLROOM B	1:00 PM–4:00 PM	Vice-Chair Council on Representation Executive Retreat (Invitation Only)	WATERFRONT A

MAKE A WILL, MAKE A WAY

The Hope Foundation has a partnership with FreeWill, an easy online resource that more than 100 Hope supporters in 12 different states have used to create their wills and leave a gift to Hope. You can make a will in as little as 20 minutes, at no cost, and get peace of mind for the future.

Visit *The Hope Foundation* table near registration to learn more

SCAN THE QR CODE BELOW TO CREATE A LEGACY WITH THE CAUSES YOU CARE ABOUT MOST.

THE HOPE
FOUNDATION
FOR CANCER RESEARCH

FREEWILL 



SWOG Spring 2026 Plenary: A Dialogue with Members

FRIDAY, MAY 1 • 2 – 4 PM PT • GRAND BALLROOM (STREET LEVEL) & ONLINE

This group meeting is the first under the leadership of
SWOG's new group chairs
Dr. Dawn L. Hershman and **Dr. Primo "Lucky" N. Lara, Jr.**



At the plenary session, Drs. Hershman and Lara will review the group's extraordinary accomplishments and impact over recent years, will recognize and honor the leaders who helped pilot those achievements, and will welcome new leadership.



**Michael
LeBlanc, PhD**
SWOG Group
Statistician



We will also
hear from



James M. Rae, PhD
Vice Chair,
Translational
Medicine &
Biobanking

The Chairs will outline their vision for the next era of SWOG success.
Central to that vision is **you**, SWOG's members.

So the second half of the spring plenary will be
an interactive town hall-style forum
... a dialogue on the future of your cooperative group.

***Bring your questions for the new leadership. Bring your concerns and ideas.
The chairs want to hear from you and speak to you, SWOG's members.***

THANKS TO

Our Top Accruers

Patient volunteers power our trials —
and SWOG members connect us to them.

SWOG-Credited Registrations to SWOG-Managed Trials July 1 through December 31, 2025



- University of Texas
MD Anderson Cancer Center LAPS
- Northwestern University LAPS
 - Yale University -
Yale Cancer Center LAPS
 - City of Hope
Comprehensive Cancer Center
- STCC at DHR Health Institute for
Research and Development
 - University of Oklahoma
Health Sciences Center LAPS
- University of Rochester LAPS



- Southeast Clinical Oncology
Research Consortium NCORP
- Heartland Cancer Research NCORP
- University of Kansas Cancer Center -
MCA Rural MU NCORP
- Michigan Cancer Research Consortium
NCORP
- Cancer Research of Wisconsin and
Northern Michigan Consortium



THANKS TO

Our Top Performing Sites

To help our data management sites track their performance relative to that of others, we have developed a metric based on the quality and timeliness of data and biospecimen submissions. Data management institutions with at least 10 SWOG accruals in the prior 13 months are scored on this scale.

Sites in the Excellent category who have 10 or more registrations in the previous 13 months as of 1/1/2026 are:



Rhode Island Hospital

Sutter Cancer Research Consortium

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center

Instituto Nacional de Enfermedades Neoplasicas

Case Western Reserve University

STCC at DHR Health Institute for Research and Development

Banner University Medical Center – Tucson

Ohio State University Comprehensive Cancer Center

University of Kentucky/Markey Cancer Center

Cancer Research Consortium of West Michigan NCORP

UC San Diego Moores Cancer Center

Oregon Health and Science University

THANKS TO

Our Meeting Supporters!

We are grateful to these partners for contributing to the success of the 2026 group meetings

Bronze Meeting Sponsors



Spring 2026 Exhibitors

Foundation Medicine

Natera

NCI CIRB

nCoup

IROC

Upcoming Funding & Career Development Opportunities

Leadership and Project Development Course
apply by **June 1**

SEED Fund
apply by **July 1**

CRA/Nurse Travel Support
apply by **July 15**

Secondary Data Analysis
Rolling

See all Hope Foundation programs at
thehopefoundation.org/funding-opportunities

THE HOPE
FOUNDATION
FOR CANCER RESEARCH

Take Action Symposium

Advanced Practice Providers as Catalysts for Access, Enrollment, and Retention in Oncology Research!

Presented by SWOG Recruitment & Retention Committee

OBJECTIVES:

- 1** *Highlight the vital role Advanced Practice Providers (APPs) play in improving patient access and sustained participation in oncology clinical trials.*
- 2** *Describe current challenges and emerging opportunities for APP involvement in oncology research.*
- 3** *Outline practical strategies for defining APP roles, strengthening compliance and training, and optimizing workflows across MD/APP/CRC research teams.*



TARGET AUDIENCE:

Investigators, research professionals, and patient advocates, NCORP and LAPS



SPEAKERS



Christa Braun-Inglis,
DNP, APRN, FNP-BC, AOCNP
Hawaii MU NCORP



Amy Koffarnus,
BS, CCRP
CROWN NCORP



Alyssa Mader,
DNP
Wisconsin NCORP



Matthias Weiss,
MD
Wisconsin NCORP



Dana Reeves,
APRN
Ozarks NCORP



Daniel Mackey,
MD
Ozarks NCORP



Ashley Buscetta,
MSN, FNP-BC,
CWOCN
NCORP Project
Scientist

MODERATOR

SWOG Clinical Trials Partnerships (CTP)

HOW SWOG PARTNERS WITH INDUSTRY TO CONDUCT CANCER CLINICAL TRIALS

SWOG CTP Update Forum

THURSDAY, APRIL 30 • 5:30 – 6:30 PM PT • GRAND BALLROOM A (STREEL LEVEL) & ONLINE

- **SWOG CTP overview**

- Joint study development process
- Scientific areas of interest
- Types of trials

- **SWOG CTP active trials**

- **21CTP.LEUK01**: Phase II trial for patients with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia
- **21CTP.HN01 (CAPT-HN)**: Phase II study in recurrent metastatic head and neck cancer with cohorts defined by type of and/or response to prior systemic therapies



To apply to open either study, complete its feasibility survey at swogctp.org/trials.

- **Accrual completed: TROPION Breast 03 FDA registration trial**

- **SWOG CTP trials in development:**

- **21CTP.BREAST01 (MONITOR)**: Phase II platform trial using circulating tumor DNA to monitor treatment response in HR+, HER2- metastatic breast cancer
- **26CTP.LEUK02 (APEX-MF)**: Randomized open label trial for treatment-naïve, cytopenic myelofibrosis
- **26CTP.BMT01**: HA-1 TCR T cell phase II treatment trial

- **Site logistics: operations & data management**

- Feasibility survey outreach and site selection
- Site funding and contracts
- Site activation process and engagement
- Lessons learned

- **Novel CTP projects and other collaborative opportunities**

All are invited!

Learn more: swogctp.org

Email us: CTP@swog.org

For a one-on-one appointment with our Research Site Coordination Manager: sitecoordination@swogctp.org

The first lecture of the SWOG Spring 2026 Group Meeting Vice Chair's Council on Representation Lecture

THURSDAY, APRIL 30 • 7:30 – 8:30 AM PT • PACIFIC HI (PACIFIC CONCOURSE) & ONLINE

“The Generalizability Gap: How Real-World Data Can Transform Cancer Clinical Trial Evidence”

by

Shannon Silkensen, PhD

Center for Biomedical
Informatics and Information
Technology (CBIIT),
National Cancer Institute



How can real-world data be used to expand the generalizability of cancer clinical trial findings to better reflect real-world patient populations?

What role can real-world data play in helping us assess the long-term effectiveness of interventions beyond the lifespan of traditional RCTs?

Dr. Silkensen will speak on the role of real-world data in expanding the impact of cancer clinical trials.

Dr. Silkensen is a health science administrator in NCI CBIIT's Clinical & Translational Research Informatics Branch. The programs she leads include the NCI's Real-World Data Program, which works to improve the quality, completeness, and collection of patient data in electronic health records during routine clinical care. This data can be transformed into real-world evidence that offers critical insights into patient outcomes and healthcare practices.

Irene Tami-Maury, DMD, MSc, DrPH,

of the University of Texas School of Public Health, will introduce Dr. Silkensen

All are invited!

ORP Jeri & Noboru Oishi Symposium

FRIDAY, MAY 1 • 8:00 AM – 10:30 AM PT • BAYVIEW ROOM (BAY LEVEL)

<i>Time</i>	<i>Topic</i>	<i>Speaker(s)</i>
8:00 – 8:10 am	Opening & Announcements	<i>Connie Szczepanek, RN, BSN Joyce Nancarrow Tull, RN, MSN</i>
8:10 – 9:10 am	FDA BIMO Inspections	<i>Chrissy Cochran, PhD Director, Office of Bioresearch Monitoring Inspectorate Office of Inspections and Investigations, FDA</i>
9:10 – 9:40 am	Practical Lessons from FDA Inspections	<i>Moderator: Kira Pavlik, MPH, CCRP, Yale Cancer Center Sandy Annis, BA, CCRP; University of Kansas Cancer Center Erin Cebula, MPH, CCRP; Wilmot Cancer Institute Christina Weiss, BS, CCRP; Yale Cancer Center Joyce Nancarrow Tull, RN, MSN; UCSD Moores Cancer Center</i>
9:40 – 10:15 am	Quality Assurance in FDA Registration Trials	<i>Laura Gonzales, RN, BSN; SWOG Cancer Research Network Quality Assurance Manager</i>
10:15 – 10:30 am	Poll Everywhere	<i>Everyone: What are the topics you want to hear more about?</i>

PLEASE KEEP THIS AGENDA AND USE THE FILLABLE STATEMENT BELOW TO DOCUMENT YOUR EDUCATIONAL CREDITS.

I certify that I attended _____ hours of this meeting. The topics of the meeting contribute to my education and professional advancement in clinical research.

Signature _____ Date _____

Oishi Education Sub-Committee Co-Chairs:

Kira Pavlik, MPH, CCRP – kira.pavlik@yale.edu Joyce Nancarrow Tull, MSN, RN – jntull@health.ucsd.edu

Give to Support SWOG's Work

Advance Research, Education, and Group Meetings!



Thank you for improving and lengthening lives through your work with SWOG.

Make an impact for our members and patients when you donate to The Hope Foundation, SWOG's public charity. Join in giving today, making a planned gift, or establishing a monthly gift.

thehopefoundation.org/donate

THE HOPE
FOUNDATION
FOR CANCER RESEARCH

THE FRANK AND LINDA MEYSKENS ANNUAL ENDOWED LECTURESHIP ON ADVANCES IN CANCER PREVENTION

“Integrated Precision Prevention in Early-Onset Colorectal Cancer: From Genetic, Lifestyle, and Environmental Risk Factors to Microbiome Modulation”



by **Ulrike Peters, PhD, MPH**

Fred Hutch Cancer Center

Presented within the Prevention, Screening, and Surveillance committee session

Thursday, April 30 • 4:30 – 6:30 pm PT • Bayview (Bay Level)

Since the early 1980's, Dr. Frank Meyskens has been a leader in the recognition, development, and clinical usage of prevention in the management of cancer. Frank and Linda have directed the development of this lectureship to advance the explosion of knowledge that is expanding opportunities to engage prevention in personalized medicine, including early detection and genetically focused treatment options.

THE ROBERT B. LIVINGSTON TRANSLATIONAL CANCER LECTURE

This spring's lecture will occur as part of the Breast Committee session

Friday, May 1 • 4:30 pm - 6:30 pm PT • Seacliff BCD (Bay Level)



“Circulating Tumor-DNA to Guide Therapies: The Breast Is Yet to Come”

by **Ben Ho Park, MD, PhD**

Vanderbilt-Ingram Cancer Center

Dr. Robert Boyd Livingston was a superb clinician and clinical trialist who greatly impacted the field of cancer research. Within SWOG, he served as chair of both the lung cancer committee (1974-1997) and the breast cancer committee (2000-2008). In his honor, SWOG established the Dr. Robert B. Livingston Translational Breast and Lung Cancer Lectureship.



Another tax season has passed, but it's never too early to start planning for next year

As a reminder, you can make a tax-free gift from your IRA if you are 70½ or older

Here are a few reasons to direct this gift to The Hope Foundation:

- *Provide immediate support for SWOG's work*
- *Reduce a future tax burden and satisfy a Required Minimum Distribution (RMD)*
- *Give and save while building a legacy of generosity in cancer care*

Thank you!

THE HOPE
FOUNDATION
FOR CANCER RESEARCH

<https://tinyurl.com/THF-waystogive>



Spring 2026 Hematology Kickoff

2 Important Studies in Leukemia and Lymphoma Activating Soon

S2504 pirAMID: Richter transformation – R-CHOP w/wo pirtobrutinib

S2506 MOZART MZL: Marginal zone lymphoma – Identifying a new standard of care

FRIDAY, MAY 1 • 12:30 – 1:30 PM PT • SEACLIFF AB (BAY LEVEL) & ONLINE

S2504 pirAMID: Randomized phase 3 – pirtobrutinib plus R-CHOP vs. R-CHOP alone in previously untreated Richter transformation

Richter transformation (RT): the progression of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) into an aggressive form of lymphoma

RT is rare (~500 cases per year in the U.S.) and highly aggressive. Prospective trial data on treatments for RT are limited, and outcomes for these patients remain poor. They need better options.

S2504 pirAMID randomizes patients with untreated RT to R-CHOP alone or R-CHOP in combination with pirtobrutinib, a BTK inhibitor that has demonstrated promising efficacy in B-cell malignancies.

The S2504 portion of this session will cover:

- scientific rationale for the study
- study design
- key eligibility criteria
- operational considerations
- early patient identification
- proactive patient referral



*Mazyar Shadman,
MD, MPH
Study Chair*



*Deborah Stephens,
DO
Study Co-Chair*

**S2504 is the first randomized trial in the U.S. for Richter transformation.
Activation is imminent.**

All NCTN and NCORP investigators and site staff are invited!

Also on the agenda for this kickoff session:

S2506 MOZART MZL: Randomized phase 2 study in relapsed/refractory marginal zone lymphoma: mosunetuzumab alone vs. mosunetuzumab + zanubrutinib vs. mosunetuzumab + polatuzumab vedotin

Spring 2026 Hematology Kickoff

2 Important Studies in Leukemia and Lymphoma Activating Soon

S2504 pirAMID: Richter transformation – R-CHOP w/wo pirtobrutinib

S2506 MOZART MZL: Marginal zone lymphoma – Identifying a new standard of care

FRIDAY, MAY 1 • 12:30 – 1:30 PM PT • SEACLIFF AB (BAY LEVEL) & ONLINE

S2506 MOZART MZL is a randomized phase 2 trial in relapsed/refractory marginal zone lymphoma comparing:

mosunetuzumab
alone

vs.

mosunetuzumab
+ zanubrutinib

vs.

mosunetuzumab
+ polatuzumab vedotin

Despite marginal zone lymphoma (MZL) being the 3rd most common B-cell lymphoma, accounting for about 7,000 new diagnoses each year, there are limited prospective randomized trials to assess the safety and efficacy of new treatments in relapsed/refractory disease, and none previously through the NCTN.

The result: a standard of care for relapsed/refractory MZL remains undefined.

The **S2506 (MOZART MZL)** trial has emerged from a consensus effort by the NCTN groups to find a safe, efficacious, and time-limited treatment option for patients with relapsed/refractory MZL.

The S2506 portion of this session will cover:

- study background and relevance
- trial objectives: primary, secondary, exploratory
- key eligibility criteria
- study calendar
- statistical considerations and planned analyses
- study timelines for accrual and analyses



Boyu Hu, MD
Study Chair



Sonali Smith, MD
Study Co-Chair

S2506 trial activation is imminent.

NCTN and NCORP investigators and staff: come get your S2506 questions answered!

Also on the agenda for this kickoff session:

S2504 pirAMID: Randomized phase 3 – pirtobrutinib plus R-CHOP vs. R-CHOP alone in previously untreated Richter transformation

S2433 Kickoff

Phase 3 Study in Pancreatic Cancer

FRIDAY, MAY 1 • 12:45 – 1:45 PM PT • GARDEN ROOM (ATRIUM LEVEL) & ONLINE

S2433: A randomized phase 3 study of second-line chemotherapy with or without panitumumab in *KRAS* wild type, locally advanced or metastatic pancreatic adenocarcinoma

S2433 asks if adding the EGFR inhibitor panitumumab to physician's choice of second-line standard-of-care chemotherapy can extend overall survival in these patients.

S2433 includes patient-reported outcomes (PRO) comparing measures of health-related quality of life and the impact of treatment toxicity.

The kickoff will offer information and practical guidance on



S2433
background
and objectives



key eligibility
and treatment
details



study chair
review of
genomic profiles



study drug
ordering



PRO and
specimen
collection

S2433 activated in December 2025, with an enrollment goal of 94 patients.

Attend the S2433 Kickoff

Bring your questions for a Q&A with the study team.

All NCTN and NCORP investigators and staff are invited.

Hybrid session: IN-PERSON & VIRTUAL attendance options

STUDY CHAIR



Rachael
Safyan, MD

CO-CHAIR



E. Gabriel
Chiorean, MD

OTHER PRESENTERS AND PANELISTS WILL INCLUDE

Sarah Colby, MS – Statistician

Andrea Garcia – Protocol Project Manager

Harshabad Singh, MBBS, MD – TM Co-Chair

Virginia Sun, PhD, MSN, RN – PRO Co-Chair

Brian Zeller – Data Coordinator

S2424CD Kickoff

S2424CD: A Randomized Controlled Trial of an Intervention Called “Algorithm-Enabled Patients Activated in Cancer Care Through Teams” (A-PACT) to Improve Goals-of-Care Communication for People with Cancer

THURSDAY, APRIL 30 • 1:00-2:00 PM PT • SEACLIFF AB (BAY LEVEL) • ONLINE

All NCORP-based staff and investigators are invited!

We invite members from NCORP sites to learn about this new cancer care delivery trial focused on improving goals-of-care communication between patients with cancer and their clinical care team.

S2424CD features an automated screening tool to reduce the workload for each site and make trial enrollment much easier. The protocol will activate soon, and we are recruiting sites to set up the screening tool in preparation for launch.

This session will discuss:

- Trial objectives and design
- The intervention and goals of care
- Benefit of lay health navigators & education for practices and patients
- Use of EHR-integrated participant screening processes to reduce staff effort
- Financial support for the trial and IT setup
- Logistics for site participation

STUDY CHAIRS



*Ravi B. Parikh,
MD, MPP, FACP
Emory University*



*Manali I. Patel,
MD, MPH
Stanford University*



*Christopher
Manz, MD
Dana-Farber
Cancer Institute*



Nicholas J. Vogelzang, MD, GU Symposium

“New Targets and Novel Trial Designs in Genitourinary Cancers”

FRIDAY, MAY 1 • 4:15 – 6:15 PM PT • BAYVIEW ROOM (BAY LEVEL) & ONLINE

The event honors the many valuable contributions Dr. Vogelzang made in support of his colleagues and patients throughout his career within SWOG’s research network.

At this spring’s Vogelzang Symposium, 2025 Vogelzang Scholar Alexander Zhu, DO, will present, and a new Vogelzang Scholar will be announced. The symposium will include talks on prostate, bladder, and kidney cancer, each followed by a brief Q&A session



4:15

Introduction
Daniel Petrylak, MD
Yale University



4:20

My Journey in Clinical Trials – Reflections as the 2025 Vogelzang Scholar
Alexander Zhu, DO,
Vogelzang Scholar
University of Washington



4:35

Introduction of 2026 Vogelzang Scholar Martin Ma (University of Washington)
Thomas Flaig, MD
University of Colorado Anschutz



4:40

The Future of Targeted Therapies in Prostate Cancer: Opportunities for SWOG
Laura Graham, MD
University of Colorado



5:05

Beyond EV-Pembrolizumab: Novel Therapies in Urothelial Carcinoma
Abhishek Tripathi, MD
City of Hope



5:30

New Systemic Therapies for Renal Cell Carcinoma
Mamta Parikh, MD
University of California – Davis



5:40

Radioligand Therapies in Renal Cell Carcinoma
Andrei Iagaru, MD
Stanford University



5:55

How Do We Design Clinical Trials in All Tumor Types Based on Therapeutic Layering?
Fed Ghali, MD
Yale University

SWOG Group Meeting App

The SWOG group meeting mobile app is your pocket guide to the meeting.

With key features in an easily accessible format, the app not only replaces the agenda book as your on-site companion, it contains the agenda book – as a PDF you can flip through on your phone.

WITH THE APP, YOU CAN

1 create your schedule, annotate sessions, and add them to your calendar

3 access zoom links for hybrid sessions

2 access a directory of presenters and session leaders, along with other attendees who have opted in

The app also offers a single go-to source for speakers and presenters:

4 access individual meeting agendas

- find travel and lodging information and links
- view speaker guidelines, update photo and bio

5 access the full agenda book itself as a PDF



swog.org/appleapps26



swog.org/googleapps26

DON'T HAVE THE APP YET?
Download the app with the appropriate QR code or URL at left

DON'T WANT TO INSTALL YET ANOTHER APP?
Access the web browser version with the QR code or URL at right.



swog.org/meetingappS26

Committees

Disease & Research Committees

Breast: Lajos Pusztai, MD, DPhil

Cancer Care Delivery: Scott Ramsey, MD, PhD & Veena Shankaran, MD

Early Therapeutics & Rare Cancers: Razelle Kurzrock, MD

Gastrointestinal: Philip Philip, MD, PhD

Genitourinary: Seth Lerner, MD

Leukemia: Harry Erba, MD, PhD

Lung: Jhanelle Gray, MD

Lymphoma: Chair-Elect, Sonali Smith, MD

Melanoma: Sapna Patel, MD

Myeloma: Amrita Krishnan, MD

Palliative Care: Robert Krouse, MD & Marie Bakitas, PhD

Prevention, Screening, & Surveillance: Banu Arun, MD & Jason Zell, DO

Symptom Management & Survivorship: Norah Lynn Henry, MD, PhD & Michael Fisch, MD

Modality Committees

Imaging: Lawrence Schwartz, MD

Immunotherapeutics: Katerina Politi, PhD & Siwen Hu-Lieskovan, MD, PhD

Radiation Oncology: Chul Soo Ha, MD

Surgery: Syed Ahmad, MD

Transplant & Cell Therapies: Patrick Hagen, MD

Research Support Committees

Adolescents & Young Adults: Rebecca Johnson, MD

Advanced Practice Providers: Christa Braun-Inglis, DNP, APRN & Jamie Myers, PhD, RN

Oncology Research Professionals: Connie Szczepanek, RN, BSN

Patient Advocates: Barbara Segarra-Vazquez, DHSc & Anne Marie Mercurio, PA

Pharmaceutical Sciences: Joyce Lee, PharmD

Recruitment & Retention: Allison Caban-Holt, PhD

Veterans Affairs: Stephen Bartlett, RPh, MSPH

Administrative Committees

Board of Governors: Dawn Hershman, MD, MS & Primo Lara, Jr., MD

Conflict Management: Paul Okunieff, MD

Professional Review Committee: Paul Hesketh, MD

Publications: David Horowitz, MD

Adolescent and Young Adult Committee

FRIDAY, MAY 1 · 4:15 - 5:45 PM PT · WATERFRONT AB (ATRIUM LOBBY LEVEL)

Agenda

- A. Welcome**
Becky Johnson, MD
- B. Cancer Survival Trends Among AYAs in the U.S. and Elsewhere**
Archie Bleyer, MD
- C. Cross-NCTN Collaboration in Hodgkin Lymphoma: Trial Planning, Integration, and Innovation from S1826 to AHOD2131 and Beyond**
Mallorie Heneghan, MD
- D. A232301CD: AYA ACCESS: An Enhanced eHealth and Chat-Bot Enabled Delivery Model for Clinical Genetic Services in Community AYA Cancer Patients**
Angela Bradbury, MD
- E. S1823: A Prospective Observational Cohort Study to Assess miRNA371 for Outcome Prediction in Patients with Early Stage Germ Cell Tumors**
Lucia Nappi, MD
- F. ALTE-2131: Triptorelin and protection of ovarian reserve in AYAs with cancer**
Becky Johnson, MD
- G. Patients as Partners**
Allison Rosen, AYA Patient Advocate
- H. Q&A and discussion**

Advanced Practice Provider and Nurse Scientist Committee

FRIDAY, MAY 1 · 11:30 AM - 1:30 PM PT · WATERFRONT AB (ATRIUM LOBBY LEVEL)

Agenda

- A. **Introductions: Welcome to all our first time SWOG attendees and new members - Christa Braun-Inglis, DNP, APRN**
- B. **Review of new committee structure, goals, and planned metrics - Jamie Myers, PhD, RN, AOCNS, FAAN**
- C. **Update on NCORP Executive Committee Meeting - Jamie Myers**
- D. **Update on practice patterns measurement/metrics for impact of DCP and CTEP APP policy/guidelines effective September 7, 2021 - Monica Epstein, BSN, RN & Ashley Buscetta, MS, NP, NCI**
- E. **Update on current NCI R01-supplemented research Virginia Sun, PhD, RN**
- F. **Highlighted SWOG studies for APP support and championship Christa Braun-Inglis**
 - 1. **SWOG 2013**
 - 2. **SWOG 2414**
 - 3. **SWOG 2433**
- G. **“Concept Corner” overview – Jamie Myers**
- H. **Nurse supported trials in progress – Multiple Speakers**
- I. **MAPP update – Diane Barber, PhD, NP**
- J. **Publications – Christa Braun-Inglis**
- K. **IOB update – Siu Fun Wong, PharmD & Joyce Lee, PharmD**
- L. **APP Clinical Research Course Development-collaboration with APSHO Christa Braun-Inglis**
- M. **Open Forum**
- N. **Next meeting dates**
 - 1. **Start monthly meetings-establish schedule plans**
 - 2. **Fall meeting, October 9, 11:30-1:30 CT, Chicago**



SWOG Clinical Trials Training Course (CTTC)

Agenda for Oncology Research Professionals

THURSDAY, APRIL 30 • 7:00 AM - 5:00 PM PT

Morning Session	(Hybrid – On Site and Remote Attendees)	Grand Ballroom A
7:00 – 7:20	<i>Registration (continental breakfast provided)</i>	
7:20 – 7:30	<i>Introduction</i>	<i>Rodney Sutter, CCRP</i>
7:30 – 7:55	<i>Clinical Trials and Protocol Development</i>	<i>Dana Sparks, MAT</i>
7:55 – 8:20	<i>Data Submission</i>	<i>Laura Wells, BA</i>
8:20 – 8:30	<i>Patient Reported Outcomes</i>	<i>Monica Yee, BA, CCRP</i>
8:30 – 8:55	<i>Reports to Support Quality Data</i>	<i>Cathy Rankin, MS</i>
8:55 – 9:10	BREAK	
9:10 – 9:35	<i>Long Term Follow-Up</i>	<i>Lisa Stoppenhagen, BS,CCRP</i>
9:35 – 10:00	<i>Adverse Event Reporting</i>	<i>Gabi Herbert, MS, BS</i>
10:00 – 10:25	<i>Serious Adverse Events</i>	<i>Maggie Spillers, BSN, RN</i>
10:25 – 10:40	BREAK	
10:40 – 11:05	<i>Audits/Quality Assurance</i>	<i>Laura Gonzales, BSN, MA, RN, OCN</i>
11:05 – 11:30	<i>Specimen Tracking System</i>	<i>Christine Magner</i>
11:30 – 11:40	<i>Tips for Specimen Submission</i>	<i>Hannah Brown, BS</i>
11:40 – 12:00	<i>Scientific Impact of the CRA</i>	<i>Michael LeBlanc, PhD</i>
12:00 – 2:00	LUNCH (on your own) and Site Operations	
Afternoon Session	(On-Site Attendees Only)	Grand Ballroom BC
2:00 – 2:35	<i>(Don't let your data end up in) JEOPARDY! ...it's a Game!</i>	<i>Christine Magner</i>
2:35 – 2:45	<i>Introduction to the Practicum</i>	<i>Christine Magner</i>
2:45 – 5:00	<i>Practicum Session</i>	<i>Data Operations Center Staff and SWOG CRAs</i>

Pharmaceutical Sciences Committee and Drug Information Subcommittee Joint Meeting (Hybrid)

FRIDAY, MAY 1 • 9:00 AM – 11:00 AM PT • PACIFIC D (PACIFIC CONCOURSE LEVEL)

Agenda

1. Committee Administrative reports – Joyce Lee

- Introduction of new members
- Review of PSC Member Roster
- Summary of committee activities

2. Drug Information Sub-Committee

- Sub-committee updates – Vy Bui

- Workload Summary of Drug Information section requests
- Introduction of resident and fellow writers for 2026-2027 academic year

- Protocol review activities – Holly Chan/Jorge Avila

- NCI Aurora rollout updates – Matt Boron

3. APP Initial Order Build (IOB) Focus Group – Siu Fun Wong/Joyce Lee

- Program development updates

4. Pharmacist Liaison Report

- Review of Pharmacist Liaison Assignment List
- Disease Committee Liaison Pharmacist Reports – Open discussion

5. Open agenda - All

SWOG Latin America Initiative Symposium

FRIDAY, MAY 1 • 12:00 - 1:30 PM PT • BAYVIEW ROOM (BAY LEVEL)

Agenda

***Introductory Remarks, Drs. Mariana Chávez Mac Gregor
and Nora Sobrevilla***

Part 1: Genitourinary Cancer Collaborations

Prostate cancer disparities in Latin America and the US, Dr. Nora Sobrevilla

Advanced RCC: Evidence gaps and research priorities for mixed-resource settings, Dr. Regina Barragán

*SWOG GU trials: Studies feasible in the Latin America Initiative,
Dr. Seth Lerner*

Part 2: Round Table Discussion about Collaborations

Open discussion about areas of current and future GU collaborations

Part 3: Site Focus: SLAI Activities and GU Patient Overview by Country

*Focus: Colombia, Dr. Juan Pablo Usubillaga Velásquez
SLAI activities and GU patient overview by country, all SLAI sites*

Closing Remarks, Drs. Mariana Chávez Mac Gregor and Nora Sobrevilla

SWOG Site Operations Meeting Agenda

THURSDAY, APRIL 30 • 12:30 PM - 2:00 PM PT • GARDEN ROOM (ATRIUM LOBBY LEVEL)

Agenda

<i>Open, Welcome, and Announcements</i>		<i>Site Operations Committee</i>
<i>General Updates</i>		
<i>APP Highlights</i>		<i>Christa Braun-Inglis</i>
<i>National Cancer Institute (NCI)</i>		<i>Grace Mishkin</i>
<i>National Cancer Institute (NCI) / Central Institutional Review Board (CIRB)</i>		<i>Renee Green</i>
<i>Clinical Trials Support Unit (CTSU)</i>		<i>Leila Abraham</i>
<i>SWOG Updates</i>		
<i>SWOG Network Operations Center</i>	<i>Administration & Study Funding</i>	<i>Pat Mize</i>
	<i>Quality Assurance (QA)</i>	<i>Laura Gonzales</i>
	<i>Information Systems</i>	<i>Cara Laubach</i>
<i>Statistics & Data Management Center (SDMC)</i>		<i>Rodney Sutter</i>
<i>Closing Remarks</i>		<i>Site Operations Committee</i>

TAKE ACTION SYMPOSIUM: Advanced Practice Providers as Catalysts for Access, Enrollment, and Retention in Oncology Research!

PRESENTED BY
SWOG Recruitment & Retention Committee

THURSDAY, APRIL 30 · 2:30 PM - 4:30 PM PT · GRAND BALLROOM A (STREET LEVEL)

Target Audience: Investigators, research professionals, and patient advocates, NCORP and LAPS

Objectives:

1. Highlight the vital role Advanced Practice Providers (APPs) play in improving patient access and sustained participation in oncology clinical trials.
2. Describe the current challenges and emerging opportunities for APP involvement in oncology research.
3. Outline practical strategies for defining APP roles, strengthening compliance and training, and optimizing workflows across MD/APP/CRC research teams.

MODERATOR AND SPEAKER/PANELIST OUTLINE

Time	Discussion	Speaker/Moderator
2:30-2:35	<i>Welcome</i>	<i>Colmar Figueroa-Moseley, PhD, MPH & Kamara Mertz-Rivera, MA, CCRC</i>
2:35-2:50	<i>Objectives & Current Landscape</i>	<i>Christa Braun-Inglis, DNP, ARNP, FNP-BC, AOCNP Hawaii NCORP</i>
2:50-3:10	<i>Defining APP Responsibilities</i>	<i>Amy Koffarnus, BS, CCRP CROWN</i>
3:10-3:40	<i>Practical Strategies and Optimization</i>	<i>Alyssa Mader, DNP & Matthias Weiss, MD Wisconsin NCORP Dana Reeves, APRN & MDs & Daniel Mackey, MD Ozarks NCORP</i>
3:40-4:25	<i>Panel Discussion/Questions & Answers</i>	<i>Ashley Buscetta, MSN, FNP-BC, CWOCN NCORP Project Scientist</i>
4:25-4:30	<i>Session Evaluation and Wrap Up</i>	<i>Allison Caban-Holt, PhD, RRC Chair</i>

Transplant and Cell Therapies Committee

THURSDAY, APRIL 30 • 3:00 – 4:30 PM PT • GARDEN ROOM (ATRIUM LOBBY LEVEL)

Agenda

1. Pending Studies

- a. EA 4241: A Two Cohort Randomized Study for Patients with High Risk (Phase II) and Standard Risk (Phase III) Classical Hodgkin Lymphoma in First Relapse. *Sairah Ahmed, MD*

2. New Concept for discussion

- a. HA-1 TCR-T Cell Therapy for Post-HCT Hematologic Malignancy Relapse.
Marie Bleakley, Elizabeth Krakow, MD
- b. A Phase II Randomized Study Comparing Total Marrow and Lymphoid Irradiation (TMLI with Fractionated Total Body Irradiation (FTBI) as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplantation (PBSC-HCT) in Patients with Acute Lymphoblastic Leukemia. *Monzr M. Al Malki, MD*

3. Active Protocol Updates

- a. Plasma Cell Disorders
- SWOG 2213: Phase 3 randomized trial of daratumumab, cyclophosphamide, bortezomib and dexamethasone (D-VCD) induction followed by autologous stem cell transplant or D-VCD consolidation and daratumumab maintenance in patients with newly diagnosed AL amyloidosis. *Patrick Hagen, MD*
- b. NHL
- i. SWOG 2114: A Randomized Phase II trial of Consolidation Therapy following CD19 CAR T-cell Treatment for Relapsed/Refractory Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma. *Brian Hess, MD*
- ii. EA 4232: PTCL-STAT (Stem-cell Transplant AuTologous). *Marc Hoffmann, MD*

4. MyeloMatch Update

- a. MM3TCT-A03: A Two Cohort, Randomized, Open-Label, Phase II Multi-Center Signal-Finding Study of Venetoclax Combined with Reduced-Intensity Conditioning Followed by Allogeneic Hematopoietic Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Complete Remission: A MyeloMATCH Sub-Study. *Stephanie Tsai, MD, MS*

VA Committee

THURSDAY, APRIL 30 • 4:30– 6:00 PM PT • PACIFIC HI (PACIFIC CONCOURSE LEVEL)

Agenda

A. Introductions and Opening Comments

Stephen Bartlett, RPh, MSPH, Chair

Brittany Rogers, MD, Vice-Chair

B. Protocol Presentations for VA Consideration

1. S1900N, “A Randomized Phase II Study of TROP-2 ADC alone, PD1-VEGF bispecific alone, or combination TROP-2 ADC and PD1-VEGF bispecific in Participants with Previously-Treated Actionable Genomic Alteration Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study).”

Presenter: Dr. Chao Huang

2. S2212, “Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study.”

Presenter: Dr. Shruti Trehan

3. A032302, “Docetaxel Addition in Metastatic Castrate-Sensitive Prostate Cancer (ASPIRE).” (SWOG cross-network approved 09-DEC-2025) *Dr. R. Bruce Montgomery*

C. Storefront RFA Update

D. New SWOG-VA Initiatives

E. VA Liaison Program Updates

1. Updates, Ongoing Goals - *Dr. Jessica D. McDermott*

2. How to Apply - vamember@swog.org

F. VA Accrual Report

G. Future Meetings

- Summer VA Committee Call – Date TBD
- AVAHO – September 11-13, 2026, Austin, TX
- SWOG Fall 2026 Group Meeting – October 8-10, 2026, Chicago, IL

Barlogie-Salmon Myeloma Committee

Leadership

Chair: Amrita Y. Krishnan, MD
 Vice-Chair: Sikander Ailawadhi, MD
 Vice-Chair:.....Jing Christine Ye, MD, MSc
 Executive Officer Alex Herrera, MD
 Statisticians:Antje Hoering, PhD
 Rachael Sexton, MS
 Adam Rosenthal, MS
 Sara Threlkel, BS

Scientific Leadership

Translational Medicine: Brian A. Walker, BSc, PhD
 Radiation:Chelsea Camille Pinnix, MD, PhD
 Surgery: TBD
 Imaging:.....Eric M. Rohren, MD, PhD
 Pathology:..... Pei Lin, MD
 Early Therapeutics: Frits van Rhee, MD, PhD

Designates

NCORP Representative:.....Charles S. Kuzma, MD
 Veterans Affairs: Thomas R. Chauncey, MD, PhD
 Data Coordinators: Aubrey Gilmore, BA
Daria Chugina, MD, CCRPS
 Pasarlai Ahmadzai, MD, MPH
 Oncology Research Professionals: Brandon Richard Labadie, CCRP
 Patient Advocate:..... Paul Gater, MPhil
 Pharmaceutical Science:..... Craig Elg, PharmD
Yumena Kawasaki, PharmD
 Protocol Project Manager:..... Amy Doyle
 Clinical Trials Program Manager:.....Sharon Palmer

Time/Location

Friday, May 1, 2026 4:30 p.m. - 6:30 p.m.
 Room: Pacific HI (Pacific Concourse Level)

Agenda

Welcome & Introductions Amrita Krishnan, MD
Active Trials Updates Sikander Ailawadhi, MD
 Patrick Hagen, MD
 Amrita Krishnan, MD
Trials in Development Brea Lipe, MD
 Sikander Ailawadhi, MD
 Hira Mian, MD, FRCPC

Keynote Speaker:

Jonathan Keats, PhD
 Associate Professor, Cancer Genomics and Therapeutics Division Director of Bioinformatics and Collaborative Sequencing Center Scientific Director, Judy and Bernard Briskin Center for Multiple Myeloma Research Translational Genomics Research Institute, part of City of Hope

TM Subcommittee Update J. Christine Ye, MD, MSc

Completed Studies and Other Cooperative Group Trials

Active Studies

S2005, "A Phase II Randomized Study Comparing Ibrutinib and Rituximab vs.Venetoclax and Rituximab in Previously Untreated Waldenström's Macroglobulinemia (WM) /Lymphoplasmacytic Lymphoma (LPL)" Drs. S. Ailawadhi and D. Bhutani. Activated: 6/24/21; Closed: 4/8/22; Re-activated: 2/15/24. Temporarily closed: 11/21/25.

S2209, "A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or Ineligible for Stem Cell Transplant Comparing Upfront Bortezomib-Lenalidomide-Dexamethasone-Lite (VRd-Lite) with Daratumumab-Lenalidomide-Dexamethasone (DRd)." Drs. S. Ailawadhi, J.C. Ye, B. Lipe, T. Chauncey, and K. Gowin. Activated 5/30/23.

S2213, "Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (D-VCD) Induction Followed by Autologous Stem Cell Transplant or D-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis." Drs. P. Hagen, T. Parker, and S. Sidana. Activated 12/1/23.

A062102, "Randomized Phase II Study of Ibrutinib Maintenance Therapy Following Idecabtagene Vicleucel CAR-T in Multiple Myeloma Patients." Dr. R. Banerjee. Activated: 4/4/24.

EAA173, "Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma." Dr. M. Butler. Activated: 4/30/19.

EAA181, "Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial." Dr. K. Gowin. Activated: 10/27/20.

Barlogie-Salmon Myeloma Committee

Developing Studies

S2508, "A Phase II Study of Optimal Induction and MRD Driven Maintenance Therapy for Patients with Newly Diagnosed High-Risk Multiple Myeloma (HRMM)." Drs. B. Lipe, J.C. Ye, and A. Cowan.

S2604, "A Phase III Study for Evaluation of Maintenance Cessation in Patients with Standard Risk Myeloma Achieving Minimal Residual Disease Negativity." Dr. M. Mohyuddin.

Closed Studies

S1803, "Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)." Drs. A. Krishnan and S. Chhabra. Activated: 6/27/19. Registration Step 1 Closed to Accrual: 1/15/25.

S1211, "A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)." Drs. S. Usmani, S. Ailawadhi, and B. Lipe. Activated: 11/9/12. Closed: 6/2/16.

S1702, "A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis." Drs. T. Parker and V. Sanchorawala. Activated: 3/8/18; Closed: 9/30/19.

S1304, "A Phase II Randomized Study Comparing Two Doses of Carfilzomib with Dexamethasone for Relapse/Refractory Multiple Myeloma." Dr. S. Ailawadhi. Activated: 10/18/13. Closed: 11/6/15; Complete: 1/17/25.

S0777, "Frontline Phase III Rev/Dex +/- Vel, no upfront transplant." Dr. B. Durie. Activated: 4/1/18. Closed: 2/2/12.

S0120, "A prospective Observational Biologic Study of Asymptomatic Patients with Monoclonal Gammopathy and Plasmaproliferative Disorders." Dr. M. Dhodapkar. Activated: 6/1/02. Closed: 4/1/11.

CTN 0702, "Single Autologous Transplant with or without RVD Consolidation versus Tandem Transplant and Maintenance Therapy." Dr. G. Somlo. Activated: 2/15/11. Closed: 11/15/13.

A061402, "Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone after Radiation Therapy in Treating Patients with Solitary Plasmacytoma of Bone." Dr. A. Kuman Mahindra. Activated: 12/23/15. Closed: 8/15/19.

E1A11, "Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)." Drs. S. Kumar, A. Cohen, and J. Zonder. Activated: 11/22/13. Closed: 1/29/19.

E3A06 (was S0909), "High-risk AMM – Revlimid." Dr. M. Dhodopkar. Activated: 1/17/11. Closed: 7/14/17.

A061402, "Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone after Radiation Therapy in Treating Patients with Solitary Plasmacytoma of Bone." Dr. A. Kumar Mahindra. Activated: 12/23/15. Closed: 8/15/19.

EAA171, "Optimizing Prolonged Treatment in Myeloma Using MRD Assessment (OPTIMUM)." Dr. S. Kumar. Activated: 6/1/21. Closed 3/3/23.

Barlogie-Salmon Myeloma Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	S1803	S2005	S2209	S2213	EAA173	EAA181
AdventHealth Parker	2	-	-	-	-	-
Banner University Medical Center - Tucson	12	-	-	-	-	5
Baylor College of Medicine/Duncan Comprehensive Cancer Center	-	-	2	-	-	-
Boston Medical Center	5	-	-	3	-	-
CWRU Case Comprehensive Cancer Center LAPS	28	-	-	-	8	-
Cancer Research for the Ozarks NCORP	2	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	5	-	1	1	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	2	-	-	-
Carolinas Medical Center/Levine Cancer Institute	23	1	-	-	-	-
Cedars-Sinai Medical Center	6	-	-	-	-	-
City of Hope Comprehensive Cancer Center	118	-	5	-	-	-
Columbia University Minority Underserved NCORP	-	-	1	4	-	-
Columbus NCI Community Oncology Research Program	5	-	-	-	-	-
CommonSpirit Health Research Institute	1	-	3	-	-	-
Dayton NCI Community Oncology Research Program	5	-	-	-	-	-
Duke University - Duke Cancer Institute LAPS	3	-	-	3	-	-
Essentia Health NCI Community Oncology Research Program	-	-	1	-	-	-
Fred Hutchinson Cancer Research Center LAPS	7	-	-	-	9	-
Froedtert and the Medical College of Wisconsin LAPS	12	-	-	-	-	-
Georgia NCI Community Oncology Research Program	21	-	-	-	-	-
Gulf South Minority Underserved NCORP	4	-	-	-	-	-
Heartland Cancer Research NCORP	12	-	5	-	-	-
Henry Ford Hospital	2	1	-	-	4	2
Houston Methodist Hospital	13	-	-	1	-	-
Intermountain Medical Center	-	1	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	60	-	9	-	-	-
Kansas City Veterans Affairs Medical Center	-	-	4	-	-	-
Lahey Hospital and Medical Center	3	-	-	-	-	-
Loyola University Medical Center	26	-	-	-	3	4
MU Health Care Goldschmidt Cancer Center	3	-	-	-	-	-
Massachusetts Veterans Epidemiology Research and Info Center	-	-	1	-	-	2
Medical University of So Carolina Minority Underserved NCORP	60	-	-	-	1	1
Mercy Medical Center - Des Moines	1	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	13	-	2	-	-	-

Barlogie-Salmon Myeloma Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	S1803	S2005	S2209	S2213	EAA173	EAA181
Moffitt Cancer Center	48	-	-	-	-	-
Montana Cancer Consortium NCORP	1	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	4	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	1	-
New Mexico Minority Underserved NCORP	15	-	5	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	5	-	-	-	-	-
Oregon Health and Science University	33	-	1	-	3	9
Pacific Cancer Research Consortium NCORP	18	-	7	1	-	-
Regents of the University of Michigan	16	-	-	-	-	-
Riverside Methodist Hospital	3	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	3	-	-	-	-	-
Stanford Cancer Institute Palo Alto	-	-	3	-	-	-
Tulane University School of Medicine	-	-	-	-	2	-
UC Davis Comprehensive Cancer Center LAPS	27	-	7	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	19	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	5	-	-	5
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	2
University of Kansas Cancer Center - MCA Rural MU NCORP	35	-	-	1	-	-
University of Kentucky/Markey Cancer Center	4	-	-	-	-	-
University of Nebraska Medical Center	-	-	-	1	-	-
University of Oklahoma Health Sciences Center LAPS	3	-	3	-	-	-
University of Rochester LAPS	15	2	2	-	-	6
University of Texas MD Anderson Cancer Center LAPS	27	-	4	1	-	-
University of Utah - Huntsman Cancer Institute LAPS	16	-	-	-	4	2
Upstate Carolina Consortium Comm Oncology Research Program	4	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	1	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	18	-	2	1	-	-
Wisconsin NCI Community Oncology Research Program	23	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	5	1	4	8
ALLIANCE	226	4	12	6	-	-
CCTG	21	-	-	-	-	-
ECOG-ACRIN	188	12	10	4	-	-
NRG	117	1	5	2	-	-
Total	1,338	22	111	30	39	46

Breast Committee

Leadership

Chair: Lajos Pusztai, MD, PhD
 Vice-Chair:Priyanka Sharma, MD
 Executive Officer:..... Anne Chiang, MD, PhD
 Statisticians:Allison Meisner, PhD
Shay Bellasea, MS
 Danika Lew, MA
 Matt Chansky, BS

Scientific Leadership

Translational Medicine: Alastair M. Thompson, MD
 Andrew K. Godwin, PhD
 Radiation Oncology: Reshma Jagsi, MD
 Surgery: Joshua M.V. Mammen, MD, PhD
 Imaging:..... TBD
 Pathology:.....David L. Rimm, MD, PhD
 Early Therapeutics:Stephanie L. Graff, MD

Designates

Adolescent & Young Adults: Erin Elizabeth Roesch, MD
 Cancer Control Liaisons: Mariya Rozenblit, MD (Survivorship)
 Dawn L. Hershman, MD (Cancer Care Delivery)
 Banu Arun, MD (Prevention)
Helen K. Chew, MD (Symptom Management)
 NCORP Representative:Philip E. Lammers, MD
 Veterans Affairs:Sarah V. Colonna, MD
 Data Coordinators:Aubrey Gilmore, BA
 Gabi Herbert, MS, BS
 Larry G. Kaye
 Kevin Moralda, BS
 Oncology Research Professionals: Cameo Windham, BSN, RN
 Patient Advocates: Roberta A. Albany
 Jamie LaScala
 Pharmaceutical Science: Jorge G. Avila, PharmD
 Dawud Nael Dawud Ellayan, Pharm D
 Sr. Protocol Project Manager: Chris Kippola, BS
 Clinical Trials Program Manager:Sharon Palmer

Time/Location

Friday, May 1, 2026 4:30 p.m. - 6:30 p.m.
 Room: Seacliff BCD (Bay Level)

Agenda

4:30- 4:35 pm	Welcome and Introductions - Lajos Pusztai, MD, DPhil (Chair) and Priyanka Sharma, MD (Vice-chair)
Robert Livingston Lecture	
4:35 - 5:05 pm	Circulating Tumor-DNA to Guide Therapies: The Breast is Yet to Come - Ben Ho Park, MD, PhD Director, Vanderbilt-Ingram Cancer Center Benjamin F. Byrd, Jr. Chair in Oncology Professor of Medicine, Division of Hem / Onc Vanderbilt University Medical Center
5:05 - 5:10 pm	Q&A
Committee Business and Updates	
5:10 - 5:20 pm	Publication update – Allison Meisner, PhD
5:20 - 5:30 pm	Patient Advocate update – Roberta Albany and Jamie LaScala
5:30 - 5:40 pm	Translational Medicine Sub-Committee update - Alastair Thompson, MD and Andrew K. Godwin, PhD
5:40 - 6:15 pm	Review of open and upcoming CTSU trials
6:15 - 6:30 pm	Reports from Committee Liaisons NCORP: Philip Lammers, MD Symptom Management: Lynn Henry, MD, PhD Radiotherapy: Reshma Jagsi, MD, PhD Surgery: Joshua Mammen, MD Cancer Care Delivery: Dawn Hershman, MD Prevention: Banu Arun, MD Theranostics Subcommittee: Shane Stecklein, MD, PhD & Joanne Mortimer, MD Early Therapeutics: Stephanie Graff, MD
6:30 pm	Closing Comments and Adjourn

NCI Approved Concepts

S2511, "Randomized Phase III trial of multimodality therapy versus standard of care systemic therapy in HER2 positive (HER2+) de novo (AJCC stage IV) oligometastatic breast cancer with response to initial chemotherapy." Approved: 7/17/25.

Breast Committee

Active Studies

S2206, "Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer." Drs. Cobain and Pusztai. Activated: 10/30/23.

S2212, "Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study." Drs. Sharma and Mitri. Activated: 7/21/23.

CTSU/A011801, "The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSESSment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib." Dr. O'Sullivan. SWOG Champion: Dr. Murthy. Activated: 1/6/21.

CTSU/CCTG MA.39, "Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer." Dr. Whelan. SWOG Champion: Dr. Jagsi. Activated: 5/30/18.

CTSU/NRG-BR007, "A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)." Dr. White. SWOG Champion: Dr. Shumway. Activated: 6/7/21.

Closed Studies

S1418, "A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with ≥ 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) after Neoadjuvant Chemotherapy." Drs. Pusztai and Mammen. Activated: 11/15/16; Permanently closed: 6/30/21.

S1207, "Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e³ Breast Cancer Study-Evaluating Everolimus with Endocrine Therapy." Drs. Chavez-MacGregor and Pusztai. Activated: 9/4/13; Permanently closed: 5/1/19.

S1706, "A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer." Drs. Jagsi and Chalasani. Activated: 9/12/18. Permanently closed: 7/1/24.

S2007, "A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases." Drs. Brenner and Kaklamani. Activated: 12/15/20. Permanently closed: 4/7/25.

CTSU/A011202, "A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy." Dr. Boughey. SWOG Champion: Dr. Mammen. Activated: 2/7/14; Permanently closed: 7/1/22.

CTSU/EA1181, "(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSESSment to Optimize Therapy in HER2-Positive Breast Cancer)" Dr. Tung. SWOG Champions: Breast Committee: Dr. Tang, Imaging Committee: Dr. Lu. Activated: 2/11/20; Permanently closed: 10/19/23.

CTSU/EA1183, "FDG PET to Assess Therapeutic Response in Patients with Bone-Dominant Metastatic Breast Cancer, FEATURE." Dr. Specht. SWOG Champions: Breast Committee: Dr. Linden, Imaging Committee: Dr. Wright. Activated: 4/2/20; Permanently closed: 12/22/23.

CTSU/NRG-BR002, "A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer." Drs. Chmura and White. SWOG Champion: Dr. Jagsi. Activated: 12/24/14; Permanently closed: 5/27/22.

CTSU/NRG-BR003, "A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer." Dr. Valero. SWOG Champion: Dr. Makhoul. Activated: 6/26/15; Permanently closed: 4/22/22.

CTSU/NRG-BR004, "A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer." Dr. Geyer. SWOG Champion: Dr. Cobain. Activated: 3/12/19; Permanently closed: 7/1/22.

CTSU/NRG-BR005, "A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment without Surgery." Dr. Basik. SWOG Champion: Dr. Thompson. Activated: 4/13/17; Permanently closed: 12/2/22.

Breast Committee

Active Symptom Management and Survivorship Study

S1501, "Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III." Drs. Floyd and Leja. Activated: 09/15/17. Arms 1 and 2 permanently closed to accrual: 11/1/24.

Closed Symptom Management and Survivorship Study

S1614, "A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors." Drs. Hwang and Lok. Activated: 02/21/19; Permanently closed: 11/15/22.

S1714, "A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients." Drs. Trivedi and Hershman. Activated 03/01/19; Permanently closed: 11/15/21.

Active Cancer Care Delivery Study

S1703, "Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer." Drs. Accordino and Hershman. Activated: 7/16/18.

Closed Prevention, Screening and Surveillance Study

S1904, "Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ – Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)." Drs. Crew, and Kukafka. Activated: 9/1/20. Permanently closed: 6/14/24.

CTSU/EA1151, "Tomosynthesis Mammographic Imaging Screening Trial (TMIST)." Dr. Pisano. SWOG Champion: Dr. Arun. Activated: 7/6/17. Closed to accrual: 12/20/24.

Closed Early Therapeutics and Rare Cancers Studies

S1609, "DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors." Drs. Patel and Chae. Activated 1/13/17; Permanently closed: 3/15/23.

CTSU/EAY131, "Molecular Analysis for Therapy Choice (MATCH)". Dr. Flaherty. Activated 08/12/15; Permanently closed: 12/30/22.

Clinical Trials Partnerships (CTP)

Developing Studies

21CTP.BREAST01, "MONITOR (Molecular Assessment and Identification of ctDNA and Optimizing Treatment for HR-positive, Her2-negative Metastatic Breast Cancer)". Drs. Kalinsky, Bhave, and Ali.

Breast Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	S1706	S2007	S2206	S2212	A011801	A012103	A012301	EA1211	MA39
Arnot Ogden Medical Center/Falck Cancer Center	-	-	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	-	-	-	-	12	-	-	-	-
Banner University Medical Center - Tucson	1	-	3	-	-	-	-	-	-
Baptist Mem Health Care/Mid So Minority Underserved NCORP	3	-	6	13	-	-	-	2	-
Baylor College of Medicine/Duncan Comprehensive Cancer Center	-	-	3	8	2	2	2	-	3
Boston Medical Center	-	-	-	1	6	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	1	-	-	-	-	2	-	2
Cancer Research Consortium of West Michigan NCORP	1	-	3	16	-	-	-	-	-
Cancer Research for the Ozarks NCORP	3	-	-	12	1	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	1	12	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	2	5	19	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	7	4	1	1	1	-	-
City of Hope Comprehensive Cancer Center	-	-	3	18	-	-	-	-	1
Columbia University Minority Underserved NCORP	4	-	2	1	-	-	-	-	-
CommonSpirit Health Research Institute	2	-	1	11	-	-	-	-	2
Dayton NCI Community Oncology Research Program	-	1	-	-	-	-	-	-	-
Desert Regional Medical Center	1	-	-	-	-	-	-	-	1
Essentia Health NCI Community Oncology Research Program	-	-	1	2	1	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	5	-	-	11	-	11	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	1	-	-	-	-	-
Georgia NCI Community Oncology Research Program	2	-	2	9	-	-	-	-	-
Gulf South Minority Underserved NCORP	1	-	3	9	-	1	-	1	-
Hartford Hospital	-	-	-	4	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	12	-	-	-	1	-
Heartland Cancer Research NCORP	4	-	8	28	1	-	-	-	-
Henry Ford Hospital	2	-	3	11	2	8	2	-	3
Houston Methodist Hospital	-	-	-	-	2	2	-	-	3
Instituto Nacional De Cancerologia de Mexico	-	-	-	15	-	-	-	-	-
Intermountain Medical Center	-	-	-	12	-	-	4	-	1
Kaiser Permanente NCI Community Oncology Research Program	-	-	-	24	-	-	-	-	-
Lahey Hospital and Medical Center	-	-	1	2	1	-	7	-	-
Loma Linda University Medical Center	-	-	-	4	-	-	-	-	-
Loyola University Medical Center	-	-	3	1	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	1	-	3	-	-	1	-	-	8
Miami Cancer Institute	-	-	-	5	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	4	-	6	21	-	-	-	-	-
Montana Cancer Consortium NCORP	1	-	-	9	-	-	1	-	-
Mount Sinai Hospital	-	-	2	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	7	13	-	-	-	-	-
New Mexico Minority Underserved NCORP	6	1	-	-	-	1	-	-	-

Breast Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	S1706	S2007	S2206	S2212	A011801	A012103	A012301	EA1211	MA39
Northwell Health NCORP	-	1	3	5	-	-	-	-	-
Northwestern University LAPS	1	2	1	33	1	1	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	3	-	-	10	-	-	-	-	-
Oregon Health and Science University	-	-	4	2	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	2	-	13	25	-	-	-	-	4
Regents of the University of Michigan	3	-	4	9	2	3	-	-	14
Rhode Island Hospital	-	-	-	2	-	-	-	-	-
Salem Hospital	-	-	-	-	-	-	4	-	-
South Sound Care Foundation	-	-	6	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	1	8	46	1	-	-	-	-
Sutter Cancer Research Consortium	-	-	3	11	3	-	-	-	-
The Don and Sybil Harrington Cancer Center	3	-	-	-	3	-	4	-	-
The West Clinic - Wolf River	-	-	-	25	-	-	-	-	-
Tufts Medical Center	-	-	-	1	-	-	1	-	-
UC Davis Comprehensive Cancer Center LAPS	7	-	-	-	-	3	10	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	1	3	-	2	-	-	-	-
UC San Diego Moores Cancer Center	-	-	-	-	-	-	-	-	2
UPMC Hillman Cancer Center LAPS	1	-	6	8	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	-	1	-	-	-	7
U of Alabama at Birmingham / Deep So Research Consortium LAPS	-	2	-	6	-	-	-	-	-
University of Arkansas for Medical Sciences	2	-	-	4	2	4	-	-	-
University of Colorado Cancer Center LAPS	1	-	3	4	1	-	5	-	2
University of Kansas Cancer Center - MCA Rural MU NCORP	4	-	9	18	1	3	10	-	8
University of Kentucky/Markey Cancer Center	-	-	1	1	-	-	-	-	-
University of Mississippi Medical Center	-	-	-	1	-	-	-	-	-
University of Nebraska Medical Center	-	-	-	3	-	5	1	-	-
University of Oklahoma Health Sciences Center LAPS	1	-	3	6	-	-	-	1	-
University of Rochester LAPS	1	-	-	1	-	-	4	-	-
University of Texas Health Science Center at San Antonio	-	4	8	-	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	1	2	1	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	5	-	-	-	2	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	2	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	5	12	2	-	-	4	4
Western States Cancer Research NCORP	-	-	-	-	-	-	-	-	1
Wisconsin NCI Community Oncology Research Program	1	-	1	7	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	4	32	3	-	-	-	-
ALLIANCE	18	7	39	202	-	-	-	-	-
CCTG	6	-	-	-	-	-	-	-	-
ECOG-ACRIN	11	3	58	176	-	-	-	-	-
NRG	48	-	34	118	-	-	-	-	-
Total	160	28	290	1,076	55	46	58	9	66

Breast Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	NRGBR007	NRGBR008	NRGBR009
Arnot Ogden Medical Center/Falck Cancer Center	1	-	-
Banner MD Anderson Cancer Center	-	-	-
Banner University Medical Center - Tucson	-	-	-
Baptist Mem Health Care/Mid South Minority Underserved NCORP	-	1	-
Baylor College of Medicine/Duncan Comprehensive Cancer Center	-	-	3
Boston Medical Center	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-
Cedars-Sinai Medical Center	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-
Columbia University Minority Underserved NCORP	-	-	-
CommonSpirit Health Research Institute	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-
Desert Regional Medical Center	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	7
Georgia Cares Minority Underserved NCORP	-	-	-
Georgia NCI Community Oncology Research Program	-	-	-
Gulf South Minority Underserved NCORP	-	-	-
Hartford Hospital	-	-	-
Hawaii Minority Underserved NCORP	1	-	-
Heartland Cancer Research NCORP	-	-	1
Henry Ford Hospital	-	-	2
Houston Methodist Hospital	2	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	3
Intermountain Medical Center	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	-
Lahey Hospital and Medical Center	-	-	-
Loma Linda University Medical Center	-	-	1
Loyola University Medical Center	-	-	1
Medical University of South Carolina Minority Underserved NCORP	-	-	-
Miami Cancer Institute	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-
Montana Cancer Consortium NCORP	-	-	-
Mount Sinai Hospital	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-
New Mexico Minority Underserved NCORP	-	-	-

Breast Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	NRGBR007	NRGBR008	NRGBR009
Northwell Health NCORP	2	-	-
Northwestern University LAPS	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-
Oregon Health and Science University	1	-	-
Pacific Cancer Research Consortium NCORP	-	-	-
Regents of the University of Michigan	-	-	-
Rhode Island Hospital	-	-	-
Salem Hospital	-	-	-
South Sound Care Foundation	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-
Sutter Cancer Research Consortium	6	-	1
The Don and Sybil Harrington Cancer Center	-	-	5
The West Clinic - Wolf River	-	-	2
Tufts Medical Center	-	-	-
UC Davis Comprehensive Cancer Center LAPS	1	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-
UC San Diego Moores Cancer Center	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-
U of Alabama at Birmingham / Deep S Research Consortium LAPS	-	-	-
University of Arkansas for Medical Sciences	-	-	-
University of Colorado Cancer Center LAPS	3	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	3	-	2
University of Kentucky/Markey Cancer Center	-	-	-
University of Mississippi Medical Center	-	-	-
University of Nebraska Medical Center	1	-	2
University of Oklahoma Health Sciences Center LAPS	-	-	-
University of Rochester LAPS	-	-	-
University of Texas Health Science Center at San Antonio	10	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	1
Western States Cancer Research NCORP	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-
ALLIANCE	-	-	-
CCTG	-	-	-
ECOG-ACRIN	-	-	-
NRG	-	-	-
Total	31	1	31

Cancer Control & Prevention Committees

Leadership

Cancer Care Delivery Committee Co-Chairs: Veena Shankaran, MD
 Scott D. Ramsey, MD, PhD
 Palliative Care Committee Co-Chairs: Robert S. Krouse, MD, FACS
 Marie Bakitas, DNSc, CRNP
 Prevention, Screening & Surveillance
 Committee Co-Chairs: Banu Arun, MD
 Jason A. Zell, DO
 Symptom Management & Survivorship
 Committee Co-Chairs: Michael J. Fisch, MD, MPH
 Norah Lynn Henry, MD, PhD
 Executive Officers: Katherine D. Crew, MD, MS (CCD, Prevention,
 Symptom Management)
 Virginia Sun, PhD, MSN, RN (Palliative)
 Senior Advisor: Frank L. Meyskens, Jr., MD
 Statisticians: Katherine Guthrie, PhD
 Cathy Tangen, DrPH
 Joseph M. Unger, PhD
 Kathryn B. Arnold, MS
 Amy K. Darke, MS
 Danika Lew, MA
 Sarah Colby, MS
 Cathee Till, MS
 Matt Chansky, BS
 Sara Threlkel, BS
 Administrative Lead
 Statistics & Data Management Center (SDMC): Monica Yee, CCRP

Scientific Leadership

NCORP Representative: Scott Edward Delacroix, Jr. MD
 Helen Heng-Shan Moon, MD
 Radiation Oncology Committee: Eileen P. Connolly, MD, PhD (CCD,
 Prevention)
 Kiri A. Cook, MD (Symptom Mgmt & Survivorship)
 Erin F. Gillespie, MD (Symptom Management)
 Surgery Committee: Robert S. Krouse, MD, FACS
 Translational Medicine: James (Jimmy) Rae, PhD
 Liaisons:
 Barlogie-Salmon Myeloma Committee: Charles S. Kuzma, MD
 Breast Committee: Mariya Rozenblit, MD (Survivorship)
 Helen K. Chew, MD (Symptom Management)
 Dawn Hershman, MD, MS (CCD)
 Banu Arun, MD (Prevention)
 Philip Lammers, MD
 Early Therapeutics & Rare Cancers: Lara E. Davis, MD (Survivorship)
 Jason M. Prosek, MD

Gastrointestinal Committee: Afsaneh Barzi, MD (CCD)
 Jason A. Zell, DO (Prevention)
 Vincent Chung, MD (Palliative)
 Genitourinary Committee: Clara Hwang, MD
 Sarah P. Psutka, MD
 International Liaison: Kathy S. Albain, MD
 Leukemia Committee: Stephanie B. Tsai, MD
 Lung Committee: Gary E. Goodman, MD
 Lymphoma Committee: TBD
 Melanoma Committee: Sancy Leachman, MD, PhD (Prevention)
 Recruitment and Retention Committee: Allison M. Caban-Holt, PhD
 Veterans Affairs: Yeun-Hee Anna Park, MD (Symptom Management)
 Jacqueline Ann Gesek, BSN, RN (Nursing)

Designates

Oncology Research Professionals: Amanda R. Dinsdale, MHA, CCRC
 Amy Jo Koffarnus, BS, CCRP
 Racheal Odom, MPH
 Melina D. Rodriguez, BS
 Shirley S. Sui, BS
 Samantha Wright, MS, CCRP
 Connie Szczepanek, RN, BSN
 Rachel C. Dooley, BSN, RN, OCN
 Melissa Maria Crane, BSN, RN
 Pharmaceutical Sciences Committee: Kimberly McConnell, PharmD
 Data Coordinators: Kim Carvalho, BA
 Sam Dzingile, BA
 Manny Kharbanda, BA
 Diane Liggett, BS, CCRP
 Roxanne Topacio, CCRP
 Monica Yee, BA, CCRP
 Recruitment and Retention Specialist: Jamie Sundstrom, BS
 Patient Advocates: Barbara Segarra-Vazquez, DHS (CCD)
 Hartley "Lee" M. Jones, MBA (Survivorship)
 TBD (Prevention)
 Valerie Fraser (Palliative)
 Sr. Protocol Project Manager (Cancer Care Delivery;
 Prevention): Patricia O'Kane
 Protocol Project Manager (Symptom Management): Elsie Duran
 Protocol Project Manager (Palliative Care): Andrea Garcia
 Clinical Trials Program Manager (Palliative Care;
 Symptom Management): Laura Gildner, MS
 Clinical Trials Program Manager (CCD; Prevention): Sarah Cantu

Cancer Care Delivery (CCD) Committee

Leadership

Co-Chairs: Scott D. Ramsey, MD, PhD
 Veena Shankaran, MD, MS

Time/Location

Thursday, April 30, 2026 10:30 a.m. - 12:30 p.m.
 Room: Bayview Room (Bay Level)

Agenda

NCORP Grant Renewal Updates – Dawn Hershman, MD, MS, Scott Ramsey, MD, PhD, and Veena Shankaran, MD, MS

Patient Advocate Committee Updates – Barbara Segarra-Vazquez

Presentations

“From Patient Voice to Clinical Action: ePRO-Driven Supportive Care in Ambulatory Oncology,” Eden R. Brauer, PhD, MSN, RN, UCLA Joe C. Wen School of Nursing

“Changes in Continuous Symptom and Vital Sign Reports with Unplanned Emergency Department and Hospital Stays among Patients Receiving Systemic Therapy: Results of a Pilot Study,” Scott Ramsey MD, PhD, Fred Hutch Cancer Center

“Primary Results of CREDIT (S1912CD): A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention,” Veena Shankaran, MD, Fred Hutch Cancer Center

Active Studies

S2417CD, “A Pragmatic Randomized Controlled Trial to Evaluate the Effectiveness of an Intervention Called Current Together After Cancer (CTAC) to Promote Guideline-Concordant Colorectal Cancer Surveillance”. Drs. C. Veenstra and S. Hawley. Activated: 8/1/25.

S1703, “Randomized Non-inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Breast Cancer.” Dr. M. Accordini. Activated: 7/16/18.

Developing Studies

S2424CD, “A Randomized Controlled Trial of an Intervention called Algorithm-Enabled Patients Activated in Cancer Care Through Teams (A-PACT) To Improve Goals of Care Communication for People with Cancer”. Drs. R. Parikh, C. Manz, and M. Patel.

“Optimizing Communication Around Immediate Release of Imaging Results in Oncology (ORION).” Dr. V. Shankaran.

Recently Completed Accrual Studies

S2108CD, “A Cluster Randomized Trial Comparing an Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy.” Drs. J. Rueter, M. Trivedi, B. Symington, D. Hershman, S. Ramsey. Activated: 8/22/22. Closed: 11/22/24.

Concepts in Development

CTNow clinical trial education and clinical trial referral coordination intervention for rural patients with breast, lung, or GI cancer. Dr. I. Okado.

Patient-centered Video Education Intervention to Improve Rural Cancer Care Delivery. Drs. R. Holcombe and I. Okado.

Impact of Immediate Release of Radiology Reports on Cancer Care Delivery Systems and Oncology Providers. Dr. V. Shankaran.

Closed Studies

S1912CD, “A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT).” Dr. V. Shankaran. Activated: 7/26/21. Closed: 12/16/24.

S1904, “Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ – Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE).” Dr. K. Crew. Activated: 9/1/20. (Committee: Prevention/Epidemiology). Closed: 6/14/24.

S1415CD, “A Pragmatic Trial To Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia - Trial Assessing CSF Prescribing, Effectiveness and Risk (TrACER).” Drs. S. Ramsey, D. Hershman, G. Lyman, et al. Activated: 10/7/16. Closed: 4/15/20.

S1417CD, “Implementation of a Prospective Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer.” Dr. V. Shankaran. Activated: 4/15/16. Closed: 2/1/19.

Substudies (Economic Analyses / Cost Effectiveness from NCTN trials)

S1806, “Healthcare Cost Comparison of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle-invasive Bladder Cancer,” Dr. R. Vaidya, Dr. J. Unger

Cancer Care Delivery (CCD) Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	S1703	S1912CD	S2108CD	S2417CD	A191901	A231901CD	EAQ221CD	EAQ222CD
Banner University Medical Center - Tucson	1	-	-	-	-	-	-	-
Baptist Mem Health Care/Mid So Minority Underserved NCORP	-	-	-	-	-	1	-	-
Bay Area Tumor Institute NCORP	-	1	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	32	-	-	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	9	-	-	-	1	-	-
Cancer Research for the Ozarks NCORP	-	11	44	2	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	18	19	61	-	1	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	11	2	132	-	-	-	-	-
Columbia University Minority Underserved NCORP	29	10	-	-	-	-	-	-
Columbus NCI Community Oncology Research Program	4	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	12	2	54	-	-	-	-	-
Cotton O'Neil Cancer Center / Stormont Vail Health	1	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	3	1	-	-	-	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	132	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	12	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	4	-	31	-	-	-	-	-
Gulf South Minority Underserved NCORP	7	1	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	12	14	100	-	-	-	-	27
Heartland Cancer Research NCORP	29	7	237	2	-	-	-	-
Henry Ford Hospital	-	-	-	-	4	-	-	-
Instituto Nacional De Cancerologia de Mexico	2	-	-	-	-	-	-	-
Instituto Nacional de Enfermedades Neoplasicas	8	-	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	6	17	-	-	-	-	3	-
Lahey Hospital and Medical Center	4	-	-	-	-	-	-	-
Loyola University Medical Center	4	-	-	-	8	-	-	-
Michigan Cancer Research Consortium NCORP	26	21	94	-	-	-	-	-
Montana Cancer Consortium NCORP	5	7	69	3	-	-	-	-
Mount Sinai Hospital	9	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	6	2	-	2	-	-	-	-
Nevada Cancer Research Foundation NCORP	2	2	-	-	1	-	-	-
New Mexico Minority Underserved NCORP	17	28	-	-	-	-	-	-
Northwell Health NCORP	-	3	-	-	-	-	-	-
Our Lady of the Lake Hospital	-	2	-	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	15	30	-	-	-	-	-	-
Riverside Methodist Hospital	2	-	-	-	-	-	-	-
Salem Hospital	4	-	-	-	-	-	-	-
South Sound Care Foundation	-	-	-	-	22	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	6	37	18	-	-	-	1	-
UC Davis Comprehensive Cancer Center LAPS	2	-	-	-	3	-	-	-
Universidad de la Republica - Facultad de Medicina	2	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	5	-	-	-	-	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	12	11	95	-	-	-	-	4
University of Rochester LAPS	4	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	2	-	-	-
Upstate Carolina Consortium Community Oncology Research Prog	-	10	73	5	-	-	-	-
Western States Cancer Research NCORP	-	2	-	-	1	-	-	2
Wisconsin NCI Community Oncology Research Program	8	4	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	55	-	-	-	-	-	-	-
ALLIANCE	21	19	81	2	-	-	-	-
ECOG-ACRIN	31	31	63	-	-	-	-	-
NRG	24	16	-	-	-	-	-	-
Total	443	331	1,284	16	42	2	4	33

Palliative Care Committee

Leadership

Co-Chairs: Robert S. Krouse, MD
 Marie Bakitas, DNSc, CRNP

Time/Location

Thursday, April 30, 2026 8:00 a.m. - 10:00 a.m.
 Room: Bayview Room (Bay Level)

Agenda

1. Welcome and Introductions: Drs. Krouse and Bakitas

2. Committee Liaison Updates:

- Executive Officer: Virginia Sun, PhD
- Patient Advocates: Valerie Fraser and Lee Jones
- ORP Liaison: Shirley Sui

3. Updates on Studies:

Active Studies

S1501, "Prospective Observational Cohort Study of Patients with Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity." Drs. Floyd, Leja, and Fabian. Reopened 11/1/25.

S2408, "A Randomized Phase III Blinded Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula." Drs. Sham and Pillarisetty. Reopened 2/18/26.

S2424CD, "Algorithm-Enabled Patients Activated in Cancer Care Through Teams (A-PACT) to Improve Goals of Care Communication for People with Cancer." Drs. R. Parikh, M. Patel, and C. Manz.

Developing Studies

S2415 "Acupuncture to Decrease Symptom Burden in Patients with Metastatic Breast Cancer." Dr. Greenlee.

Secondary Studies

S1316, "Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction." Drs. Krouse and Deneve. Activated: 3/9/15. Permanently Closed: 5/15/20.

Jyotsana Parajuli Project Updates:

- Development and Initial Validation of a Palliative Care Readiness Tool for Older Adults with Cancer (NIH/NIA R15 AG081886-01A1)
- Participation of Older Adults from Underrepresented Backgrounds in SWOG Clinical Trials (SWOG ChEER Program)

4. Virtual Retreat Follow-Up

- Summary of key discussion points
- Review of top concept ideas identified during retreat
- Concept Spotlight (Brief Presentations)
 - Concept 1
 - Concept 2
 - Concept 3
- Discussion and next steps for concept development

5. Closing Remarks

Closed Studies

S1820, "A Randomized Phase II Trial of the Altering Intake, Managing Symptoms Intervention for Bowel Dysfunction in Rectal Cancer Survivors (AIMS-RC)." Dr. Sun. Activated: 12/9/19. Closed to Accrual as of 4/12/22. Permanently Closed: 4/12/22.

Palliative Care Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	S1501	S2408
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	7	-
CWRU Case Comprehensive Cancer Center LAPS	20	-
Cancer Research Consortium of West Michigan NCORP	-	7
Cancer Research for the Ozarks NCORP	11	-
City of Hope Comprehensive Cancer Center	52	-
Columbia University Minority Underserved NCORP	2	-
CommonSpirit Health Research Institute	1	-
Essentia Health NCI Community Oncology Research Program	-	1
Fred Hutchinson Cancer Research Center LAPS	4	2
Georgia NCI Community Oncology Research Program	15	-
Gulf South Minority Underserved NCORP	2	-
Heartland Cancer Research NCORP	17	4
Henry Ford Hospital	7	-
Instituto Nacional de Enfermedades Neoplasicas	5	-
Kaiser Permanente NCI Community Oncology Research Program	1	-
King Faisal Specialist Hospital and Research Centre	3	-
Lahey Hospital and Medical Center	7	-
Loyola University Medical Center	9	-
MU Health Care Goldschmidt Cancer Center	5	-
Medical University of South Carolina Minority Underserved NCORP	1	-
Michigan Cancer Research Consortium NCORP	11	-
Moffitt Cancer Center	35	-
Montana Cancer Consortium NCORP	1	-
NCORP of the Carolinas (Prisma Health NCORP)	2	-
National Cancer Center-Korea	2	-
New Mexico Minority Underserved NCORP	12	-
Northwestern University LAPS	-	6
Ohio State University Comprehensive Cancer Center LAPS	-	3
Oregon Health and Science University	1	-
Our Lady of the Lake Hospital	2	-
Regents of the University of Michigan	12	-
Southeast Clinical Oncology Research Consortium NCORP	2	-
UC Davis Comprehensive Cancer Center LAPS	2	-
UC San Diego Moores Cancer Center	-	5
USC Norris Comprehensive Cancer Center LAPS	4	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	1
University of Kansas Cancer Center - MCA Rural MU NCORP	7	-
University of Kentucky/Markey Cancer Center	-	7
University of Mississippi Medical Center	1	-
University of Nebraska Medical Center	-	2
Wayne State University - Karmanos Cancer Institute LAPS	6	-
Western States Cancer Research NCORP	2	-
Wisconsin NCI Community Oncology Research Program	-	5
ALLIANCE	39	4
ECOG-ACRIN	45	8
NRG	30	2
Total	385	57

Prevention, Screening, & Surveillance Committee

Leadership

Co-Chairs: Banu Arun, MD
 Jason A. Zell, DO

Time/Location

Thursday, April 30, 2026 4:30 p.m. - 6:30 p.m.
 Room: Bayview Room (Bay Level)

Agenda

1. Welcome and Opening Comments Banu Arun, MD & Jason Zell, DO

2. Frank & Linda Meyskens Lectureship

Integrated Precision Prevention in Early-Onset Colorectal Cancer: From Genetic, Lifestyle, and Environmental Risk Factors to Microbiome Modulation. Ulrike Peters, PhD, MPH, Professor and Associate Director, Public Health Sciences Division, Fred Hutchinson Cancer Institute

3. Closed Studies

S0820, "A Double-Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)." Drs. J. Zell, P. Brown, M.P. Lance, et al. Activated: 3/1/13. Closed: 6/30/23.

S1823, "A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors". Drs. C. Nichols and L. Nappi. Activated: 6/1/20. Closed: 5/20/24.

S1904, "Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ – Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)." Drs. K. Crew, R. Kukafka, et al. Activated 9/1/20. Closed 6/14/24.

4. Concepts in Development

A Multicenter, Double-Blind, Placebo-Controlled Randomized Trial of Finasteride to Prevent Recurrence in Patients with Low-Grade Intermediate-Risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) FIN-BC. Drs. S. Psutka and P. Hensley.

DCISionRT Biomarker for DCIS Concept. Dr. Eilleen Connolly.

QuitTech: A Technology-Enhanced Smoking Cessation Program for Cancer Patients and Survivors. Dr. Irene Tami-Maury, DMD, DrPH, MSc

5. Patient Advocate Update

6. Group Discussion

7. Other Group Prevention Studies with SWOG Accrual

CTSU/EA8184, "A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers." Dr. R. Kopp. Activated: 5/10/21.

CTSU/NRG-CC005, "FORTE (Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps)". Dr. L. Kachnic. Activated: 10/6/21.

CTSU/NRG-CC008, "A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCK]." Activated: 6/23/20

CTSU A212102, "Blinded Reference Set for Multicancer Early Detection Blood Tests." Dr. J. McGuinness. Activated: 8/1/22.

CTSU/EA2185, "Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers"/ Activated: 1/16/20. Temporarily Closed to Accrual as of 3/1/24.

Prevention, Screening, and Surveillance Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	A211801	A212102	EA1151	EA2185	EA8184	NRGCC005	NRGCC008
Arnot Ogden Medical Center/Falck Cancer Center	-	-	263	-	-	-	-
Audie L Murphy VA Hospital	-	63	-	-	4	2	-
Banner MD Anderson Cancer Center	-	-	1	-	-	-	-
Banner University Medical Center - Tucson	-	-	56	-	-	-	-
Baptist Mem Health Care/Mid So Minority Underserved NCORP	-	-	8	-	-	-	-
Baylor College of Medicine/Duncan Comprehensive Cancer Center	-	-	-	3	-	-	6
CWRU Case Comprehensive Cancer Center LAPS	-	2	290	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	2	-	-	-	-
Duke University - Duke Cancer Institute LAPS	-	-	-	-	1	-	-
Essentia Health NCI Community Oncology Research Program	-	-	100	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	105	-	-	-	-
Gulf South Minority Underserved NCORP	-	5	-	-	-	-	2
Hawaii Minority Underserved NCORP	-	-	80	-	-	-	-
Henry Ford Hospital	-	4	133	-	-	-	-
Kansas City Veterans Affairs Medical Center	-	14	-	-	-	11	-
Loyola University Medical Center	-	4	-	-	-	-	-
Malcom Randall Veterans Administration Medical Center	-	-	-	-	-	19	-
Massachusetts Veterans Epidemiology Research and Info Center	-	30	-	8	-	64	-
Medical University of South Carolina Minority Underserved NCORP	-	2	4	-	3	-	-
Memorial Hermann Texas Medical Center	-	-	8	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	463	-	-	-	-
Northwell Health NCORP	-	-	-	-	-	-	1
Oregon Health and Science University	-	-	-	4	3	14	3
Our Lady of the Lake Hospital	-	3	-	-	-	-	-
Regents of the University of Michigan	1	-	-	-	-	-	-
The Don and Sybil Harrington Cancer Center	-	6	-	-	-	-	-
Tulane University School of Medicine	-	-	2	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	-	1	1	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	124	-	-	-	-	-
UC San Diego Moores Cancer Center	-	-	-	1	-	-	-
University of Arkansas for Medical Sciences	-	-	389	3	-	-	-
University of Colorado Cancer Center LAPS	-	5	2	-	-	16	-
University of Kentucky/Markey Cancer Center	-	-	9	-	-	-	-
University of Texas Health Science Center at San Antonio	-	20	-	-	-	-	1
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	3	-
Upstate Carolina Consortium Comm Oncology Research Program	-	-	619	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	8	-	-	-	-
Western States Cancer Research NCORP	-	1	73	-	-	-	-
Total	1	283	2,615	20	12	129	13

Symptom Management & Survivorship Committee

Leadership

Co-Chairs: Michael J. Fisch, MD, MPH
 Norah Lynn Henry, MD, PhD

Time/Location

Thursday, April 30, 2026 2:00 p.m. - 4:00 p.m.
 Room: Bayview Room (Bay Level)

Agenda

Welcome & Introductions: Drs. Fisch and Henry

Patient Advocate Update: Lee Jones

Research Update:

A Comparison of Minimally Important Difference Definitions for Quality of Life in Four Clinical Trials (presented at ISOQOL 2025): Dr. Salene Jones

Updates on Concepts in Development

Updates on Active Trials

Brainstorming Session - Future Directions of the SMS Committee: Fostering Collaborations to Develop Concepts and Explore Secondary Analyses

Concepts in Development

S2435, "App-Supported Sleep Coaching for Cancer Survivors and Their Bedroom Partners." Study Chair: Dr. Rina S. Fox.

SXXXX, "RECOG: RElugolix vs. GnRH agonist: Evaluation of COGNitive outcomes in prostate cancer." Study Chairs: Drs. Clara Hwang and Laura Graham

SXXXX, "Vitamin D for Prevention of Taxane-Induced Peripheral Neuropathy." Study Chairs: Drs. Meghna Trivedi and Daniel Hertz.

Active Studies

S2013, "Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study." Study Chairs: Drs. Krishna S. Gunturu and Dawn L. Hershman. Activated: 8/16/21.

S2205, "ICE COMPRESS: Randomized Trial of Limb Cryocompression Versus Continuous Compression Versus Low Cyclic Compression for the Prevention of Taxane-Induced Peripheral Neuropathy." Study Chairs: Drs. Melissa K. Accordino and Katheryn Pennington. Activated: 3/16/23.

Closed Studies

S1600, "A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes (SIMMune)." Study Chairs: Drs. Jill Hamilton-Reeves and Jeffrey M. Holzbeierlein. Activated: 2/21/19; Permanently closed: 10/20/23.

S1614, "A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors." Drs. Jessica Hwang, Anna S. Lok, Adam Gehring, and Jordan Feld. Activation: 2/21/19; Permanently closed: 11/15/22.

S1714, "A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients." Study Chairs: Drs. Meghna S.Trivedi, Dawn L. Hershman, and Thomas H. Brannagan. Activated: 3/1/19; Permanently closed: 11/15/21.

S2010, "A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence with Endocrine Therapy in Young Women with Stage I-III Breast Cancer (ASPEN)." Study Chairs: Drs. N. Lynn Henry and Dawn L. Hershman. Activated: 1/17/23; Permanently closed: 1/15/25.

Other SWOG Studies with Symptom Management and Survivorship Component

Breast

S1706, "A Phase II Randomized, Double-Blinded, Placebo-Controlled Trial of Olaparib Administered Concurrently with Radiotherapy for Inflammatory Breast Cancer." Study Chairs: Drs. Reshma Jags, Pavani Chalasani, Jean Moran, and Corey Speers. Activated: 9/12/18; Permanently closed: 7/1/24.

Cancer Care Delivery

S1703, "Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (Stmddm) Versus Usual Care in Patients with Metastatic Hormone Receptor Positive Her-2 Negative Breast Cancer." Study Chairs: Drs. Melissa K. Accordino, Dawn Hershman, and Scott D. Ramsey. Activated: 7/16/18.

S1904, "Cluster Randomized Controlled Trial of Patient and Provider Decision Support To Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma in Situ - Making Informed Choices on Incorporating Chemoprevention into Care

Symptom Management & Survivorship Committee

(MiCHOICE).” Study Chairs: Drs. Katherine D. Crew, Rita Kukafka, Dawn L. Hershman, Parijatham Thomas, and Allison Caban-Holt. Activated: 9/1/20; Permanently closed: 6/14/24.

S1912CD, “A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT).” Study Chairs: Drs. Veena Shankaran, Ruth Carlos, Dawn L. Hershman, Shelby Langer, and Scott D. Ramsey. Activated: 7/26/21; Permanently closed: 12/16/24.

S2108CD, “A Cluster Randomized Trial Comparing an Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy.” Study Chairs: Drs. Jens Rueter, Meghna S. Trivedi, Banu E. Symington, Paul Tseng, and Dawn L. Hershman. Activated: 8/22/22; Permanently closed: 11/22/24.

GU

S1802, “Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer.” Study Chairs: Drs. Brian F. Chapin, Ana Aparicio, and Richard Valicent. Activated: 9/17/18.

S1806, “Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer.” SWOG Study Chair: Drs. Parminder Singh, Seth P. Lerner, and Sameer Jhavar. Activated: 4/19/18; Permanently closed: 4/1/24.

GI

S0820, “A Double-Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES).” Study Chairs: Drs. Jason A. Zell, Lance, and Powel H. Brown. Activated: 3/1/13; Permanently closed: 6/30/23.

Leukemia

S1925, “Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study.” Study Chairs: Drs. Deborah Stephens, Brian Hill, and Mazyar Shadman. Activated: 12/14/20.

Lung

S1914, “A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC#783608) + SBRT Versus SBRT Alone in High Risk,

Early Stage NSCLC.” Study Chairs: Drs. Megan E. Daly, Charles B. Simone, II, Karen Kelly, and Jeffrey D. Bradley. Activated: 3/25/20.

S1827, “MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK).” Study Chairs: Drs. Chad Rusthoven, Paul Brown, Jeffrey S. Wefel, Abhijit Patel, and N. Lynn Henry. Activated: 1/10/20; Permanently closed: 12/15/25.

Lymphoma

S1826, “A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age \geq 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma.” Study Chairs: Drs. Alex F. Herrera and Jonathan Friedberg. Activated: 7/19/19; Permanently closed: 12/1/22.

S1918, “A Phase II/III Randomized Study of R-miniCHOP with or without Oral Azacitidine (CC-486) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIb Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements.” Study Chairs: Drs. Elizabeth Brem and Sonali Smith. Activated: 3/19/21; Temporarily closed: 4/1/25.

Myeloma

S1803, “Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study).” Study chairs: Drs. Amrita Krishnan, Saurabh Chhabra, and Natalie S. Callander. Activated: 6/27/19; Step 1 Closed to accrual: 1/15/25.

NCTN Studies

CTSU/NRG-GI004, “Colorectal Cancer Metastatic dMMR Immunotherapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/ Bevacizumab Combination Chemotherapy with or Without Atezolizumab or Atezolizumab Monotherapy in the First Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer.” Dr. Caio Max Sao Pedro Rocha Lima and Michael Overman. Activated: 11/7/17; Temporarily closed: 6/4/20; Reactivated: 1/29/21; Permanently closed: 9/2/25.

Symptom Management & Survivorship Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	S2010	S2013	S2205	A211901	A222004	ACCL1931	EAQ202	EAQ211
Audie L Murphy VA Hospital	-	26	-	-	-	-	-	-
Banner University Medical Center - Tucson	-	5	-	-	-	-	-	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	-	-	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	2	-	1	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	12	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	4	168	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	1	19	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	26	45	38	-	1	-	-	-
Columbus NCI Community Oncology Research Program	-	37	-	-	-	-	-	-
CommonSpirit Health Research Institute	13	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	-	-	-	-	-	1
Georgia Cares Minority Underserved NCORP	-	35	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	20	74	-	2	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	9	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	4	-	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	9	9	43	-	-	-	-	-
Heartland Cancer Research NCORP	25	268	-	-	-	-	-	-
Henry Ford Hospital	-	29	4	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	27	13	-	-	-	-	-	-
Instituto Nacional de Enfermedades Neoplasticas	24	-	-	-	-	-	-	-
Intermountain Medical Center	-	3	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	28	85	-	-	-	-	-	-
Lahey Hospital and Medical Center	12	63	-	-	-	-	-	-
Massachusetts Veterans Epidemiology Research and Information Center	-	63	-	-	-	-	-	-
Mercy Medical Center - Des Moines	-	9	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	20	14	-	-	-	-	-	-
Moffitt Cancer Center	10	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	7	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	-	-	39	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	3	-	4	-
New Mexico Minority Underserved NCORP	21	-	26	-	-	-	-	-
Northwestern University LAPS	7	-	-	-	-	-	-	-

Symptom Management & Survivorship Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	S2010	S2013	S2205	A211901	A222004	ACCL1931	EAQ202	EAQ211
Oregon Health and Science University	-	12	-	-	-	1	-	-
Our Lady of the Lake Hospital	-	25	-	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	11	3	-	-	-	-	-	-
Regents of the University of Michigan	31	-	-	-	-	-	-	-
Rhode Island Hospital	-	-	17	-	-	-	-	-
STCC at DHR Health Institute for Research and Development	18	55	21	7	-	-	-	-
Salem Hospital	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	2	185	87	-	-	-	-	-
Stanford Cancer Institute Palo Alto	-	-	-	-	-	5	-	4
The Don and Sybil Harrington Cancer Center	10	4	-	-	1	-	-	-
Tufts Medical Center	-	-	-	-	-	-	1	-
UC Davis Comprehensive Cancer Center LAPS	7	13	-	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	6	-	-	-	-	-	-
UC San Diego Moores Cancer Center	2	2	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	5	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	12	-	-	-	-	-	-
Universidad de la Republica - Facultad de Medicina	4	22	-	-	-	-	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-	6	-	-	-	-	-
University of Arkansas for Medical Sciences	6	25	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	3	38	-	-	-	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	18	88	22	1	-	2	-	2
University of Kentucky/Markey Cancer Center	-	-	-	-	-	-	-	-
University of Mississippi Medical Center	1	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	2	-	-	-	-	-	-	-
University of Rochester LAPS	-	-	-	-	-	-	-	12
University of Texas Health Science Center at San Antonio	17	53	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	1	3	-	6	2	-	-	-
Upstate Carolina Consortium Community Oncology Research Program	-	-	23	-	-	-	-	-
Western States Cancer Research NCORP	-	1	4	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	8	33	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	3	-	-	-	-	-
ALLIANCE	42	372	76	-	-	-	-	-
ECOG-ACRIN	37	125	13	-	-	-	-	-
NRG	87	291	139	-	-	-	-	-
Total	565	2,361	523	16	7	8	44	19

Symptom Management & Survivorship Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	NRGCC010	NRGCC011
Audie L Murphy VA Hospital	-	-
Banner University Medical Center - Tucson	-	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	2
Cancer Research Consortium of West Michigan NCORP	-	-
Cancer Research for the Ozarks NCORP	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-
Columbia University Minority Underserved NCORP	-	-
Columbus NCI Community Oncology Research Program	-	-
CommonSpirit Health Research Institute	-	-
Dayton NCI Community Oncology Research Program	-	1
Essentia Health NCI Community Oncology Research Program	-	-
Georgia Cares Minority Underserved NCORP	-	-
Georgia NCI Community Oncology Research Program	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-
Gulf South Minority Underserved NCORP	13	-
Hawaii Minority Underserved NCORP	-	-
Heartland Cancer Research NCORP	-	-
Henry Ford Hospital	-	-
Instituto Nacional De Cancerologia de Mexico	-	-
Instituto Nacional de Enfermedades Neoplasicas	-	-
Intermountain Medical Center	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-
Lahey Hospital and Medical Center	-	4
Massachusetts Veterans Epidemiology Research and Information Center	-	-
Mercy Medical Center - Des Moines	-	-
Michigan Cancer Research Consortium NCORP	-	-
Moffitt Cancer Center	-	-
Montana Cancer Consortium NCORP	-	-
Mount Sinai Hospital	-	2
NCORP of the Carolinas (Prisma Health NCORP)	-	-
Nevada Cancer Research Foundation NCORP	-	-
New Mexico Minority Underserved NCORP	-	-
Northwestern University LAPS	-	-

Symptom Management & Survivorship Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	NRGCC010	NRGCC011
Oregon Health and Science University	-	-
Our Lady of the Lake Hospital	-	-
Pacific Cancer Research Consortium NCORP	-	-
Regents of the University of Michigan	-	-
Rhode Island Hospital	-	-
STCC at DHR Health Institute for Research and Development	-	-
Salem Hospital	-	12
Southeast Clinical Oncology Research Consortium NCORP	-	-
Stanford Cancer Institute Palo Alto	-	-
The Don and Sybil Harrington Cancer Center	-	-
Tufts Medical Center	-	-
UC Davis Comprehensive Cancer Center LAPS	-	2
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-
UC San Diego Moores Cancer Center	-	-
UPMC Hillman Cancer Center LAPS	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-
Universidad de la Republica - Facultad de Medicina	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-
University of Arkansas for Medical Sciences	-	-
University of Colorado Cancer Center LAPS	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	12
University of Kentucky/Markey Cancer Center	-	3
University of Mississippi Medical Center	-	-
University of Oklahoma Health Sciences Center LAPS	2	-
University of Rochester LAPS	-	-
University of Texas Health Science Center at San Antonio	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-
Upstate Carolina Consortium Community Oncology Research Program	-	-
Western States Cancer Research NCORP	-	-
Wisconsin NCI Community Oncology Research Program	-	-
Yale University - Yale Cancer Center LAPS	-	-
ALLIANCE	-	-
ECOG-ACRIN	-	-
NRG	-	-
Total	15	38

Early Therapeutics & Rare Cancers Committee

Leadership

Chair: Razelle Kurzrock, MD
 Vice-Chair: Young Kwang Chae, MD, MPH
 Executive Officer: Neeraj Agarwal, MD
 Statisticians: Megan Othus, PhD
 Anna B. Moseley, MS
 Sara Threlkel, BS

Designates

Data Coordinator: Christine Magner
 Veterans Affairs: Jimmy Ruiz, MD
 Oncology Research Professionals: Adam Platt, BS
 Pharmaceutical Science: Craig Elg, PharmD
 Sun "Coco" Yang, PharmD, PhD
 Patient Advocate: TBD
 Protocol Project Manager: Catrina De Los Santos-Mireles
 Protocol Project Manager: Erin Rogers, MS (comboMATCH)
 Clinical Trials Program Manager: Laura Gildner, MS
 Early Therapeutics Liaisons
 Breast Committee Liaison: Stephanie L. Graff, MD
 Cancer Control Liaison: Jason M. Prosek, MD
 Lara E. Davis, MD (Survivorship)
 Genitourinary Committee Liaison: Parminder Singh, MD
 Imaging: TBD
 Lung Committee Liaison: Shirish M. Gadgeel, MD
 Lymphoma Committee Liaison: Nasheed Mohammad Hossain, MD
 Melanoma Committee Liaison: TBD
 Myeloma Committee Liaison: Frits van Rhee, MD, PhD

Time/Location

Thursday, April 30, 2026 9:00 a.m. - 11:00 a.m.
 Room: Seacliff AB (Bay Level)

Agenda

9:00 - 9:10 am Welcome and Introduction - Razelle Kurzrock, MD
 9:10 - 9:30 am SN2426, "A Randomized Phase II Study of Amivantamab Versus Cetuximab in Immunocompromised Participants with Recurrent Inoperable or Metastatic Cutaneous Squamous Cell Carcinoma
 21CTP.HN01, "CAPT-HN-A Phase II Study of Combined Amivantimab, Carboplatin, and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer - Paul Swiecki, MD

9:30 - 9:50 am CNS Working Group and DART CNS Data - Manmeet Ahluwalia, MD
 9:50 - 10:10 am S2012, "Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas" - David Zhen, MD
 10:10 - 10:30 am Overview of Clinical Outcomes of DART - Sandip Patel, MD
 10:30 - 10:40 am Updates from Sarcoma Working Group - Lara Davis, MD
 10:40 - 10:50 am MD Anderson Cancer Center, NCI CIMAC (Cancer Immune Monitoring and Analysis Centers) Updates on S1609: Treatment with Ipilimumab and Nivolumab for Rare Cancers (DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors) - Luisa Maren Solis Soto, MD
 10:50 - 11:00 am Wrap Up - Razelle Kurzrock, MD

Active Studies

SN2426, "A Randomized Phase II Study of Amivantamab (JNJ-61186372) and hyaluronidase (rHuPH20) versus Cetuximab in Immunocompromised Participants with Recurrent Inoperable or Metastatic Cutaneous Squamous Cell Carcinoma." Dr. Swiecicki, Geiger (NRG Study Chair) Activated: 1/28/26.

S2012, "Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)." Drs. Zhen, Chiorean, Burgess, Swisher. Activated: 12/2/21.

CTS/A071401, "Phase II Trial of SMO/AKT/NF2/CDK Inhibitors in Progressive Meningiomas with SMO/AKT/NF2/CDK Pathway Mutations." Dr. Brastianos. SWOG Champion: Dr. Piccioni. Activated: 8/28/2015. New patient registration (Step 1) to the NF2, CDKN2A, CDK4, CDK6, CCND1, CCND2, CCND3, and CCNE1 Cohort (Abemaciclib Cohort) is closed to accrual as of 10/3/22.

CTS/A092001, "Phase 2 Randomized Trial of Neoadjuvant or Palliative Chemotherapy with or Without Immunotherapy for Peritoneal Mesothelioma." SWOG Champion: Dr. P.S.K. Raghav. Activated: 10/15/21.

Early Therapeutics & Rare Cancers Committee

CTSU/AGCT1531, "A Phase III Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors." SWOG Champion: Dr. D'Souza Activated: 5/8/17. Stratum 2 is temporarily closed to accrual 12/17/24.

CTSU/AOST2031, "A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma." SWOG Champion: Dr. Hofstetter. Activated: 2/15/22

CTSU/AOST2032, "A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma." SWOG Champion: Dr. J. A. Livingston. Activated: 2/17/23 Temporarily Closed to Accrual as of 9/6/23

CTSU/ HN.11 (CCTG-HN11), "SPECT-CT Guided Elective Contralateral Neck Treatment (SELECT) for Patients with Lateralized Oropharyngeal Cancer: A Phase III Randomized Controlled Trial SWOG." Champion: Dr. Paul Swiecicki. Activated: 9/29/22

Developing Studies

S2505, "Phase III Randomized Study Testing Non-Inferiority of Short-Course Ultra-Fractionated Radiation (UHRT-5) Versus Standard Fractionation (RT-25) for High-Risk, Resectable Soft Tissue Sarcoma." Dr. Harris

Closed Studies

CTSU/A071702, "A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hyper-mutated Recurrent Glioblastoma." SWOG Champion: Dr. M. Ahluwalia. Activated: 10/30/20. Pre-Registration is temporarily Closed to accrual 12/12/23. Closed: 6/2/25.

CTSU/EA2183, "A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma." Dr. Uboho. SWOG Champion: Dr. Saeed. Activated: 2/6/20. Closed: 5/23/25:

CTSU/A071601, "Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas." Dr. Brastianos. SWOG Champion: Dr. Ahluwalia. Activated: 8/4/17. Temporarily Closed (Cohort A): 9/8/20. Closed: 5/10/24

S1609, "DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors." Drs. Patel, Chae, and Kurzrock. Activated: 1/13/17. Closed: 3/15/23.

CTSU/NRG-GY006, "A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women

with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer." Dr. Leath. SWOG Champion: Dr. Robinson. Activated: 1/15/16. Closed: 9/22/22

CTSU/NRG-GY020, "A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer." Dr. Backes. SWOG Champion: Dr. Robinson. Activated: 2/7/20. Closed: 8/29/22.

NCICOVID, "NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study." Dr. Karim. Activated: 5/21/20. Closed: 2/1/22.

CTSU/NRG-GY009, "A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer." Dr. O'Cearbhaill. SWOG Champion: Dr. Robinson. Activated: 5/12/17. Closed 10/14/21

CTSU/NRG-HN007, "An Open-Label, Phase III Study of Platinum-Gemcitabine with or without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma." Dr. Brigitte B. Y. Activated: 9/8/20; Closed: 10/28/21

CTSU/EAY131, "Molecular Analysis for Therapy Choice (MATCH)." Activated: 8/12/2015. Closed: 12/23/22

CTSU/NRG-BN007, "A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab versus Temozolomide in Patients with Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma." Dr. Lassman. SWOG Champion: Dr. Ahluwalia. Activated: 8/6/20. Closed: 3/29/23.

CTSU/EA3163, "Phase II Randomized Trial of Neoadjuvant Chemotherapy Followed by Surgery and Post-Operative Radiation versus Surgery and Post-Operative Radiation for Organ Preservation of T3 and T4a (and Selected T4b) Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)." Dr. Saba. SWOG Champion: Dr. Swiecicki. Activated: 3/28/18. Closed: 11/7/23

Proposed Studies

NRG-BN1803, "NRG-COG Phase II Trial of Radiation Plus Concurrent and Adjuvant ONC201 for Newly Diagnosed, H3 K27M-Mutant Gliomas." SWOG Champion: Dr. Ahluwalia.

Early Therapeutics & Rare Cancers Committee

NRG-OV1821, "A Randomized Phase II Trial of Olaparib Versus Olaparib + Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer." Dr. Robinson.

NRG-BN1855, "A Randomized Phase II/III Open Label Study of Ipilimumab and Nivolumab Vs Te-mozolomide in Patients with Newly Unmethylated MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Glioblastoma." Dr. M. Ahluwalia.

NRG-HN1854, "An Open-label, Phase III Study of Platinum-Gemcitabine with or Without Nivolumab in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma." Dr. P. Swiecicki.

NRG-UC1805, "Randomized Phase III Trial of Radiation +/- Pembrolizumab for High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer." Dr. W. Robinson.

ComboMatch

Proposed Studies

EAY191-S9, "Phase 2 study of Inavolisib in combination with Ribociclib in PIK3CA aberrated Head & Neck + Endometrial cancers." Drs. B. Nelson and J. Rodon.

Developing Studies

EAY191-S7, "A Phase 2 Study Investigating Safety and Efficacy of Trastuzumab Deruxtecan (DS8201/T-DXd) and ATR Inhibitor, Ceralasertib (AZD6738) in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Advanced Solid Tumors." Dr. K. Raghav.

Closed Studies

EAY191-S3, "Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors." Drs. R. Basho and H. Mahdi. Activated: 3/6/23. Closed: 12/18/25.

Clinical Trials Partnerships (CTP)

Active Studies

21CTP.HN01, CAPT-HN: "A Phase II Study of Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer." Drs. Swiecicki, Rodriguez, and Brenner. Activation: 9/15/25

Early Therapeutics & Rare Cancers Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	EAY191-S3	S2012	A071401	AGCT1531	EAY191	EAY191A3	EAY191A6	EAY191E4
Baylor College of Medicine/Duncan Comp Cancer Center	-	1	-	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	1	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	2	-	-	-	-	-	-
Carolinas Medical Center/Levine Cancer Institute	-	5	-	-	-	-	-	-
Cedars-Sinai Medical Center	2	-	-	-	5	-	-	-
CommonSpirit Health Research Institute	-	1	1	-	-	-	-	-
Duke University - Duke Cancer Institute LAPS	1	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	16	-	-	-	-	-	-
Froedtert and the Medical College of Wisconsin LAPS	-	1	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	3	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	1	-	-	1	-	1	-
Heartland Cancer Research NCORP	-	1	-	-	-	-	-	-
Henry Ford Hospital	-	2	1	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	6	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	1	4	-	-	-	-	-	-
Moffitt Cancer Center	-	9	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	1	-	-	-	-
Northwestern University LAPS	-	5	1	-	-	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	10	-	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	1	1	-	-	-	-	-	-
Regents of the University of Michigan	-	2	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	1	-	-	-	-	-	-
The Don and Sybil Harrington Cancer Center	-	-	-	1	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	1	-	4	-	1	3
UC San Diego Moores Cancer Center	-	-	2	2	1	-	-	-
University of Colorado Cancer Center LAPS	-	-	1	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	3	-	-	-	10	2	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	1	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	2	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	3	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	10	2	-	-	-	-	-
ALLIANCE	6	21	-	-	-	-	-	-
ECOG-ACRIN	9	14	-	-	-	-	-	-
NRG	10	10	-	-	-	-	-	-
Total	33	133	9	4	21	2	2	3

Gastrointestinal Committee

Leadership

Chair: Philip A. Philip, MD, PhD, FRCP
 Vice-Chair: Elena Gabriela Chiorean, MD, FASCO
 Executive Officer: Hagen Kennecke, MD, MHA
 Statisticians: Katherine A. Guthrie, PhD
 Sarah Colby, MS
 Sara Threlkel, BS

Scientific Leadership

Gastroesophageal: Syma Iqbal, MD
 Zev A. Wainberg, MD
 Pancreatic: Davendra P.S. Sohal, MD
 Andrew M. Lowy, MD (Surgical representative)
 Hepatobiliary: Anthony B. El-Khoueiry, MD
 Rachna T. Shroff, MD
 Syed A. Ahmad, MD (Surgical representative)
 Colon: Marwan G. Fakhri, MD
 Philip J. Gold, MD
 Sepideh Gholami, MD (Surgical representative)
 Neuroendocrine Tumors: Nageshwara Arvind Dasari, MD
 Aman Chauhan, MD
 Ano-Rectal: Lisa A. Kachnic, MD
 Hagen F. Kennecke, MD
 Imaging: Anthony F. Shields, MD, PhD
 Pathology: Mary Kay Washington, MD, PhD
 Radiation Oncology: Lisa A. Kachnic, MD
 Surgery: Stephen W. Behrman, MD
 Syed A. Ahmad, MD
 Flavio Rocha, MD
 Translational Medicine: Gabriel N. Duda, PhD, DMD
 Eric Collisson, MD
 HEARD: Rachel Safyan, MD
 Colmar Figueroa-Moseley, PhD, MPH

Designates

Cancer Control Liaisons: Jason A. Zell, DO (Prevention)
 Vincent Chung, MD (Palliative Care)
 Community Liaisons: Gary L. Buchsacher, MD, PhD (Medical Oncology)
 Mohamed E. Salem, MD (Medical Oncology)
 Flavio Rocha, MD (Surgical)
 David Horowitz, MD (Radiation Oncology)
 AYA Committee Liason: Christopher Cann, MD
 Veterans Affairs: Rangaswamy Govindarajan, MD
 Data Coordinators: Alex Rangel, BS
 Brian Zeller
 Christine Magner

Oncology Research Professionals: Samantha Elliott, CCRP
 Adriana Gamboa Guzman, BA
 Patient Advocate (Colon): Angela "Marielle" McLeod, MHA
 Patient Advocate (Pancreatic): TBD
 Pharmaceutical Science: Jane E. Rogers, PharmD
 Safae Chouraichi, PharmD
 Protocol Project Manager: Andrea Garcia
 Clinical Trials Program Manager: Laura Gildner, MS

Time/Location

Friday, May 1, 2026 4:30 p.m. - 6:30 p.m.
 Room: Garden Room (Atrium Lobby Level)

Agenda

1. Welcome
2. Announcements & Introductions Philip Philip
E. Gabriela Chiorean
3. HEARD Subcommittee Initiatives Rachel Safyan, Colmar Figueroa -
Moseley, Marielle McLeod
4. Molecular Testing for Pancreatic and Biliary Cancers and Clinical Trials Applications Harsh Singh
5. SWOG Led Active Trials
 - a. S1922 Michael Overman
 - b. S2001 Vincent Chung
 - c. S2104 Heloisa Soares/S. Ahmad
 - d. S2107 Van Morris
 - e. S2012 David Zhen/E. Gabriela Chiorean
 - f. S2303 Anwaar Saeed/Paul Oberstein
 - g. S2408 Jonathan Sham/Venu Pillarisetty
 - h. S2433 Rachael Safyan/E. Gabriela Chiorean
6. Gastroesophageal Syma Iqbal, Zev Wainberg
 - a. Major recent clinical results
 - b. NCTN trials update
 - c. Future SWOG plans
7. Pancreatic Davendra Sohal, Andrew Lowy
 - a. Major recent clinical results
 - b. NCTN trials update
 - c. Future SWOG plans

Gastrointestinal Committee

- 8. Colon
 - Marwan Fakih, Philip Gold, Sepideh Gholami
 - a. Major recent clinical results
 - b. NCTN trials update
 - c. Future SWOG plans
- 9. Anal and Rectal
 - Hagen Kennecke, Lisa Kachnic
 - a. Major recent clinical results
 - b. NCTN trials update
 - c. Future SWOG plans
- 10. Hepatobiliary
 - Anthony El-Khoueiry, Rachna Shroff
 - a. Major recent clinical results
 - b. NCTN trials update
 - c. Future SWOG plans
- 11. Neuroendocrine
 - Arvind Dasari, Aman Chauhan
 - a. Major recent clinical results
 - b. NCTN trials update
 - c. Future SWOG plans
- 12. Discussion/Other Business
- 13. Adjourn

Gastroesophageal

Active Studies

- S2303**, "Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS \geq 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)." Dra. Saeed and Oberstein. Activated: 5/6/24
- A022102**, "Randomized Phase III Trial of mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab for First-Line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma." SWOG Champion: Dr. Oberstein. Activated: 1/17/19.
- EA2174**, "A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma." SWOG Champion: Dr. Kelly. Activated: 1/17/19. Temporarily Closed to Accrual as of 12/29/22.
- EA2212**, "A Randomized Phase II Study of Perioperative Atezolizumab +/- Chemotherapy in Resectable MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer." SWOG Champion: Emerson Chen Temporarily Closed to Accrual as of 12/4/24

Closed Studies

- A021302**, "Impact of Early FDG-PET Directed Intervention on Preoperative Therapy for Locally Advanced Gastric Cancer: A Random Assignment Phase II Study." Activated by SWOG: 4/1/16. Closed to Accrual on 6/1/17. SWOG Champion: S. Iqbal.
- EA2183**, "A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)." Activated: 2/6/20. Closed to Accrual as of 5/23/25. SWOG Champion: D. Horowitz

Pancreatic

Active Studies

- S2408**, "A Randomized Phase III Blinded Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula." Drs. J. Sham, V. Pillarisetty, and R. Krouse. Activated: 2/14/25
- S2433**, "Randomized Phase III Study of Second-Line Chemotherapy with or without Panitumumab for Locally Advanced or Metastatic KRAS Wild Type Pancreatic Adenocarcinoma." Drs. R. Safyan, E. Chiorean, and H. Singh. Activated: 12/26/25

- EA2192**, "APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation." SWOG Champions: E. Chiorean and P. Philip. Activated: 4/29/21.

Closed Studies

- S2001**, "Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or 2 Mutations." Drs. V. Chung, and M. Pishvaian. Activated: 12/4/20; Closed to Accrual as of 10/23/25
- EA2186**, "A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)." Activated: 6/18/20. Closed to Accrual as of 10/17/23. SWOG Champion: D. Zhen.
- RTOG-0848**, "Gemcitabine, with and without Erlotinib, Followed by a Second Randomization with and without Chemoradiation, as Adjuvant Treatment for Pancreatic Head Cancer: A Phase III RTOG/SWOG/NCIC/EORTC Study." Activated 11/7/09; Closed to accrual as of 1/18/19. SWOG Champion: P. Philip.

Gastrointestinal Committee

A021501, "Preoperative Extended Chemotherapy vs Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas." Activated: 12/1/16, Closed to accrual as of 5/6/19. SWOG Champion: S. Ahmad.

EA2161, "A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET)." Activated: 2/1/17, Closed to Accrual as of 12/27/19

A022106, "A Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/ Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)." Activated: 12/1/23, Closed to Accrual as of 12/24/25. SWOG Champion: G. Botta

A021804, "A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma." Activated: 11/2/20. Closed to Accrual as of 6/2/25. SWOG Champion: C. Lopez.

A021806, "A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer." Activated: 7/1/20. Closed to accrual as of 1/5/26. SWOG Champion: S. Behrman

Neuroendocrine

Active Studies

S2104, "Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors." Activated: 10/14/21. Drs. Study Chairs: H. Soares, and S. Ahmad.

S2012, "Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC #783608) in Patients with Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)." Activated: 12/2/21. Drs. D. Zhen, E. Chiorean, E. Burgess, E. Swisher, and L. Byers.

Closed Studies

A021602, "Randomized Double-Blinded Phase III Study of CABozantinib versus Placebo IN Advanced Neuroendocrine Tumors after Progression on Prior Therapy (CABINET)." Activated: 7/18/18. Closed to Accrual as of 9/8/23. SWOG Champion: J. Strosberg.

EA2142, "Randomized Phase II Study of Platinum and Etoposide Versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas." Activation 11/6/15, Closed to Accrual as of 4/1/21. SWOG Champion: H. Soares

Hepatobiliary

Closed Studies

S1815, "A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers." Dr. R. Shroff. Activated: 12/3/18. Permanently Closed: 2/15/21.

NRG-GI003, "A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma." Activated: 6/21/17, Closed to accrual as of 1/14/26. SWOG Champion: Anthony El-Khoueiry.

EA2187, "A Phase 2 Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma." Activated: 1/31/20. Permanently Closed: 3/22/23. SWOG Champion: Stacy Stein.

RTOG-1112, "Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma." L. Dawson. SWOG Champion: T. Mitin

EA2197, "Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial." Activated: 12/22/20, Closed to accrual as of 4/18/25. SWOG Champion: F. Rocha.

Colorectal

Active Studies

S1922, "Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma." Activated: 12/16/19. Dr. M. Overman

A022101, "A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)." Activated: 1/10/23. SWOG Champion: S. Gholami

EA2222, "A Randomized Phase III Study of Systemic Therapy with or Without Hepatic Arterial Infusion for Unresectable Colorectal Liver Metastases: The PUMP Trial." Activated: 10/19/23. SWOG Champion: Skye Mayo

NRG-GI008, "Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)." Activated: 3/10/22. SWOG Champions: P. Philip & C. Eng

Closed Studies

S2107, "Randomized Phase II Trial of Encorafenib and Cetuximab with or without Nivolumab for Patients with Microsatellite Stable, BRAFV600E

Gastrointestinal Committee

Anal

Metastatic Colorectal Cancer." Dr. Van Morris, MD. Activated: 6/6/22, Study closed to accrual 10/1/24

S1613, "A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification." Dr. Kanwal Raghav. Activated: 10/19/17. Step 3 permanently closed: 11/30/23

S0820, "A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)." Dr. Jason Zell. Activated: 3/1/13. Permanently Closed: 6/30/23

A021502, "Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair." Activated: 9/12/17, Closed to Accrual as of 1/17/23. SWOG Champion: Chris Lieu

A021703, "Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)." Activated: 9/30/19, Closed to Accrual as of 12/15/22. SWOG Champion: Stacey Cohen.

E7208, "A Randomized Phase II Study of Irinotecan and Cetuximab With or Without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-Type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy." Activated 10/18/10, Closed to Accrual as of 7/7/17. SWOG Champion: H. Hochster.

NRG-GI004/ S1610, "Colorectal Cancer Metastatic dMMR/MSI-H Immunotherapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/ Bevacizumab/Atezolizumab Combination versus Single Agent Atezolizumab in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer." Activated: 11/7/17, Closed to Accrual as of 9/2/25. SWOG Champion: M. Overman.

NRG-GI005, "Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)." Dr. A. Scott. Activated: 12/16/19, Closed to Accrual as of 2/12/24. SWOG Champion: A. Scott

Active Studies

EA2176, "Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients." Activated: 10/15/20, Closed to Accrual as of 9/23/24. SWOG Champion: Van Morris

Closed Studies

N1048, "A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision." Activated: 4/15/12. Accrual target: 1120 / Final accrual: 1194. SWOG Champion: Cathy Eng.

InterAACT EA2133, "An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin plus 5-Fluorouracil Versus Carboplatin plus Weekly Paclitaxel in Patients with Inoperable Locally Recurrent or Metastatic Disease." Activated: 2/15/16. Accrual target: 80 / Final accrual: 12. SWOG Champion: Van Morris.

NRG-GI002, "A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer." Activated: 10/12/16, Closed to Accrual as of 5/14/19. SWOG Champion: Lisa Kachnic

EA2165, "A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer." Activated: 4/13/18, Closed to Accrual as of 4/4/22. SWOG Champion: Van Morris

A022104, "The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients with Locally Advanced Rectal Cancer." Activated 11/9/22, Closed to Accrual as of 7/21/25. SWOG Champion: A. Dasari

EA2201, "A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma." Activated 5/13/21, Closed to Accrual as of 1/14/25. SWOG Champion: T. May Cho

EA2182, "A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)." Activated: 11/12/19, Closed to Accrual as of 10/30/24. SWOG Champion: James D. Murphy.

Gastrointestinal Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	S1922	S2001	S2104	S2107	S2303	A021806	A022001
Banner University Medical Center - Tucson	-	-	11	-	-	1	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	2	-	-	-	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	-	-	-	-	-
Boston Medical Center	-	-	-	-	-	1	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	2	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	2	-	-	-
Cancer Research for the Ozarks NCORP	-	1	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-	-	1	-	-
Carle Cancer Center NCI Community Oncology Research Program	1	1	2	2	-	-	-
Cedars-Sinai Medical Center	-	-	1	-	2	-	-
City of Hope Comprehensive Cancer Center	-	6	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	1	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	2	3	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	2	-	-	2	-
Gulf South Minority Underserved NCORP	-	-	-	3	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	-	1	-	-
Heartland Cancer Research NCORP	1	1	-	3	-	-	-
Henry Ford Hospital	-	4	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	-	-
Intermountain Medical Center	-	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	1	-	-	6	4	1	-
Loma Linda University Medical Center	-	-	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	1	-	-	-	-
Michigan Cancer Research Consortium NCORP	2	2	-	4	4	-	-
Moffitt Cancer Center	-	-	2	-	-	-	-
Montana Cancer Consortium NCORP	-	-	1	-	1	-	-
Mount Sinai Hospital	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	1	-	-	-	-
Northwell Health NCORP	-	-	-	-	-	1	-
Northwestern University LAPS	1	-	1	-	1	1	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	1	-	-	-	-
Oregon Health and Science University	-	-	3	-	4	5	-

Gastrointestinal Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	S1922	S2001	S2104	S2107	S2303	A021806	A022001
Pacific Cancer Research Consortium NCORP	1	2	5	2	1	-	-
Regents of the University of Michigan	4	3	2	-	-	4	-
STCC at DHR Health Institute for Research and Development	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	2	4	4	-	-	-
Sutter Cancer Research Consortium	-	1	-	-	-	-	-
The Don and Sybil Harrington Cancer Center	-	-	-	-	-	2	-
The West Clinic - Wolf River	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	2	-	4	-	-	-
UC San Diego Moores Cancer Center	-	-	-	-	1	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	5	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	1	-	3	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	1	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	1	-	-	-	-
University of Colorado Cancer Center LAPS	-	4	-	9	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	-	1	-	-
University of Kentucky/Markey Cancer Center	-	-	4	-	-	-	-
University of Nebraska Medical Center	-	-	-	-	1	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-	2	-	-	-
University of Rochester LAPS	1	-	-	-	2	12	-
University of Texas Health Science Center at San Antonio	-	-	-	-	-	3	-
University of Texas MD Anderson Cancer Center LAPS	15	-	-	10	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	1	7	-	2	-	1
Vanderbilt University - Ingram Cancer Center LAPS	-	5	-	1	1	-	-
Virginia Mason Medical Center	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	1	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	1	1	-	-	-
Yale University - Yale Cancer Center LAPS	-	1	2	-	2	2	1
ALLIANCE	12	8	12	8	26	-	-
ECOG-ACRIN	3	16	11	14	6	-	-
NRG	3	9	8	10	4	-	-
Total	45	73	86	88	74	37	2

Gastrointestinal Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	A022101	A022102	A022104	CCTG032	CCTGNE1	EA2174	EA2176
Banner University Medical Center - Tucson	-	-	-	-	1	-	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	-	-	-	-	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	13	-	-	-	-
Boston Medical Center	-	3	6	-	-	2	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	2	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	2	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	9	-	-	-	-
Gulf South Minority Underserved NCORP	1	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-	-	-
Henry Ford Hospital	-	-	5	-	-	-	1
Houston Methodist Hospital	-	-	-	-	-	-	-
Intermountain Medical Center	-	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	-	-	-	-	8
Loma Linda University Medical Center	-	-	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-	-	-
Moffitt Cancer Center	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	-	-	1	-
Northwestern University LAPS	-	-	-	-	-	-	1
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-	3	-	-
Oregon Health and Science University	-	-	-	1	-	-	4

Gastrointestinal Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	A022101	A022102	A022104	CCTG032	CCTGNE1	EA2174	EA2176
Pacific Cancer Research Consortium NCORP	-	-	-	2	-	-	-
Regents of the University of Michigan	-	-	1	-	-	-	-
STCC at DHR Health Institute for Research and Development	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	1	-	-	-	-	-
The Don and Sybil Harrington Cancer Center	-	-	1	-	-	-	-
The West Clinic - Wolf River	-	-	17	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	4	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	7	5	3	-	-	4
UC San Diego Moores Cancer Center	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	1	1	-	-	1	3
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	1	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	-	-	2
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	-	1
University of Colorado Cancer Center LAPS	-	-	-	-	2	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	8	-	-	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	-	-
University of Nebraska Medical Center	-	1	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-	-	-	-	-
University of Rochester LAPS	-	8	23	-	-	-	-
University of Texas Health Science Center at San Antonio	-	-	8	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-	-	-	10
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	9	-	-	-	-
Virginia Mason Medical Center	-	-	8	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	6	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-
Total	1	36	110	8	6	6	34

Gastrointestinal Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	EA2182	EA2192	EA2197	EA2222	NRGG1004	NRGG1006	NRGG1008
Banner University Medical Center - Tucson	-	-	-	-	-	-	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	-	-	-	-	-	2
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	-	-	-	-	1
Boston Medical Center	2	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	4	-	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	-	1
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	-	-	5
Gulf South Minority Underserved NCORP	-	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-	-	-
Henry Ford Hospital	2	-	-	-	-	-	1
Houston Methodist Hospital	-	-	-	-	1	-	-
Intermountain Medical Center	-	-	-	-	-	-	2
Kaiser Permanente NCI Community Oncology Research Program	-	-	-	-	-	-	-
Loma Linda University Medical Center	-	-	-	-	-	-	1
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-	-	-
Moffitt Cancer Center	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	-	1
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	-	-	-
Northwell Health NCORP	-	-	1	-	-	-	1
Northwestern University LAPS	-	-	-	-	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-
Oregon Health and Science University	1	4	6	2	-	-	-

Gastrointestinal Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	EA2182	EA2192	EA2197	EA2222	NRGG1004	NRGG1006	NRGG1008
Pacific Cancer Research Consortium NCORP	-	-	-	-	-	-	-
Regents of the University of Michigan	-	-	-	1	-	-	-
STCC at DHR Health Institute for Research and Development	-	-	-	-	-	-	1
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	2	-	-	-	-	2
The Don and Sybil Harrington Cancer Center	-	-	-	-	-	-	-
The West Clinic - Wolf River	-	-	-	-	-	-	5
UC Davis Comprehensive Cancer Center LAPS	-	-	1	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	1	-	-	-	-	-	-
UC San Diego Moores Cancer Center	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	1	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	2	-	-	-	-	-	8
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	-	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-	3	-	-	-
University of Nebraska Medical Center	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-	-	-	1	1
University of Rochester LAPS	-	-	-	-	1	-	15
University of Texas Health Science Center at San Antonio	-	-	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-	13	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	-	-	3
Virginia Mason Medical Center	-	-	1	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	1	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-
Total	14	6	9	6	15	1	50

Genitourinary Committee

Leadership

Chair: Seth P. Lerner, MD
 Vice-Chair: Daniel P. Petrylak, MD
 Chair Emeritus: Ian M. Thompson, Jr., MD
 Executive Officer: Neeraj Agarwal, MD
 Statisticians: Cathy M. Tangen, DrPH
 Melissa Plets, MS
 Sam Callis, MS
 Gabby Lopez, MS
 Sara Threlkel, BS

Scientific Leadership

Translational Medicine: Joshua J. Meeks, MD, PhD (GU Chair)
 Roger Li, MD (Bladder)
 Amir Goldkorn, MD (Prostate)
 Sumanta “Monty” K. Pal, MD (Renal)
 Radiation Oncology: James B. Yu, MD
 Daniel A. Hamstra, MD
 Imaging: Evan Y. Yu, MD
 Hiram Shaish, MD
 John D. Hazle, PhD
 Immunotherapeutics: Shuchi Gulati, MD (Medical Onc)
 Robert Svatek, MD (Urologic Onc)
 Pathology: M. Scott Lucia, MD
 Surgery: Kelly L. Stratton, MD
 Early Therapeutics: Parminder Singh, MD
 Bladder Organ Site Chairs: Siamak Daneshmand, MD (Localized)
 Thomas W. Flaig, MD (Advanced)
 Prostate Organ Site Chairs: Daniel W. Lin, MD (Localized)
 Tanya B. Dorff, MD (Advanced)
 Renal Organ Site Chairs: Brian Shuch, MD (Localized)
 Ulka N. Vaishampayan, MD (Advanced)

Designates

Cancer Control: Clara Hwang, MD
 Sarah P. Psutka, MD, MSC
 Accrual Champion: Jessica D. McDermott, MD
 NCORP: Scott Edward Delacroix, Jr., MD
 Helen Heng-Shan Moon, MD
 Veterans Affairs: Michael M. Goodman, MD
 Aihua Edward Yen, MD
 Data Coordinators: Laura Wells, BA
 Tonya Johnson, BS
 Michele Counts, BS
 Oncology Research Professionals: Abigail L. Cornette, MS
 Gary Lee Duvall, RN

Patient Advocates: Darrell Nakagawa (Bladder)
 Joël R. Pointon, MPH (Prostate)
 Laura B. Esfeller, MA (Renal)
 Pharmaceutical Science: Stephanie Elise Trexler, Pharm D
 Senior Protocol Project Manager: Megan Keim
 Clinical Trials Program Manager: Sarah Cantu

Time/Location

Saturday, May 2, 2026 9:15 a.m. - 11:15 a.m.
 Room: Grand Ballroom A (Street Level)

Agenda

9:15 - 9:30 am: Chair’s Welcome and Opening Remarks - Seth Lerner
 9:30 - 9:55 am: Cancer Control - Clara Hwang and Sarah Psutka
 9:55 - 11:15 am: Review of open approved trials - all organ site chairs

Prostate – Dan Lin and Tanya Dorff
 Renal – Brian Shuch and Ulka Vaishampayan
 Bladder – Sia Daneshmand and Tom Flaig

Cancer Control

Organ Site Chairs: Drs. Clara Hwang and Dr. Sarah Psutka

Active Studies

S1600, “A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes.” Drs. J. Hamilton-Reeves and J. Holzbeierlein. Activated: 2/21/19. Closed to Accrual and Treatment 10/20/23.

S1823, “A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients with Early Stage Germ Cell Tumors”, PI: Craig Nichols– Activated 6/1/20. Closed to Accrual 5/20/24. GU Champions: Thomas Frye & Anishka D’Souza

S1931 (Companion Study): Examining Psychosocial and Emotional Issues for Metastatic Kidney Cancer. PI: Cristiane Bergerot.

S1937 (Companion Study): Assessment of Quality of Life for S1937: A Phase III Randomized Trial of Eribulin with or without Gemcitabine Versus Standard of Care (Physician’s Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy. QoL Study Chair: Dr. Afsaneh Barzi. On hold until accrual picks up on S1937.

Genitourinary Committee

Prostate

Organ Site Chairs: Dr. Tonya Dorff (Advanced) and Dr. Daniel W. Lin (Local).

Priority Study

S2210, “Targeted neoadjuvant treatment for patients with localized prostate cancer and germline DNA repair deficiency.” Dr. H. Cheng. Activated 8/14/23. Temporarily Closed to Accrual 1/22/26.

Active Studies

S2312, “A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature.” Dr. Paul Corn. Activated 9/3/24. Revision #1 released 1/15/26.

S1802, “Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer.” Drs. B. Chapin, A. Aparicio, and R. Valicenti. Activated: 9/17/18. Revision #5 released 8/15/24.

CTSU/A031102, “A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors.” Dr. D. Quinn. Activated: 7/1/15. Closed to Accrual 10/26/22.

CTSU/EA8171, “Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer.” Dr. M. Liss. Activated: 7/9/18. Closed to Accrual 2/28/25.

CTSU/EA8184, “A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers.” Dr. R. Kopp. Activated: 5/10/21. Closed to Accrual 6/26/25.

CTSU/EA8191, “Phase III Study of Local or Systemic Therapy Intensification Directed by PET in Prostate Cancer Patients with Post-Prostatectomy Biochemical Recurrence (INDICATE).” Dr. N. Vapiwala. Activated: 10/8/2020. Arms A & B Closed to Accrual 1/31/25.

CTSU/NRG-GU002, “Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or Without Adjuvant Docetaxel.” Dr. D. Raben. Activated: 12/30/16. Closed to Accrual 9/6/22.

CTSU/NRG-GU008, “Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *Intensifying Treatment for Node Positive Prostate Cancer by Varying the Hormonal Therapy.” Dr. D. Lin. Activated: 3/5/20; Temporarily Closed: 6/24/21; Re-activated: 12/1/21.

CTSU/NRG-GU009, “Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*).” Dr. S. Zhang. Activated: 10/15/20; Temporarily Closed: 6/24/21; Re-activated: 12/15/21. Closed to Accrual 8/18/25.

CTSU/NRGGU010, “Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (GUIDANCE).” Drs. N Desai and A. Berlin. Activated: 11/3/21. Groups 3 and 4 Closed to Accrual 11/22/24.

CTSU/NRGGU011, “A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadioTherapy with or Without ANDrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean).” Dr. B. Koontz.

Closed Studies

S1216, “A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer.” Drs. N. Agarwal, A. Goldkorn, S. Gupta, et al. Activated: 3/6/13; Permanently Closed: 7/15/17. All participants off of treatment and follow up by 7/15/25. FDAAA/IRB Completed.

CTSU/NRG-GU005, “Phase III IGRT and SBRT Vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer.” Dr. A. Solanki. Activated: 11/16/17; Closed to accrual: 6/8/22. Closed to Accrual and Treatment 6/8/22.

CTSU/NRG-GU006, “A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy with or Without Enhanced Anti-Androgen Therapy with Apalutamide in Recurrent Prostate Cancer.” Dr. J. Zeng. Activated: 4/27/18; Permanently Closed: 5/19/20.

CTSU/RTOG-0924, “Androgen Deprivation Therapy and High Dose Radiotherapy with or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial. Dr. T. Marshall. Activated: 7/7/11; Permanently Closed: 6/24/19.

Genitourinary Committee

CTSU/NRG-GU007, “Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (with Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen Deprivation Therapy (ADT) and Radiotherapy In High Risk Prostate Cancer (With Initial Phase I).” Dr. D. VanderWeele. Activated: 6/3/19; Temporarily Closed: 5/5/21; Reactivated of dose level 2 (phase I) for 1 additional patient: 9/14/21; Temporarily closed to accrual for phase I dose level 2: 11/4/21; Re-activated to accrual for phase I/dose level 3: 12/6/21; Temporarily Closed: 7/11/22.

CTSU/EA8153, “Cabazitaxel with Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHARTED2 Trial.” Dr. P. Corn. Activated: 2/8/18; Permanently Closed: 4/2/21; Tobacco use assessment sub-study permanently closed: 10/8/21.

CTSU/AGCT1531, “A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors.” Dr. A. D’Souza. Activated: 5/8/17; PRO study Temporarily Closed: 2/12/21. Stratum 2 Temporarily Closed to Accrual as of 12/17/24. AYA-HEARS Ototoxicity PRO Study Temporarily Closed to Accrual as of 02/12/21.

Renal

Organ Site Chairs: Dr. Ulka Vaishampayan (Advanced) and Dr. Brian Shuch (Local).

Priority Study

S1931, “Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial).” Drs. H. Kim and U. Vaishampayan. Activated: 11/16/20. Revision #10 released on 2/2/26.

Concepts in Development

S2419, “Phase III Double Blinded Trial of Immune-Based Therapy with a Live Biotherapeutic CBM588, or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma [BioFront Trial].” Drs. P. Barata and U. Vaishampayan. Under CIRB initial review as of 2/5/26. Target activation 4/1/26.

Active Studies

CTSU/AREN1721, “A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups.” Dr. M. Parikh. Activated: 10/9/18; Temporarily Closed: 3/24/21; Re-activated: 2/7/22. Closed to Accrual 3/24/23.

CTSU/A031704, “PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE].” Dr. T. Zhang. Activated: 5/9/19; Step 1 temporarily closed: 3/8/21; Step 1 re-activated: 3/26/21. Closed to Accrual 5/15/24.

CTSU/A031801, “A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (Radical).” Dr. M. Parikh. Activated: 12/13/19. Closed to Accrual 12/19/25.

CTSU/A031901, “Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A randomized Phase 3 non-Inferiority Trial.” Dr. D. Vaena. Activated: 12/10/20. Closed to Accrual 11/29/22.

Closed Studies

S1500, “A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET).” Drs. S. Pal and P. Lara. Activated 4/5/16; Permanently Closed: 12/15/19.

S0931, “EVEREST: Everolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study.” Drs. C. Ryan, E. Heath, P. Lara, et al. Activated: 4/1/11; Permanently Closed: 9/15/16.

S2200, “A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2)” Drs. B. Maughan and S. Pal. Activated 9/19/22. Temporarily closed to accrual 1/17/26. Permanently Closed: 3/1/26.

CTSU/E2810, “Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy.” Dr. S. Pal. Activated: 8/8/12; Permanently closed: 7/25/17.

CTSU/A031501, “Phase III Randomized Adjuvant study of Pembrolizumab in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation.” Dr. G. Sonpavde. Activated: 9/21/17; Permanently Closed: 8/24/21.

CTSU/EA8143, “A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC).” Drs. P. Lara and B. Shuch. Activated: 2/2/17; Permanently Closed: 6/9/21.

Genitourinary Committee

Bladder

Organ Site Chairs: Dr. Thomas Flaig (Advanced) and Dr. Siamak Daneshmand (Local).

Priority Study

S1937, “A Phase III Trial of Eribulin (NSC #707389) with or Without Gemcitabine Versus Standard of Care (Physician’s Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy.” Drs. S. Sadeghi and P. Lara. Activated: 2/16/21. Temporary Closure: 5/30/23. Re-opened Arms 1&3 to accrual and permanently closed Arm 2 on 2/15/24. Revision #4 had Sacituzumab govitecan removed as a treatment option on 2/3/25.

Concepts in Development

S2611, “A Randomized Comparison of Intravesical Therapies (ARCIS): A randomized phase III study of intravesical gemcitabine and docetaxel (GEM-DOCE) versus intravesical cimetidine, methotrexate, and gemcitabine (CRETO-GEM) for the treatment of bacille Calmette-Guérin (BCG)-unresponsive and BCG-exposed non-muscle invasive bladder cancer (NMIBC).” Dr. M. Tyson. Reviewed by the GU Steering Committee on 1/21/2026, received “pending” decision. Concept withdrawn from GUSC. Plan to resubmit to GUSC on 4/22 for May review date.

Active Studies

S2427, “Bladder preservation with chemoradiotherapy or immunoradiotherapy after a good response to neoadjuvant chemotherapy in patients with muscle invasive bladder cancer (BRIGHT).” Dr. L. Ballas. Activated 9/4/25. Revision #1 released 1/15/26.

CTSU/A031701, “A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations.” Drs. A. Gupta and S. Gupta. Activated: 8/1/18.

CTSU/A031803, “Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer.” Drs. D. Tyson and C. Ramamurthy. Activated: 1/6/20. Closed to accrual: 7/23/25.

CTSU/EA8185, “Phase II Study of Bladder-Sparing Chemoradiation with MEDI4736 (Durvalumab) in Clinical Stage III, Node Positive Bladder Cancer (INSPIRE).” Drs. T. Mitin and J. Meeks. Activated: 8/25/20. Closed to accrual: 10/2/23.

CTSU/EA8192, “A Phase II/III Trial of MEDI4736 (Durvalumab) and

Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy” Drs. S. Psutka and A. Tripathi. Activated: 5/6/21. Arm C Closed to Accrual as of 4/25/25.

Closed Studies

S1011, “A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer.” Drs. S. Lerner, A. Alva, and T. Koppie, et al. Activated: 8/1/11; Permanently Closed: 4/15/17. Listed as FDAAA/IRB Completed on 1/8/25.

S1602, “A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG Naïve High-Grade Non-Muscle Invasive Bladder Cancer.” Drs. R. Svatek, A. Alva, and S. Lerner. Activated: 2/7/17; Permanently Closed: 12/15/20.

S1605, “Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer.” Drs. P. Black, P. Singh, and S. Lerner. Activated: 2/7/17; Permanently Closed: 7/5/19. FDAAA/IRB Completed.

S2011, “Randomized Phase II Trial of Gemcitabine, Avelumab, and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery for Cisplatin Ineligible Muscle-Invasive Urothelial Carcinoma.” Drs. Sonpavde, M. Liss, and S. Lerner, et al. Activated: 10/6/21. Closed to Accrual: 11/15/23. Administratively Complete.

S1806, “Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer.” Drs. P. Singh, S. Lerner, J. Efstathiou, et al. Activated: 4/19/19. Step 1 accrual closed 3/1/24. Revision #10 released 8/15/2025. Closed to accrual and treatment: 4/1/24.

Translational Medicine

Chair: Dr. Joshua Meeks

Bladder Chair: Dr. Joshua Meeks

Prostate Chair: Dr. Amir Goldkorn

Renal Chair: Dr. David Braun

Diverse Studies of Interest

S1609, “DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors.” Drs. S. Patel, Y. Chae, R. Kurzrock, et al. Activated: 1/13/17; Permanently Closed: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 13, 14, 15, 16, 17, 18, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 39, 41, 42, 43, 44, 45, 48, 51, 52, and 53; Temporarily Closed: 38, 40, 46, and 51. Closed to Accrual 3/15/2023.

Genitourinary Committee

CTSU/A031702, "A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)" Dr. S. Liu. Activated: 4/12/19; Open Cohorts: A, C, D, J, H, L. Temporarily Closed Cohorts: B, E, F, G, I, K.

CTSU/EAY 131, "Molecular Analysis for Therapy Choice (MATCH)." Dr. V. Villalobos. Activated: 8/12/15; Closed to Accrual 12/23/2022.

CTSU/EA8134, "InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)." Dr. C. Pettaway. Activated: 9/8/17.

Genitourinary Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	S1802	S1931	S1937	S2200	S2210	S2312	S2427	A021804
Arnot Ogden Medical Center/Falck Cancer Center	-	-	-	-	-	-	-	-
Audie L Murphy VA Hospital	-	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	7	1	-	-	-	-	-	-
Banner University Medical Center - Tucson	7	2	-	-	-	-	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	6	-	1	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	2	1	1	-	-	-	-	-
Cancer Research for the Ozarks NCORP	1	-	-	-	-	1	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	3	-	1	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	1	1	-	-	-	-	-	-
Carolinas Medical Center/Levine Cancer Institute	11	-	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	4	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	5	3	-	7	1	1	-	-
Columbia University Minority Underserved NCORP	2	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	3	-	5	-	-	-	-	-
Dayton NCI Community Oncology Research Program	5	-	-	-	-	-	-	-
Desert Regional Medical Center	2	-	-	-	-	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	26	-	-	-	3	-	-	-
Georgia Cares Minority Underserved NCORP	1	-	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	6	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	83	3	2	1	1	-	-	-
Hartford Hospital	-	-	-	-	-	1	-	-
Hawaii Minority Underserved NCORP	-	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	11	1	-	3	-	1	-	-
Henry Ford Hospital	31	-	4	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia	8	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	41	-	-	-	-	-	-	-
Intermountain Medical Center	2	-	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	19	2	-	-	-	-	-	-
Lahey Hospital and Medical Center	-	-	-	-	-	-	-	-
Loyola University Medical Center	9	1	2	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	8	-	3	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	15	-	4	2	-	4	-	-
Montana Cancer Consortium NCORP	5	-	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	12	-	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	1	-	-	-	-	-	-	-

Genitourinary Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	S1802	S1931	S1937	S2200	S2210	S2312	S2427	A021804
New Mexico Minority Underserved NCORP	-	2	1	-	-	-	-	-
Northwell Health NCORP	-	-	-	-	-	-	-	-
Northwestern University LAPS	-	1	1	1	-	2	-	-
Ohio State University Comprehensive Cancer Center LAPS	2	-	-	-	-	-	-	-
Oregon Health and Science University	-	3	3	1	1	-	-	1
Regents of the University of Michigan	2	27	2	-	-	-	-	-
Rhode Island Hospital	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	9	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	-	-	-	-
The West Clinic - Wolf River	-	-	5	-	-	-	-	-
Tulane University School of Medicine	-	9	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	17	4	5	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	9	-	3	-	-	-	-	-
UC San Diego Moores Cancer Center	7	-	-	-	-	-	-	-
UCLA / Jonsson Comprehensive Cancer Center	-	4	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	4	2	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	9	2	17	-	-	-	-	-
U Alabama at Birmingham / Deep South Research Consortium LAPS	-	7	-	-	-	-	-	-
University of Arkansas for Medical Sciences	9	-	-	1	-	1	-	-
University of Cincinnati Cancer Center-UC Medical Center	8	3	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	10	-	10	-	-	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	7	-	3	-	-	-	-	-
University of Kentucky/Markey Cancer Center	2	-	1	-	-	-	-	-
University of Mississippi Medical Center	1	-	1	1	-	-	-	-
University of Nebraska Medical Center	7	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	47	6	8	3	-	5	-	-
University of Rochester LAPS	26	3	-	-	-	-	-	-
University of Texas Health Science Center at San Antonio	2	7	-	-	-	1	-	-
University of Texas MD Anderson Cancer Center LAPS	88	-	-	-	-	10	-	-
University of Utah - Huntsman Cancer Institute LAPS	19	2	4	3	-	-	-	-
Upstate Carolina Consortium Community Oncology Research Program	3	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	8	-	-	-	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	1	-	-	-	-	-	-	-
Western States Cancer Research NCORP	-	-	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	15	1	1	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	1	-	3	-	-	-	-	-
ALLIANCE	122	8	7	2	-	6	-	-
ECOG-ACRIN	106	17	21	6	-	4	1	-
NRG	120	16	2	4	-	-	-	-
Total	990	145	123	35	6	37	1	1

Genitourinary Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	A031701	A031702	A031801	A031803	A032102	A032103	A032201	CCTG-PR26
Arnot Ogden Medical Center/Falck Cancer Center	-	-	-	-	-	-	-	-
Audie L Murphy VA Hospital	-	-	-	2	-	-	-	-
Banner MD Anderson Cancer Center	-	-	-	-	-	-	-	-
Banner University Medical Center - Tucson	-	-	-	-	-	2	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	-	6	-	3	-	-
CWRU Case Comprehensive Cancer Center LAPS	11	-	-	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Carolinas Medical Center/Levine Cancer Institute	-	-	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Desert Regional Medical Center	-	-	-	-	-	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	-	-	-	-	-	1	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	-	1	16	-	-	-	-
Hartford Hospital	1	-	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	2	-	-	-	-	-	-	-
Henry Ford Hospital	-	2	-	-	-	1	-	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-	-	-	-	-	-
Intermountain Medical Center	-	-	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Lahey Hospital and Medical Center	-	7	-	-	-	-	1	-
Loyola University Medical Center	-	1	-	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	1	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	1	-	-	-	-	-	-

Genitourinary Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	A031701	A031702	A031801	A031803	A032102	A032103	A032201	CCTG-PR26
New Mexico Minority Underserved NCORP	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	-	-	-	-	-
Northwestern University LAPS	-	-	-	-	-	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-
Oregon Health and Science University	-	6	-	-	-	7	2	1
Regents of the University of Michigan	-	-	-	-	-	3	-	-
Rhode Island Hospital	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	-	-	-	-
The West Clinic - Wolf River	-	-	-	-	-	-	-	-
Tulane University School of Medicine	-	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	11	-	7	5	2	2	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	-	-	-	2	-
UC San Diego Moores Cancer Center	-	-	-	-	-	-	-	-
UCLA / Jonsson Comprehensive Cancer Center	-	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	5	-	-	-	-	-	-
U Alabama at Birmingham / Deep South Research Consortium LAPS	-	1	1	12	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	-	1	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	-	-	-	-	-	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	1	-	-	-	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	2	-	-
University of Mississippi Medical Center	-	1	-	-	-	2	-	-
University of Nebraska Medical Center	-	-	-	-	-	2	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-	-	-	1	-	-
University of Rochester LAPS	2	3	-	-	-	5	-	-
University of Texas Health Science Center at San Antonio	-	-	-	6	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	6	-	-	-	-	-
Upstate Carolina Consortium Community Oncology Research Program	-	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	-	-	-	-
Western States Cancer Research NCORP	-	-	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-
Total	28	28	15	47	2	32	5	1

Genitourinary Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	EA8134	EA8171	EA8191	EA8192	EA8212	NRGGU008	NRGGU009	NRGGU010
Arnot Ogden Medical Center/Falck Cancer Center	-	-	-	-	-	-	-	4
Audie L Murphy VA Hospital	-	49	-	-	-	-	-	-
Banner MD Anderson Cancer Center	-	-	-	-	26	-	1	3
Banner University Medical Center - Tucson	-	-	-	-	-	-	1	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	-	-	29	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Carolinas Medical Center/Levine Cancer Institute	-	-	-	-	-	-	1	-
Cedars-Sinai Medical Center	-	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Desert Regional Medical Center	-	-	-	-	-	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	33	-	16	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	11	-	-	71	6	16	6
Hartford Hospital	-	-	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	2	-	-	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-	-	-	-
Henry Ford Hospital	-	1	-	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	2	-	-	-
Instituto Nacional De Cancerologia	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	2	-	-	-	-	-	-	-
Intermountain Medical Center	-	-	-	-	-	-	-	3
Kaiser Permanente NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Lahey Hospital and Medical Center	-	-	-	-	-	-	-	-
Loyola University Medical Center	-	-	-	-	6	-	-	-
Medical University of South Carolina Minority Underserved NCORP	1	-	3	-	17	-	-	1
Michigan Cancer Research Consortium NCORP	-	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-	-
Mount Sinai Hospital	-	-	2	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	1	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	-	-	-

Genitourinary Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	EA8134	EA8171	EA8191	EA8192	EA8212	NRGGU008	NRGGU009	NRGGU010
New Mexico Minority Underserved NCORP	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	-	1	-	-	4	20	3
Northwestern University LAPS	-	-	-	-	-	-	-	4
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-
Oregon Health and Science University	-	15	18	-	32	-	-	-
Regents of the University of Michigan	-	-	-	-	-	-	-	1
Rhode Island Hospital	-	-	-	-	-	-	1	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	-	-	6	11
The West Clinic - Wolf River	-	-	-	-	-	-	-	-
Tulane University School of Medicine	-	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	-	-	4	-	1	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	-	-	3	-	-
UC San Diego Moores Cancer Center	-	-	1	-	5	-	2	2
UCLA / Jonsson Comprehensive Cancer Center	-	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	18	-	-	-	20	-	-	-
U Alabama at Birmingham / Deep South Research Consortium LAPS	-	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	3	-	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	1	-	-	2	-	-	17	13
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	-	-	3	11	7
University of Kentucky/Markey Cancer Center	-	-	-	4	15	-	-	-
University of Mississippi Medical Center	-	-	-	-	-	-	2	-
University of Nebraska Medical Center	-	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	6	-	7	-	4	4
University of Rochester LAPS	-	-	-	-	-	-	-	-
University of Texas Health Science Center at San Antonio	-	13	2	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	-	-	-
Upstate Carolina Consortium Community Oncology Research Program	-	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	9	-	4	4
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	-	-	-	-
Western States Cancer Research NCORP	-	-	-	-	-	-	2	1
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-
Total	25	91	66	6	260	16	89	67

Genitourinary Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	NRGGU011	NRGGU012	NRGGU013
Arnot Ogden Medical Center/Falck Cancer Center	-	-	-
Audie L Murphy VA Hospital	-	-	-
Banner MD Anderson Cancer Center	-	-	-
Banner University Medical Center - Tucson	-	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-
Carolinas Medical Center/Levine Cancer Institute	-	-	-
Cedars-Sinai Medical Center	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-
Columbia University Minority Underserved NCORP	-	-	-
CommonSpirit Health Research Institute	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-
Desert Regional Medical Center	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	1
Fred Hutchinson Cancer Research Center LAPS	7	-	7
Georgia Cares Minority Underserved NCORP	-	-	-
Georgia NCI Community Oncology Research Program	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	-
Gulf South Minority Underserved NCORP	5	2	-
Hartford Hospital	-	-	-
Hawaii Minority Underserved NCORP	-	-	-
Heartland Cancer Research NCORP	-	-	-
Henry Ford Hospital	-	-	-
Houston Methodist Hospital	-	-	-
Instituto Nacional De Cancerologia	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-
Intermountain Medical Center	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	-
Lahey Hospital and Medical Center	-	-	-
Loyola University Medical Center	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-
Montana Cancer Consortium NCORP	-	-	-
Mount Sinai Hospital	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-

Genitourinary Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	NRGGU011	NRGGU012	NRGGU013
New Mexico Minority Underserved NCORP	-	-	-
Northwell Health NCORP	-	-	-
Northwestern University LAPS	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-
Oregon Health and Science University	6	-	-
Regents of the University of Michigan	-	-	-
Rhode Island Hospital	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-
Sutter Cancer Research Consortium	3	1	-
The West Clinic - Wolf River	-	-	-
Tulane University School of Medicine	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-
UC San Diego Moores Cancer Center	-	3	-
UCLA / Jonsson Comprehensive Cancer Center	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-
U Alabama at Birmingham / Deep South Research Consortium LAPS	-	-	-
University of Arkansas for Medical Sciences	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-
University of Colorado Cancer Center LAPS	2	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-
University of Mississippi Medical Center	-	-	-
University of Nebraska Medical Center	-	2	-
University of Oklahoma Health Sciences Center LAPS	-	2	5
University of Rochester LAPS	-	-	-
University of Texas Health Science Center at San Antonio	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-
Upstate Carolina Consortium Community Oncology Research Program	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-
Virginia Mason Medical Center	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-
Western States Cancer Research NCORP	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-
ALLIANCE	-	-	-
ECOG-ACRIN	-	-	-
NRG	-	-	-
Total	23	10	13

Immunotherapeutics Committee

Leadership

Co-Chairs: Siwen Hu-Lieskovan, MD, PhD
 Katerina Politi, PhD
 Executive Officer: Anne Chiang, MD, PhD
 Statisticians: Michael LeBlanc, PhD
 Katie Minichiello, MS
 Matt Chansky, BS

Designates

Data Coordinators: Michele Counts
 Pharmaceutical Science: Jordan P. McPherson, PharmD
 Kimberly McConnell, PharmD
 Protocol Project Manager: Robin Kamucheka
 Clinical Trial Program Manager: Sharon Palmer

Time/Location

Friday, May 1, 2026 8:30 a.m. - 10:30 a.m.
 Room: Seacliff CD (Bay Level)

Agenda

8:30 - 8:35 am Welcome & Immunotherapeutics Committee Update
 Siwen Hu-Lieskovan & Katerina Politi
SWOG Immunotherapeutics Committee Co-Chairs

8:35 – 8:50 am iMATCH Pilot Update: Stage II Update
 Paul Swiecicki, Katerina Politi, Siwen Hu-Lieskovan
S2101 Study Chairs

8:50 – 8:55 am Q & A

8:55 – 9:10 am Immunotherapeutic Strategies in Small Cell Lung
 Cancer - Anne Chi-An Chiang, MD, PhD
Executive Officer, Immunotherapeutics
Associate Cancer Center Director, Yale School of Medicine

9:10 – 9:25 am Alliance Immunotherapeutics Update
 Elad Sharon, MD, MPH
Associate Professor of Medicine
Dana Farber Cancer Institute

9:25 – 9:30 am Q & A

9:30 – 9:45 am ECOG-ACRIN Immunotherapeutics Update
 Yana G. Najjar, MD
Associate Professor of Medicine, University of
Pittsburgh, Director, Clinical and Translational Research
Center

9:45 – 9:50 am Q & A

9:50 – 10:05 am NRG Immunotherapeutics Update
 Susanna V Ulahannan, MD
Associate Professor of Medicine, University of
Oklahoma Health, Director Oklahoma TSET Phase 1
Program

10:05 – 10:10 am Cancer Immune Monitoring and Analysis Center
 (CIMAC) Update - Gheath Alatrash, MD
Associate Professor, University of Texas MD Anderson
Cancer Center, MDA CIMAC Co-Lead

10:10 – 10:15 am Q & A

10:15 – 10:30 am Final Comments & Closing Remarks
 Siwen Hu-Lieskovan & Katerina Politi
SWOG Immunotherapeutics Committee Co-Chairs

Active Studies

S2101, “Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study.” Drs. Hu-Lieskovan, Swiecicki and Politi. Activation: 10/14/22.

Immunotherapeutics Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	<i>S2101</i>
<i>Essentia Health NCI Community Oncology Research Program</i>	1
<i>Froedtert and the Medical College of Wisconsin LAPS</i>	5
<i>Heartland Cancer Research NCORP</i>	1
<i>Michigan Cancer Research Consortium NCORP</i>	1
<i>New Mexico Minority Underserved NCORP</i>	1
<i>Northwestern University LAPS</i>	1
<i>Pacific Cancer Research Consortium NCORP</i>	1
<i>Regents of the University of Michigan</i>	15
<i>UC Irvine Health/Chao Family Comprehensive Cancer Center</i>	2
<i>University of Arkansas for Medical Sciences</i>	2
<i>University of Utah - Huntsman Cancer Institute LAPS</i>	12
<i>ALLIANCE</i>	13
<i>ECOG-ACRIN</i>	11
<i>NRG</i>	10
<i>Total</i>	<i>76</i>

Leukemia Committee

Leadership

Chair: Harry P. Erba, MD, PhD
 Vice-Chair: Anjali S. Advani, MD
 Executive Officer:..... Alex Herrera, MD
 Statisticians: Megan Othus, PhD
 Anna Moseley, MS
 Matt Chansky, BS

Scientific Leadership

Translational Medicine:..... Jerald P. Radich, MD
 Pathology: David R. Head, MD
 Radiation Oncology:..... Austin Sim, MD
 Cytogenetics Liaison:..... Min Fang, MD, PhD

Designates

Cancer Control:..... Stephanie B. Tsai, MD
 Veterans Affairs: Tsewang Tashi, MD
 Data Coordinators: Roula Bustami
 Louise Highleyman, BA
 Cassie Villasin
 Oncology Research Professionals: Breanne Burke, BS
 Callie Wiskus, BS, CCRP
 Patient Advocate:..... Gail Sperling, MPH
 Pharmaceutical Science:..... Holly O. Chan, PharmD
 Yumena Kawasaki, PharmD
 Protocol Project Manager:..... Amy Doyle
 Protocol Project Manager:..... Samantha Bankston (MyeloMATCH)
 Clinical Trials Program Manager:..... Sharon Palmer
 Clinical Trials Program Manager:..... Sarah Cantu (MyeloMATCH)

Time/Location

Thursday, April 30, 2026 5:15 p.m. - 7:15 p.m.
 Room: Garden Room (Atrium Lobby Level)

Agenda

1. Updates in Leukemia Translational Medicine - Cecilia Yeung
2. Updates in ALL - Ibrahim Aldoss
3. MyeloMATCH - Laura Michaelis
4. Updates in CLL - Debbie Stephens and Mazyar Shadman

AML/MDS Studies

Closed Studies

S1612, “A Randomized Phase II/III Trial of “Novel Therapeutics” Versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older.” Drs. L. Michaelis, R. Walter, S. Assouline, et al. Activated: 12/22/17; Complete: 6/26/24.

S0919, “A Phase II Study of Idarubicin and Ara-C in Combination with Pravastatin for Poor-Risk Acute Myelogenous Leukemia (AML).” Dr. A. Advani. Re-Activated: 4/1/13; Closed: 9/15/17; Complete: 10/21/21.

S1203, “A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (NSC-701852) (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML).” Drs. Garcia-Manero and Pagel. Activated: 12/15/12; Closed: 11/4/15; Complete: 03/29/22.

CTS/A041701, “A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy.” Dr. L. Liesveld. Activated: 1/16/19. Closed: 9/16/24.

ALL Studies

Active Studies

S1905, “A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) / T-Cell Lymphoblastic Lymphoma (T-LBL).” Drs. A. Advani, N. Papadantonakis, and C. Yeung. Activated: 8/17/20.

CTS/A041501, “A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL.” Dr. A. Advani. Activated: 6/1/17. Temporarily closed to accrual: 1/16/26.

Developing Studies

S2507, “A Phase II Randomized Study of Blinatumomab with or without Revumenib for Patients with KMT2Ar B-ALL with persistent measurable residual disease (MRD).” Drs. I. Aldoss, A. Advani, W. Stock, J. McNeer, and C. Saygin.

Leukemia Committee

Closed Studies

S0333, “A Phase II Study of Double Induction Chemotherapy for Newly Diagnosed Non-L3 Adult Acute Lymphoblastic Leukemia with Investigation of Minimal Residual Disease and Risk of Relapse Following Maintenance Chemotherapy.” Drs. Forman and O’Donnell. Activated: 4/15/05; Closed: 11/1/09.

S1312, “A Phase I Study of Inotuzumab Ozogamicin in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Patients with Relapsed/Refractory CD22-Positive Acute Leukemia (Including B-ALL, Mixed Phenotypic Leukemia, and Burkitt’s Leukemia).” Drs. A. Advani and Liedtke. Activated: 4/1/14; Closed: 8/2/19.

S1318, “A Phase II Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients ≥ 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphocytic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients ≥ 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL and Philadelphia-Chromosome-Like Signature (Ph-like) ALL (Newly Diagnosed or Relapsed/Refractory) with Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF).” Drs. A. Advani and K. O’Dwyer. Activated: 1/12/15; Closed: 9/29/21.

CLL Studies

Active Studies

S1925, “Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL): EVOLVE CLL/SLL Study.” Drs. D. Stephens, B. Hill, J. Pagel, et al. Activated: 12/14/20.

Developing Studies

S2504, “A Randomized Phase II Study of Pirtobrutinib Plus R-CHOP vs. R-CHOP for Patients with Previously Untreated Richter Transformation (RT).” Drs. M. Shadman, D. Stephens, and A. Danilov.

Closed Studies

CTSU/EA9161, “A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL).” Dr. M. Shadman. Activated: 1/3/19. Closed: 4/30/21.

CTSU/A041702, “A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL).” Dr. B. Hill. Activation: 1/4/19. Closed: 7/15/22.

CML Studies

Closed Studies

S1712, “A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease.” Drs. K. Sweet and J. Radich. Activated: 7/20/18. Closed: 10/20/22.

MDS/MPN Studies

Developing Studies

S2603 “A Phase II Study of Nuvisertib and Decitabine-Cedazuridine for Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs).” Drs. A. Coltoff, A. Gerds, and F. El Chaer.

MyeloMATCH

Active Studies

MYELOMATCH, “Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MyeloMATCH Clinical Trials.” Drs. J. Radich and S. Jiwani. Activated: 5/16/24.

MM1YA-S01, “A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7+3) vs. (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger who are Considered High-Risk (Adverse) Acute Myeloid Leukemia as Determined by myeloMATCH; A myeloMATCH Clinical Trial.” Drs. P. Shami and T. Lin. Activated: 5/16/24.

MM10A-S03, “A Randomized Phase II trial of C-DEC, Venetoclax, and Enasidenib Compared with Azacitidine and Venetoclax for Newly Diagnosed Older Adults with IDH2 mutant AML: A myeloMATCH Substudy.” Drs. E. Huselton and U. Borate. Activated: 4/1/25

Developing Studies

MM10A-S04, “A Phase II Trial of ASTX727 with Standard Duration Versus Shorter Duration of Venetoclax in Genomically Heterogenous AML Among Adults Aged 60 or Older and Less Fit for Intensive Therapy: A myeloMATCH Substudy.” Drs. U. Borate and J. Jayanshu.

Leukemia Committee

MM10A-S05, "A RAS-Activated Biomark Driven Phase II Study Evaluating the Addition of Tuspentinib to CPX-351 Induction Therapy in Older Fit Adults with Acute Myeloid Leukemia: A myeloMATCH Substudy." Drs. J. Appelbaum, B. Jonas, and M. Konopleva.

MM1-S06, "A Phase II Study of Novel Agents with Venetoclax and the DNMT1 Inhibitor Cedazuridine-Decitabine for Newly Diagnosed Acute Myeloid Leukemia/Myelodysplastic Syndromes with TP53 Mutations (NAVIGATE-TP53): A myeloMATCH Substudy." Drs. R. Shallis, E. Winer, D. Sallman.

Clinical Trials Partnerships (CTP)

Active Studies

21CTP.LEUK01, "A Phase II Trial of Asciminib, Dasatinib, Prednisone, and Blinatumomab for Participants with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia." Drs. Advani, Liedtke and Radich. Activation: 5/15/25

Developing Studies

26CTP.LEUK02, "A Randomized Open Label Trial Comparing Momelotinib vs Dose-Adjusted Ruxolitinib for Treatment-Naïve, Cytopenic Myelofibrosis." Drs. Coltoff, Gerds, Borate, and Chen.

Leukemia Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	S1905	S1925	MYELOMATCH	MM1YA-S01	MM10A-S03	MM10A-EA02	MM1YA-CTG01	A041501
Banner University Medical Center - Tucson	-	1	5	1	-	1	-	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	-	6	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	2	7	-	-	-	-	-	4
Cancer Research for the Ozarks NCORP	-	1	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	5	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	1	-	-	-	-	-	-
Carolinas Medical Center/Levine Cancer Institute	-	-	3	-	-	1	1	-
Cedars-Sinai Medical Center	-	-	4	-	-	2	-	-
City of Hope Comprehensive Cancer Center	6	2	-	-	-	-	-	-
Dartmouth College - Dartmouth Cancer Center LAPS	-	1	-	-	-	-	-	-
Duke University - Duke Cancer Institute LAPS	-	1	7	3	1	1	-	-
Essentia Health NCI Community Oncology Research Program	-	1	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	4	3	-	-	-	-	-	-
Froedtert and the Medical College of Wisconsin LAPS	-	-	11	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	12	-	1	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	-	-	3	-	-	-	-	-
Henry Ford Hospital	-	3	6	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-
Intermountain Medical Center	-	-	-	-	-	-	-	2
Kaiser Permanente NCI Community Oncology Research Program	-	2	-	-	-	-	-	-
Loyola University Medical Center	-	1	12	-	1	3	-	-
Massachusetts Veterans Epidemiology Research and Information Center	-	-	5	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	5	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	7	19	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	1	-	-	-	-	-
Mount Sinai Hospital	-	-	-	1	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	16	3	-	-	-	-
New Mexico Minority Underserved NCORP	-	-	1	-	-	-	-	-
Northwell Health NCORP	-	-	-	-	-	-	-	-

Leukemia Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	S1905	S1925	MYELOMATCH	MM1YA-S01	MM10A-S03	MM10A-EA02	MM1YA-CTG01	A041501
Northwestern University LAPS	-	1	33	2	-	-	-	3
Ohio State University Comprehensive Cancer Center LAPS	-	-	9	2	-	-	-	-
Oregon Health and Science University	1	-	6	1	-	-	-	8
Our Lady of the Lake Hospital	-	-	2	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	-	1	27	-	-	-	-	-
STCC at DHR Health Institute for Research and Development	-	1	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	2	-	-	-	-	-	-
Stanford Cancer Institute Palo Alto	-	-	-	-	-	-	-	8
UC Davis Comprehensive Cancer Center LAPS	-	4	3	-	-	-	-	2
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	4	-	-	-	-	-	3
UC San Diego Moores Cancer Center	-	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	6	-	-	-	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-	41	4	-	-	1	1
University of Arkansas for Medical Sciences	-	-	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	2	-	-	-	-	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	1	43	5	-	-	3	-
University of Kentucky/Markey Cancer Center	-	-	5	-	-	2	-	-
University of Nebraska Medical Center	-	-	3	1	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	5	-	-	-	-	-
University of Rochester LAPS	4	14	53	5	-	3	1	7
University of Utah - Huntsman Cancer Institute LAPS	-	21	9	-	-	-	-	1
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	-	-	-	-
Western States Cancer Research NCORP	-	-	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	11	2	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	7	1	-	1	-	5
ALLIANCE	2	49	206	9	-	-	-	-
CCTG	-	14	56	-	-	-	-	-
COG	1	-	-	-	-	-	-	-
ECOG-ACRIN	2	18	186	12	3	-	-	-
NRG	-	6	35	1	2	-	-	-
Total	24	172	862	53	8	14	6	44

Leukemia Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	A041701	A041703	A042001	EA9152	EA9171	EA9181	EA9213
Banner University Medical Center - Tucson	-	-	-	-	-	-	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-	-	-	-	-
Carolinas Medical Center/Levine Cancer Institute	-	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	-	-	-
Dartmouth College - Dartmouth Cancer Center LAPS	-	-	-	-	-	-	-
Duke University - Duke Cancer Institute LAPS	-	-	-	-	-	3	-
Essentia Health NCI Community Oncology Research Program	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	-	-	3
Froedtert and the Medical College of Wisconsin LAPS	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	-	-	4	-
Heartland Cancer Research NCORP	-	-	-	-	-	-	-
Henry Ford Hospital	4	-	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	3	-
Intermountain Medical Center	-	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	-	-	-	-	-
Loyola University Medical Center	-	-	-	-	-	3	-
Massachusetts Veterans Epidemiology Research and Information Center	-	-	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	-	-	-	-	-	-	-
Northwell Health NCORP	2	-	-	-	-	-	-

Leukemia Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	A041701	A041703	A042001	EA9152	EA9171	EA9181	EA9213
Northwestern University LAPS	1	-	1	-	-	4	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-
Oregon Health and Science University	-	-	-	-	-	-	-
Our Lady of the Lake Hospital	-	-	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	-	-	-	-	-	-	-
STCC at DHR Health Institute for Research and Development	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-	-	-
Stanford Cancer Institute Palo Alto	-	-	3	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	1	-	-	-	12	-
UC San Diego Moores Cancer Center	-	-	-	-	-	2	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-	2	-	-	-	-
University of Arkansas for Medical Sciences	4	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	1	-	-	-	4	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	-	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	-	-
University of Nebraska Medical Center	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-	-	-	-	-
University of Rochester LAPS	27	3	4	-	-	13	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	-	3	-
Western States Cancer Research NCORP	-	-	-	-	2	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	2	3	2	1	-
ALLIANCE	-	-	-	-	-	-	-
CCTG	-	-	-	-	-	-	-
COG	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-
Total	38	5	12	3	4	52	3

Lung Committee

Leadership

Chair: Jhanelle E. Gray, MD
 Vice-Chair: Roy S. Herbst, MD, PhD
 Executive Officer:..... Anne Chiang, MD, PhD
 Statisticians: Yingqi Zhao, PhD
 Mary Redman, PhD
 Mia Hsieh, MS
 Katie Minichiello, MS
 James Moon, MS
 Sara Threlkel, BS

Scientific Leadership

Translational Medicine:
 Biology/Pathology Fred R. Hirsch, MD, PhD
 Ignacio I. Wistuba MD
 Imaging:..... Chadwick L. Wright MD, PhD
 Myrna C. Godoy, MD, PhD
 Radiation Oncology:..... Henry Park, MD
 Surgery: Wayne L. Hofstetter, MD
 Subcommittee Chairs:
 Early Stage Disease:..... Raymond Osarogiagbon, MD
 Eric Miguel Toloza, MD, PhD
 Locally Advanced Disease:..... Mary B. Daly, MD
 Tina Cascone, MD, PhD
 Shirish Gadgeel, MD (Early Therapeutics)
 Metastatic Disease: Rachel E. Sanborn, MD
 Sarah B. Goldberg, MD
 Community Engagement:..... Paul J. Hesketh, MD
 Suzanne Cole, MD

Designates

Cancer Control Liaison: Gary E. Goodman, MD
 Veterans Affairs: Chao H. Huang, MD
 Data Coordinators: Amy Johnson, CCRP
 Kevin Moralda, BS
 Larry Kaye
 Louise Highleyman, BA
 Pasarlai Ahmadzai, MD, MPH
 Clinical Research Project Manager: TBD
 Oncology Research Professionals: Lisa G. Davis, RN
 Patient Advocate:..... Barbara Martin, MS
 Pharmaceutical Science:..... Joyce Lee, PharmD
 Safae Ghouraiichi, PharmD
 Protocol Project Managers: Justine Trevino
 Gabe Chadwell (Lung-MAP)
 Sr. Protocol Project Manager:..... Jennifer Beeler, MA (Lung-MAP)

Clinical Trials Program Manager:..... Sarah Cantu
 Crystal Miwa (Lung-MAP)

Time/Location

Saturday, May 2, 2026 9:30 a.m. - 12:30 p.m.
 Room: Garden Room (Atrium Lobby Level)

Agenda

General Update & Accruals: Jhanelle E. Gray, MD

Upcoming Meetings and Deadlines

Accruals, Abstracts, and Publications

Thoracic Surgery Session: Eric Toloza, MD, PhD

Thoracic Radiation Session: Megan Daly, MD

Translational Medicine Session: Ignacio Wistuba, MD

Community Engagement: Paul J. Hesketh, MD & Lucy Gansauer, MSN, RN

Thoracic Medical Oncology: Jhanelle Gray, MD

S2409, "PRISM: A Multicohort PReclison SCLC Subtype Maintenance Phase II Trial of Durvalumab Versus Biomarker-Directed Novel Agents in Combination with Durvalumab in Extensive Stage Small Cell Lung Cancer (ES-SCLC)." Activated: 9/8/25; Accrual Goal: 900; Accrual: 21. Anne Chiang, MD and Alberto Chiappori

S2414 "A randomized phase III trial incorporating pathologic response in participants with early stage non-small cell lung cancer to optimize immunotherapy in the adjuvant setting (INSIGHT)". Activated: 3/14/25; Accrual Goal: 306; Accrual: 3. Jeremy Cetnar, MD, MS and Raymond Osarogiagbon, MD

CTIU2317/S2402, "Perioperative versus Adjuvant Systemic Therapy in Patients with Resectable Non-Small Cell Lung Cancer (PROSPECT LUNG)." Activated: 12/11/24; Accrual Goal: 1100. Accrual: 8. Raid Aljumaily, MD and Raymond Osarogiagbon, MD

LUNGMAP, "A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung- Map Screening Study)." Activated: 1/28/19; Accrual Goal: 6000; Accrual: 3937. Karen Reckamp, MD and David R. Gandara, MD

S1800E, "A Randomized Phase II Study of Docetaxel and Ramucirumab with or without Cemiplimab for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer

Lung Committee

(Lung-MAP Non-Matched Sub-Study).” Activated: 4/28/25; Accrual Goal: 378; Accrual: 69. Saiama Waqar, MD, MSCI and Tina Li, MD

S1900J, “A Phase II Study of Amivantamab SC in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with High MET Amplification (Lung-MAP Sub-Study).” Activated: 9/27/24; Accrual goal: 88; Accrual: 12; 4 (revision 1). Shirish Gadageel, MD and Christian Rolfo, MD

S1900G, “A Randomized Phase II Study of Capmatinib plus Osimertinib (Tagrisso) with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung- MAP Sub-Study).” Activated: 4/3/23; Accrual Goal: 66 (60 eligible); Accrual: 31; 24 (revision 1). Sarah Goldberg, MD, MPH and Ross Camidge, MD, PhD

S1900K, “A Randomized Phase II Study of Tepotinib with or without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study).” Activated: 12/18/2023; Accrual Goal: 56; Accrual: 24. Paul Paik, MD and Xiuning Le, MD, PhD

Open Discussion

Active Studies

LUNGMAP, “A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study).” Drs. Reckamp, Waqar, Redman, et al. Activation: 1/28/19.

S1900G, “A Randomized Phase II Study of INC280 (Capmatinib) plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study).” Drs. Goldberg and Camidge. Activation: 4/3/23.

S1900K, “A Randomized Phase II Study of Tepotinib with or without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study).” Drs. Paik and Le. Activation: 12/18/23.

S1900J, “A Phase II Study of Amivantamab Hyaluronidase in Participants with MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study).” Drs. Rolfo and Gadageel. Activation: 9/27/24.

S1800E, “A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or without Cemiplimab (REGN2810) for Participants Previously Treated with Platinum-based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study).” Drs. Waqar and Li. Activation: 4/28/25.

S2409, “PRISM: PREcision in SCLC via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC).” Drs. Chiang, Chiappori, Kim, et al. Activation: 9/8/25.

S2414, “A Randomized Phase III Trial Incorporating Pathologic Complete Response in Participants with Early Stage Non Small Cell Lung Cancer to Optimize Immunotherapy in the Adjuvant Setting (INSIGHT).” Drs. Cetnar and Osarogiagbon. Activation: 3/14/25.

CTSU/A081801, “Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO).” Dr. Gray. Activation: 6/3/20.

CTSU/A151216, “Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST).” Dr. Gandara. Activation: 8/18/14.

CTSU/EA5182, “Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC).” Dr. Goldberg. Activated:10/22/20.

CTSU/NRG-LU007, “Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial.” Dr. Park. Activated: 8/17/20.

Closed Studies

CTSU/NRG-CC003, “Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer.” Dr. Gaspar. Activation: 12/7/15; Temporary closure: 5/28/20; Reactivation: 7/27/20; Permanent closure: 6/21/22.

S1800A, “A Phase II Randomized Study of Ramucirumab Plus Pembrolizumab (MK-3475) Versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study).” Drs. Reckamp and Dragnev. Activation: 5/17/19. Permanently closed: 10/20/20.

S1800D, “A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1

Lung Committee

- Therapy (Lung-MAP Non-Match Sub-Study)." Drs. Wrangle and Husain. Activation: 2/15/22. Permanently closed: 3/10/23.
- S1900A**, "A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)." Drs. Riess and Wheatley-Price. Activation: 1/28/19. Permanently closed: 2/2/21.
- S1900B**, "A Phase II Study of Selpercatinib (LOXO-292) in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)." Drs. Elamin and Gray. Activation: 2/10/20. Permanently closed: 5/1/21.
- S1900C**, "A Phase II Study of Talazoparib Plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)." Drs. Skoulidis and Suga. Activation: 1/16/20. Permanently closed: 12/18/20.
- S1900E**, "A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN Lung-MAP Sub-Study)." Drs. Padda and Gerber. Activation: 4/2/21. Permanently closed: 12/27/24.
- S1900F**, "A Randomized Phase II Study of Carboplatin and Pemetrexed with or Without Selpercatinib (LY3527723) in Participants with Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy (Lung-MAP Sub-Study)." Drs. Gray and Elamin. Activation: 7/25/22. Permanently closed: 6/27/23.
- S1929**, "Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)." Drs. Karim, Reckamp, Gay, et al. Activation: 6/15/20; Step 1 Registration Permanently Closed 8/15/22; Step 2 Permanently Closed 10/15/22.
- S1934**, "NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy Before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer." Drs. Osarogiagbon, Huang, Decker, et al. Activation: 9/9/21; Temporary closure: 11/5/21; Reactivation: 2/15/22; Permanently closed 3/1/23.
- CTSU/EA5163/S1709**, "INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis." Dr. Chiang. Activation: 2/28/19. ; Closed to accrual: 3/1/24.
- S1701**, "A Randomized Phase II Trial of Carboplatin-Paclitaxel with or without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma." Drs. Tsao and Koczywas. Activation: 8/9/18; Closed to accrual: 10/15/22.
- S1827**, "MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)." Drs. Rusthoven, Brown, Wefel, et al. Activation: 1/10/20. Permanently closed to accrual: 12/15/25.
- S1914**, "A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC." Drs. Daly, Simone, Kelly, et al. Activation: 3/25/20. Closed to accrual: 9/6/24.
- S1933**, "A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status." Drs. Aljumaily, Mitin, and Wozniak. Activation: 6/15/20. Permanently closed to accrual: 2/15/26.
- S2302**, "PRAGMATICA: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer" Drs. Reckamp and Dragnev. Activation: 3/6/23; Closed to accrual: 12/20/24.
- CTSU/E4512**, "A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein." Dr. Li. Activation: 8/18/14; Closed to accrual: 5/10/24.
- CTSU/EA5181**, "Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC." Dr. Harkenrider. Activation: 4/9/20; Closed to accrual: 11/20/23.
- CTSU/NRG-LU002**, "Maintenance Systemic Therapy versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial." Dr. Gomez. Activation: 4/7/17; Temporary closure: 11/12/21; Closed to accrual: 12/06/23.
- CTSU/NRG-LU005**, "Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation

Lung Committee

Plus Atezolizumab." Dr. Hsu. Activation: 5/28/19; Closed to US and Canadian sites 6/23/22; Closed to accrual: 12/31/23.

CTSU/EA5191, "A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC." Dr. Massarelli. Activated: 5/22/20; Closed to accrual: 10/13/23.

NCI-Approved Concepts

S1900N, "A Randomized Phase II Study of Sacituzumab Govitecan Alone, Ivonescimab Alone, or Sacituzumab Govitecan and Ivonescimab in Participants with Previously-Treated Actionable Genomic Alteration Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Scott and Riess.

S2404, "Accelerating Drug Efficacy Evaluation thru Growth Rate and Overall Survival Correlations" Dr. Lawrence Schwartz and Dr. Karen Reckamp.

Concepts in Development

S1900P, "A Phase II Study of Sapanisertib Plus Serabelisib Plus Paclitaxel Versus Standard of Care Chemotherapy in Participants with NFE2L2, KEAP1 or PI3K Pathway-Positive Stage IV Squamous Cell Lung Cancers (ECOG-ACRIN Lung-MAP Sub-Study)." Drs. Paik and Riano.

S1900Q, "A Phase II Study of Zongertinib and Trastuzumab Deruxtecan in Participants with HER2-Positive Stage IV Non-Small Cell Lung Cancer (Alliance Lung-MAP Sub-Study)." Drs. Parikh and Doroshow.

S2608, "Sequencing of Immunotherapy and Chemoradiotherapy in Unresectable Stage III Non-small Cell Lung Cancer: A Randomized Phase III Study (SIMON)." Dr. Park.

Lung Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	LUNGMAP	S1800E	S1827	S1900E	S1900G	S1900J	S1900K	S1914
Arnot Ogden Medical Center/Falck Cancer Center	7	-	-	-	-	-	-	3
Ascension Via Christi Hospitals Wichita	1	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	-	-	1	-	-	-	-	1
Banner University Medical Center - Tucson	-	-	-	-	-	-	-	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	44	2	3	2	-	-	1	10
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	5	-	-	-	-	-
Boston Medical Center	-	-	7	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	11	-	2	2	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	4	-	-	-	-	-	-	7
Cancer Research for the Ozarks NCORP	52	-	-	-	-	-	-	9
Cancer Research of Wisconsin and Northern Michigan Consortium	39	-	7	4	-	-	-	8
Carle Cancer Center NCI Community Oncology Research Program	3	-	1	1	-	-	-	6
Carolinas Medical Center/Levine Cancer Institute	-	-	2	-	-	-	-	-
Cedars-Sinai Medical Center	21	-	-	1	1	-	-	4
City of Hope Comprehensive Cancer Center	5	-	1	-	-	-	-	-
Columbia University Minority Underserved NCORP	13	-	-	-	-	-	-	-
Columbus NCI Community Oncology Research Program	28	-	6	-	-	-	-	-
CommonSpirit Health Research Institute	39	-	1	-	-	-	-	1
Corewell Health William Beaumont University Hospital	-	-	-	-	-	-	-	-
Cotton O'Neil Cancer Center / Stormont Vail Health	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	2	-	-	-	-	-	-	-
Duke University - Duke Cancer Institute LAPS	-	-	-	-	-	-	-	-
Essentia Health NCI Community Oncology Research Program	18	-	-	-	-	-	-	3
Fred Hutchinson Cancer Research Center LAPS	6	-	-	-	2	-	-	-
Froedtert and the Medical College of Wisconsin LAPS	2	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	6	-	1	-	-	-	-	2
Georgia NCI Community Oncology Research Program	75	2	3	1	-	-	-	9
Grupo Oncologico Cooperativo de Investigacion	-	-	1	-	-	-	-	-
Gulf South Minority Underserved NCORP	20	-	3	-	-	-	-	3
Hartford Hospital	3	-	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	29	-	2	-	-	1	-	-
Heartland Cancer Research NCORP	156	1	9	6	-	-	-	40
Henry Ford Hospital	20	-	-	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia	-	-	1	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	8	-	-	-	-	-
Intermountain Medical Center	1	-	-	-	-	-	-	1
Kaiser Permanente NCI Community Oncology Research Program	93	-	-	8	-	-	1	3
Kansas City Veterans Affairs Medical Center	3	-	-	-	-	-	-	-
Lahey Hospital and Medical Center	35	-	-	-	-	-	-	4
Loma Linda University Medical Center	6	-	-	-	-	-	-	-
Loyola University Medical Center	26	-	-	-	-	-	-	1
Malcom Randall Veterans Administration Medical Center	22	1	-	-	-	-	-	-
Massachusetts Veterans Epidemiology Research and Information Center	65	-	4	1	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	25	-	-	2	1	-	-	-
Mercy Medical Center - Des Moines	8	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	129	1	4	7	2	-	-	12
Mission Hospital	1	-	-	-	-	-	-	-

Lung Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	LUNGMAP	S1800E	S1827	S1900E	S1900G	S1900J	S1900K	S1914
Moffitt Cancer Center	21	1	1	1	1	-	-	-
Montana Cancer Consortium NCORP	10	-	1	1	-	-	-	1
Mount Sinai Hospital	-	-	-	-	-	-	-	9
NCORP of the Carolinas (Prisma Health NCORP)	20	-	-	1	-	-	-	-
National Cancer Center-Korea	-	-	1	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	15	-	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	115	-	1	2	-	-	-	8
Northwell Health NCORP	-	-	-	-	-	-	-	1
Northwestern University LAPS	31	1	1	-	2	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	2	-	-	-	-	-	1	-
Oregon Health and Science University	13	-	-	-	1	-	1	1
Our Lady of the Lake Hospital	4	-	-	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	23	-	-	-	-	-	-	-
Regents of the University of Michigan	1	-	-	-	-	-	-	-
Salem Hospital	7	-	-	2	-	-	-	-
South Sound Care Foundation	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	56	-	8	1	-	-	1	14
Sutter Cancer Research Consortium	79	-	-	1	1	-	-	-
The Don and Sybil Harrington Cancer Center	13	-	-	1	-	-	-	-
The James Graham Brown Cancer Center at University of Louisville	-	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	48	3	1	2	1	-	-	11
UC Irvine Health/Chao Family Comprehensive Cancer Center	32	1	1	-	-	-	-	5
UC San Diego Moores Cancer Center	17	1	-	1	-	-	-	-
UPMC Hillman Cancer Center LAPS	91	2	12	7	-	-	-	2
USC Norris Comprehensive Cancer Center LAPS	-	-	7	-	-	-	-	7
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	11	-	-	-	-	-	-	17
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	15	-	4	-	1	1	1	6
University of Kansas Cancer Center - MCA Rural MU NCORP	109	3	1	1	-	-	-	-
University of Kentucky/Markey Cancer Center	58	3	1	-	-	-	-	-
University of Mississippi Medical Center	1	-	-	-	-	-	-	-
University of Nebraska Medical Center	-	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	35	1	1	-	-	-	-	6
University of Rochester LAPS	66	-	-	6	-	-	1	-
University of Texas Health Science Center at San Antonio	-	-	-	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	3	-	7	-	-	-	-	6
University of Utah - Huntsman Cancer Institute LAPS	2	1	4	-	-	-	1	5
Upstate Carolina Consortium Community Oncology Research Program	42	-	3	-	-	-	-	3
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	1	-	-	-	-	-	-	-
Western States Cancer Research NCORP	2	-	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	44	-	4	1	-	-	-	13
Yale University - Yale Cancer Center LAPS	32	2	5	3	4	-	-	11
ALLIANCE	916	14	29	21	3	1	4	42
CCTG	-	-	39	-	-	-	-	-
ECOG-ACRIN	382	5	11	19	-	-	6	31
NRG	522	4	89	12	3	-	-	91
Total	3,857	49	304	118	23	3	18	417

Lung Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	S1933	S2302	S2402	S2414	A081801	A082002	A151216	EA5162
Arnot Ogden Medical Center/Falck Cancer Center	-	-	-	-	-	-	-	-
Ascension Via Christi Hospitals Wichita	-	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	-	-	-	-	1	-	1	-
Banner University Medical Center - Tucson	-	2	-	-	-	-	7	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	1	16	1	1	4	-	26	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	-	-	-	-	-	-
Boston Medical Center	-	2	-	-	-	-	3	-
CWRU Case Comprehensive Cancer Center LAPS	-	18	-	-	21	-	59	-
Cancer Research Consortium of West Michigan NCORP	-	3	-	-	-	-	1	-
Cancer Research for the Ozarks NCORP	4	5	-	-	-	-	1	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	8	-	1	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	8	-	-	-	-	-	-
Carolinas Medical Center/Levine Cancer Institute	-	21	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	9	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	3	-	-	-	-	5	-
Columbia University Minority Underserved NCORP	1	7	-	-	-	-	-	-
Columbus NCI Community Oncology Research Program	-	4	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	1	-	-	-	-	2	-
Corewell Health William Beaumont University Hospital	-	-	-	-	-	-	2	-
Cotton O'Neil Cancer Center / Stormont Vail Health	-	-	-	-	-	-	3	-
Dayton NCI Community Oncology Research Program	-	-	-	-	1	-	8	-
Duke University - Duke Cancer Institute LAPS	-	2	-	1	-	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	10	-	-	-	-	15	3
Froedtert and the Medical College of Wisconsin LAPS	-	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	1	-	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	-	18	-	-	-	-	10	-
Grupo Oncologico Cooperativo de Investigacion	-	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	7	1	-	1	-	1	-
Hartford Hospital	-	4	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	7	-	-	-	-	-	-
Heartland Cancer Research NCORP	5	52	-	-	-	-	-	-
Henry Ford Hospital	1	-	-	-	2	-	44	1
Houston Methodist Hospital	-	2	-	-	-	-	8	-
Instituto Nacional De Cancerologia	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-	-	-	-	-	-
Intermountain Medical Center	-	-	-	-	1	-	3	-
Kaiser Permanente NCI Community Oncology Research Program	-	27	-	-	6	-	208	-
Kansas City Veterans Affairs Medical Center	-	1	-	-	-	-	-	-
Lahey Hospital and Medical Center	2	12	-	1	1	-	30	-
Loma Linda University Medical Center	-	-	-	-	-	-	10	-
Loyola University Medical Center	-	8	-	-	-	-	26	-
Malcom Randall Veterans Administration Medical Center	-	4	-	-	-	-	-	-
Massachusetts Veterans Epidemiology Research and Information Center	-	9	-	-	13	-	34	-
Medical University of South Carolina Minority Underserved NCORP	-	19	-	-	-	-	-	-
Mercy Medical Center - Des Moines	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	18	-	-	-	-	11	-
Mission Hospital	-	-	-	-	-	-	-	-

Lung Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	S1933	S2302	S2402	S2414	A081801	A082002	A151216	EA5162
Moffitt Cancer Center	-	52	-	-	28	-	83	-
Montana Cancer Consortium NCORP	1	1	-	-	-	-	-	-
Mount Sinai Hospital	-	2	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	-	-	1	-
National Cancer Center-Korea	-	-	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	1	3	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	-	1	-	3	-
Northwestern University LAPS	-	18	-	-	-	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	6	-	-	-	-	-	-
Oregon Health and Science University	-	3	-	-	8	-	24	-
Our Lady of the Lake Hospital	-	-	-	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	-	1	-	-	-	-	4	-
Regents of the University of Michigan	-	6	-	-	-	-	51	-
Salem Hospital	-	-	-	-	-	-	-	-
South Sound Care Foundation	-	3	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	7	-	1	-	-	-	-
Sutter Cancer Research Consortium	-	1	-	-	1	1	11	-
The Don and Sybil Harrington Cancer Center	-	-	-	-	-	-	-	-
The James Graham Brown Cancer Center at University of Louisville	-	-	-	-	-	-	5	-
UC Davis Comprehensive Cancer Center LAPS	-	15	-	-	1	2	46	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	1	-	-	-	-	15	-
UC San Diego Moores Cancer Center	-	-	-	-	-	-	5	-
UPMC Hillman Cancer Center LAPS	5	10	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	3	-	-	-	-	12	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	12	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	12	-	-	-	-	3	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	-	24	-
University of Colorado Cancer Center LAPS	-	3	-	-	2	-	58	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	5	-	-	1	-	31	-
University of Kentucky/Markey Cancer Center	-	9	-	-	-	1	5	-
University of Mississippi Medical Center	-	-	-	-	-	-	26	-
University of Nebraska Medical Center	-	-	-	-	1	-	-	-
University of Oklahoma Health Sciences Center LAPS	18	10	3	-	-	-	-	-
University of Rochester LAPS	-	14	1	-	-	-	-	-
University of Texas Health Science Center at San Antonio	-	1	-	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-	-	-	2	-
University of Utah - Huntsman Cancer Institute LAPS	-	4	-	-	-	-	-	-
Upstate Carolina Consortium Community Oncology Research Program	-	1	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	10	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	-	-	1	-
Western States Cancer Research NCORP	-	-	-	-	-	-	1	-
Wisconsin NCI Community Oncology Research Program	-	5	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	14	-	-	7	-	57	-
ALLIANCE	5	154	-	-	-	-	-	-
CCTG	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	90	-	-	-	-	-	-
NRG	2	55	-	-	-	-	-	-
Total	47	838	6	5	101	4	986	4

Lung Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	EA5182	EA5221	EA5231	NRGLU008
Arnot Ogden Medical Center/Falck Cancer Center	-	-	-	-
Ascension Via Christi Hospitals Wichita	-	-	-	-
Banner MD Anderson Cancer Center	-	-	-	-
Banner University Medical Center - Tucson	-	-	-	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	2	-	-	2
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	-	-
Boston Medical Center	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	1	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-	-
Carolinas Medical Center/Levine Cancer Institute	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-
Columbus NCI Community Oncology Research Program	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-
Corewell Health William Beaumont University Hospital	-	-	-	-
Cotton O'Neil Cancer Center / Stormont Vail Health	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-
Duke University - Duke Cancer Institute LAPS	-	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-
Froedtert and the Medical College of Wisconsin LAPS	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	-
Georgia NCI Community Oncology Research Program	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	-	-
Gulf South Minority Underserved NCORP	-	-	-	-
Hartford Hospital	1	-	1	-
Hawaii Minority Underserved NCORP	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-
Henry Ford Hospital	-	-	-	-
Houston Methodist Hospital	2	-	-	-
Instituto Nacional De Cancerologia	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-	-
Intermountain Medical Center	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	8	-	-	-
Kansas City Veterans Affairs Medical Center	-	1	-	-
Lahey Hospital and Medical Center	-	-	-	-
Loma Linda University Medical Center	-	-	-	-
Loyola University Medical Center	-	-	-	-
Malcom Randall Veterans Administration Medical Center	-	-	-	-
Massachusetts Veterans Epidemiology Research and Information Center	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-
Mercy Medical Center - Des Moines	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-
Mission Hospital	-	-	-	-

Lung Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	EA5182	EA5221	EA5231	NRGLU008
Moffitt Cancer Center	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-
Mount Sinai Hospital	8	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-
National Cancer Center-Korea	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-
New Mexico Minority Underserved NCORP	-	-	-	-
Northwell Health NCORP	-	-	-	-
Northwestern University LAPS	-	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-
Oregon Health and Science University	-	-	-	-
Our Lady of the Lake Hospital	-	-	-	-
Pacific Cancer Research Consortium NCORP	-	-	-	-
Regents of the University of Michigan	-	-	-	-
Salem Hospital	-	-	-	-
South Sound Care Foundation	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	3
The Don and Sybil Harrington Cancer Center	-	-	-	-
The James Graham Brown Cancer Center at University of Louisville	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	1	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	-
UC San Diego Moores Cancer Center	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-	-	-
University of Arkansas for Medical Sciences	-	1	-	-
University of Cincinnati Cancer Center-UC Medical Center	1	-	-	-
University of Colorado Cancer Center LAPS	-	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-
University of Mississippi Medical Center	-	-	-	-
University of Nebraska Medical Center	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-	-
University of Rochester LAPS	-	2	-	-
University of Texas Health Science Center at San Antonio	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-
Upstate Carolina Consortium Community Oncology Research Program	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-
Western States Cancer Research NCORP	1	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-
ALLIANCE	-	-	-	-
CCTG	-	-	-	-
ECOG-ACRIN	-	-	-	-
NRG	-	-	-	-
Total	25	4	1	5

Lymphoma Committee

Leadership

Chair-Elect: Sonali M. Smith, MD
 Vice-Chair: TBD
 Executive Officer: Alex Herrera, MD
 Statisticians: Michael LeBlanc, PhD
 Hongli Li, MS
 Gabby Lopez, MS
 Matt Chansky, BS

Scientific Leadership

Translational Medicine: Alexey Danilov, MD, PhD
 Radiation Oncology: Nicholas Burden Figura, MD
 Imaging: Lawrence H. Schwartz, MD
 Immunotherapeutics: Sweetha Thiruvengadam, MD
 Pathology: Joo Y. Song, MD
 Early Therapeutics: Nasheed Mohammad Hossain, MD

Designates

Adolescent & Young Adults: Boyu Hu, MD
 Cancer Control: TBD
 Veterans Affairs: Helen Ma, MD
 Data Coordinators: Alex Rangel, BS
 Gabi Herbert, MS, BS
 Laura Wells, BA
 Daria Chugina, MD, CCRPS
 Oncology Research Professionals: Erin M. Cebula, MPH
 Jacob Kedroske, BA
 Patient Advocate: Tricia Hernandez, MS
 Pharmaceutical Science: Dawud Nael Dawud Ellayan, PharmD
 Martina Fraga, PharmD
 Protocol Project Manager: Erin Rogers
 Clinical Trials Program Manager: Laura Gildner, MS

Time/Location

Saturday, May 2, 2026 11:45 a.m. - 1:45 p.m.
 Room: Grand Ballroom A (Street Level)

Agenda

1. **Welcome & Introductions** - Sonali Smith, MD
2. **Looking Back and Looking Forward: SWOG Lymphoma Committee Efforts Over the Past Decade**
 - Follicular Lymphoma
 - Hodgkin Lymphoma
 - DLBCL
 - Correlative Sciences

3. New studies

S2506: Marginal zone lymphoma - Dr. Hu
 S2504: Richter's transformation - Dr. Shadman

4. SWOG Trial Updates

a.	S2308	Nilanjan Ghosh, MD, PhD
b.	S2207	Jennifer Amengual, MD / Patrick Reagan, MD
c.	S1925 CLL	Deborah Stephens, DO
d.	S1918 phase 2 result timing	Elizabeth Brem, MD / Sonali Smith, MD

5. Open Studies From Other Groups

a.	EA4232 T-cell ASCT	Marc Hoffmann, MD
b.	AO51902 T-cell	Jennifer Amengual, MD
c.	AO52101 older MCL	Tyrel Phillips, MD
d.	AHOD2131 HL	Boyu Hu, MD

Developing Studies

S2506, "MOZART MZL: A Randomized 3-Arm Phase II Study Evaluating Mosunetuzumab Alone and In Combination with Either Zanubrutinib or Polatuzumab Vedotin for The Treatment of Patients with Relapsed/Refractory Marginal Zone Lymphoma." Drs. B. Hu, B. Hu, and S. Smith.

Active Studies

S1918, "A Phase II/III Randomized Study of R-miniCHOP With or Without CC-486 (Oral Azacytidine) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements." Drs. E. Brem and S. Smith. Activated: 3/19/21. Temporarily closed to accrual: 4/1/25.

S2114, "A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma." Drs. B. Hess and N. Hossain. Activated: 2/23/2023.

S2207, "Randomized phase II study of the addition of Targeted therapeutic agents to tafasitamab-based therapy in non-transplant-eligible patients with Relapsed/refractory Large B-cell Lymphoma." Drs. J. Amengual, P. Reagan, and S. Smith. Activated: 6/30/2023

Lymphoma Committee

S2308, “Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma.” Drs. N. Ghosh and J. Friedberg. Activated: 8/1/2024

CTSU/A051902, “A Randomized Phase II Study of CHO(E)P vs Oral Azacitidine-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-cell Lymphomas.” Dr. Mehta-Shah. SWOG Champion: Dr. J. Amengual. Activated 7/30/2021. Temporarily closed to accrual: 8/4/25.

CTSU/A052101, “A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients with Mantle Cell Lymphoma (INTERCON).” Dr. Beaven. SWOG Champion: Dr. T. Phillips. Activated 09/08/2023.

CTSU/AHOS2131, “A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma.” Dr. Henderson. SWOG Champion: Dr. B. Hu. Activated 04/28/2023.

Closed Studies

S1608, “Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma.” Dr. P. Barr. Activated: 8/10/17. Closed: 7/15/2024

CTSU/A051701, “Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas.” Dr. Abramson. SWOG Champion: Dr. S. Smith. Activated: 8/7/19. Closed: 12/14/2023.

CTSU/ANHL1931, “A Randomized Phase 3 trial of Nivolumab in Combination with Chemo immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B cell Lymphoma.” Dr. Roth. SWOG Champion: Dr. M. Kamdar. Activated 6/7/2021. Closed: 5/28/25.

CTSU/EA4151, “A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission.” Dr. Fenske. SWOG Champion: Dr. B. Till. Activated: 8/29/17. Closed 10/3/24.

CTSU/EA4181, “A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CA-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients \leq 70 years Old with Untreated Mantle Cell Lymphoma.” Dr.

Wagner-Johnson. SWOG Champion: Dr. S. Spurgeon. Activated: 10/3/19. Closed: 4/7/2023

Active Leukemia Studies

S1905, “A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL).” Drs. Advani, N.Papadantonakis, and C. Yueng. Activated: 8/17/20.

S1925, “A Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study.” Dr. D. Stephens. Activated: 12/14/20.

Developing Leukemia Studies

S2504, “A Randomized Phase II Study of Pirtobrutinib Plus R-CHOP vs. R-CHOP for Patients with Previously Untreated Richter Transformation (RT).” Drs. M. Shadman, D. Stephens, and A. Danilov.

Closed Cancer Care Delivery Study

S1912CD, “A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT).” Dr. V. Shankaran. Activated 7/26/2021. Closed 12/16/2024.

Lymphoma Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	S1608	S1918	S2114	S2207	S2308	A051902	A052101	AHOD2131	ANHL1931
Banner University Medical Center - Tucson	2	-	2	-	3	-	-	-	-
Baptist Mem Health Care/Mid So Minority Underserved NCORP	-	1	2	-	1	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	4	-	-	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	3	-	5	-	-	-	-	5	-
Cancer Research for the Ozarks NCORP	1	1	-	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	1	2	-	3	-	-	-	-	-
Carolinas Medical Center/Levine Cancer Institute	-	-	14	-	13	-	-	-	-
Cedars-Sinai Medical Center	-	1	-	6	2	-	-	3	1
City of Hope Comprehensive Cancer Center	8	11	-	-	9	-	-	19	15
Columbia University Minority Underserved NCORP	-	6	6	2	-	3	-	1	3
Columbus NCI Community Oncology Research Program	1	-	-	-	-	-	-	-	-
Dartmouth College - Dartmouth Cancer Center LAPS	-	-	1	-	-	-	-	-	-
Duke University - Duke Cancer Institute LAPS	-	-	-	-	2	-	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	-	-	-	-	1	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	-	7	-	-	-
Froedtert and the Medical College of Wisconsin LAPS	-	-	5	-	6	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	2	-	-	1	-	-	-	-
Gulf South Minority Underserved NCORP	-	2	-	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	1	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	1	-	-	-	2	-	-	-	-
Henry Ford Hospital	-	-	-	-	2	-	-	3	-
Intermountain Medical Center	-	1	-	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	3	3	-	-	-	-	-	8	-
Loyola University Medical Center	-	-	2	-	-	-	-	-	-
Medical University of So Carolina Minority Underserved NCORP	2	3	21	-	5	-	-	2	-
Michigan Cancer Research Consortium NCORP	1	8	-	1	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	1	-	-	-	-	-	1
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	-	-	-	-

Lymphoma Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	S1608	S1918	S2114	S2207	S2308	A051902	A052101	AH02131	ANHL1931
Northwestern University LAPS	1	-	-	-	-	-	-	-	1
Ohio State University Comprehensive Cancer Center LAPS	-	2	-	-	4	-	-	-	-
Oregon Health and Science University	-	-	4	-	5	-	-	5	-
Pacific Cancer Research Consortium NCORP	-	-	12	1	2	-	-	-	-
Rhode Island Hospital	-	-	-	-	1	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	6	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	7	-	-	-	-	-	-	2
UC San Diego Moores Cancer Center	-	-	-	-	-	-	-	-	-
U of Alabama at Birmingham / Deep So Research Consortium LAPS	-	-	-	-	7	-	-	-	-
University of Arkansas for Medical Sciences	-	-	9	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	1	-	-	-
University of Colorado Cancer Center LAPS	-	-	-	-	7	-	-	1	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	8	-	16	-	5	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	-	-	-	-
University of Nebraska Medical Center	-	-	-	-	-	-	2	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	1	-	-	-	-	-	-
University of Rochester LAPS	16	-	10	8	16	8	16	25	10
University of Texas Health Science Center at San Antonio	-	-	-	2	-	-	-	1	-
University of Texas MD Anderson Cancer Center LAPS	3	-	-	-	19	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	1	12	-	-	7	-	-	8	-
Upstate Carolina Consortium Community Oncology Research Prog	1	1	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	5	-	1	-	1	-	-
Wisconsin NCI Community Oncology Research Program	-	2	-	-	2	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	-	1	1	-
ALLIANCE	17	42	55	7	54	-	-	-	-
ECOG-ACRIN	5	17	13	-	28	-	-	-	-
NRG	11	7	7	4	11	-	-	-	-
Total	78	136	183	34	232	19	26	82	33

Lymphoma Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	EA412	EA4151	EA4232
Banner University Medical Center - Tucson	-	1	-
Baptist Mem Health Care/Mid So Minority Underserved NCORP	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	23	-
Cancer Research Consortium of West Michigan NCORP	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-
Carolinas Medical Center/Levine Cancer Institute	-	14	-
Cedars-Sinai Medical Center	-	-	-
City of Hope Comprehensive Cancer Center	-	18	-
Columbia University Minority Underserved NCORP	1	-	-
Columbus NCI Community Oncology Research Program	-	-	-
Dartmouth College - Dartmouth Cancer Center LAPS	-	-	-
Duke University - Duke Cancer Institute LAPS	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	15	-
Froedtert and the Medical College of Wisconsin LAPS	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-
Gulf South Minority Underserved NCORP	-	-	-
Hawaii Minority Underserved NCORP	-	-	-
Heartland Cancer Research NCORP	-	-	-
Henry Ford Hospital	-	-	-
Intermountain Medical Center	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	11	-	-
Loyola University Medical Center	-	5	-
Medical University of So Carolina Minority Underserved NCORP	-	2	-
Michigan Cancer Research Consortium NCORP	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	2	-
Nevada Cancer Research Foundation NCORP	1	-	-

Lymphoma Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	<i>E4412</i>	<i>EA4151</i>	<i>EA4232</i>
<i>Northwestern University LAPS</i>	-	-	-
<i>Ohio State University Comprehensive Cancer Center LAPS</i>	-	-	-
<i>Oregon Health and Science University</i>	-	7	-
<i>Pacific Cancer Research Consortium NCORP</i>	-	-	-
<i>Rhode Island Hospital</i>	-	-	-
<i>Southeast Clinical Oncology Research Consortium NCORP</i>	-	-	-
<i>UC Irvine Health/Chao Family Comprehensive Cancer Center</i>	-	-	-
<i>UC San Diego Moores Cancer Center</i>	-	1	-
<i>U of Alabama at Birmingham / Deep So Research Consortium LAPS</i>	7	5	-
<i>University of Arkansas for Medical Sciences</i>	-	-	-
<i>University of Cincinnati Cancer Center-UC Medical Center</i>	-	2	-
<i>University of Colorado Cancer Center LAPS</i>	-	-	-
<i>University of Kansas Cancer Center - MCA Rural MU NCORP</i>	-	-	-
<i>University of Kentucky/Markey Cancer Center</i>	-	3	-
<i>University of Nebraska Medical Center</i>	-	-	-
<i>University of Oklahoma Health Sciences Center LAPS</i>	-	-	-
<i>University of Rochester LAPS</i>	-	11	1
<i>University of Texas Health Science Center at San Antonio</i>	-	-	-
<i>University of Texas MD Anderson Cancer Center LAPS</i>	-	-	-
<i>University of Utah - Huntsman Cancer Institute LAPS</i>	-	20	-
<i>Upstate Carolina Consortium Community Oncology Research Prog</i>	-	-	-
<i>Wayne State University - Karmanos Cancer Institute LAPS</i>	-	1	-
<i>Wisconsin NCI Community Oncology Research Program</i>	-	-	-
<i>Yale University - Yale Cancer Center LAPS</i>	-	5	-
<i>ALLIANCE</i>	-	-	-
<i>ECOG-ACRIN</i>	-	-	-
<i>NRG</i>	-	-	-
Total	20	135	1

Melanoma Committee

Leadership

Chair: Sapna P. Patel, MD
 Vice-Chair: Roger S. Lo, MD, PhD
 Executive Officer:..... Hagen Kennecke, MD, MHA
 Statisticians: Michael Wu, PhD
 Megan Othus, PhD
 James Moon, MS
 Gabby Lopez, MS
 Matt Chansky, BS

Scientific Leadership

Translational Medicine: TBD
 Radiation Oncology: TBD
 Surgery: John Robert Hyngstrom, MD
 Dermatology: TBD
 Imaging: TBD
 Medical Oncology: TBD
 Pathology: TBD
 Non-Melanoma Skin Cancer: Nikhil I. Khushalani, MD
 Early Therapeutics: TBD
 SWOG's ECOG Liaisons: Sunandana Chandra, MD
 Gerald Paul Wright, Jr., MD
 ECOG's SWOG Liaisons: David H. Lawson, MD
 Michael Lowe, MD

Designates

Prevention: Sancy Leachman, MD, PhD
 Data Coordinator: Michele Counts, BS
 Tonya Johnson, BS
 Oncology Research Professionals: Kathryn Allen, BA, CCRP
 Patient Advocate: Sara Selig, MD, MPH
 Pharmaceutical Science: Sun "Coco" Yang, PharmD, PhD
 Stephanie Elise Trexler, PharmD
 Protocol Project Manager: Catrina De Los Santos-Mireles
 Clinical Trials Program Manager: Laura Gildner, MS

Time/Location

Saturday, May 2, 2026 11:30 a.m. - 1:30 p.m.
 Room: Grand Ballroom B (Street Level)

Agenda

Welcome & Introductions - Sapna Patel, MD

Keynote Speaker: "Meet our New Patient Advocate: Sara Selig"
 Sara Selig, MD, MPH

Active Studies

A091903, "A Randomized Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with Resected Mucosal Melanoma."
 SWOG Champion: K. Tsai, MD (SWOG) Activated 06/01/2022. Temporarily Closed to Accrual as of 10/10/2023. Registration to Arm 3 is Temporarily Closed to Accrual as of 06/16/2025.

Developing Studies

S2601, "Multicenter Selective Lymphadenectomy Trial – III: A randomized phase 3 noninferiority trial of selective lymphadenectomy of index lymph nodes vs. full therapeutic lymphadenectomy in patients with stage III melanoma achieving major pathologic response to neoadjuvant immunotherapy". Dr. Faries

Closed Studies

CTSU/EA6141, "Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma." SWOG Champion: Dr. K. Kim. Activated: 09/10/2015. Closed to accrual as of 1/8/2026.

S2015, "Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma." Dr. Mammen. Activated: 04/08/22. Closed to accrual as of 8/28/2025.

CTSU/EA6192, "The BAMB2 (BRAF, Autophagy, MEK Inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib with or Without Hydroxychloroquine in Advanced BRAF V600E/K Melanoma with Elevated LDH". SWOG Champion: Dr. Truong. Activated:10/23/2020. Closed to accrual as of 9/3/2025.

CTSU/EA6174, "STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab, a Phase III Trial." SWOG Champion: Dr. Hsu. Activated: 10/01/2018. Closed to Accrual as of 07/01/2024.

S2000, "A Randomized Phase II Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases." Dr. Eroglu. Activated: 09/23/2020. Closed: 6/18/2024

S1801, "A Phase II Randomized Study of Adjuvant Versus Neoadjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High Risk Melanoma." Dr. Patel. Activated: 12/06/18. Closed: 05/05/2022.

Melanoma Committee

S1512, “A Phase II and Pilot Trial of PD-1 Blockade with MK-3475

(Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM).” Drs. Kendra and Hu-Lieskovan. Activated: 10/20/16. Closed: 06/04/2021.

S1607, “A Phase II Study of Combining Talimogene Laherparepvec (T-VEC)

(NSC-785349) and MK-3475 (Pembrolizumab) in Patients with Advanced Melanoma who have Progressed on Anti-PD1/L1 Based Therapy.” Dr. Hu-Lieskovan. Activated: 10/02/17. Closed: 11/1/20.

S1616, “A Phase II Randomized Study of Nivolumab (NSC-748726)

with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent.” Dr. VanderWalde. Activated: 07/17/2017. Closed: 07/15/2020.

S1404, “A Phase III Randomized Study of MK3475 versus High-Dose

Interferon a-2b for Resected High-Risk Melanoma.” Dr. Patel. Activated: 10/15/2015. Closed: 11/02/2017.

CTSU/EA6134, “DREAMseq (Doublet, Randomized Evaluation in Advanced

Melanoma Sequencing) a Phase III Trial.” SWOG Champion: Dr. Chmielowski. Activated: 7/13/15. Closed: 9/30/2021.

CTSU/EA6183, “A Phase II Neoadjuvant Study of Encorafenib with

Binimetinib in Patients with Resectable Locoregional Metastases from Cutaneous or Unknown Primary Melanoma (Stages III N1B/C/D).” SWOG Champion: C. D. Lao, MD, MPH Activated: 02/18/2020. Closed: 09/23/2022.

Melanoma Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	S2015	A091903	EA6141	EA6192	EA6194
Banner MD Anderson Cancer Center	39	-	-	-	-
Banner University Medical Center - Tucson	-	-	-	1	1
Cancer Research Consortium of West Michigan NCORP	112	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	1	-	-
Cedars-Sinai Medical Center	30	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	3	-	-
Columbia University Minority Underserved NCORP	9	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	2	-	-
Duke University - Duke Cancer Institute LAPS	20	-	-	-	-
Froedtert and the Medical College of Wisconsin LAPS	15	-	-	-	-
Georgia NCI Community Oncology Research Program	11	-	-	-	-
Intermountain Medical Center	44	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	6	-	31	-	-
Medical University of So Carolina Minority Underserved NCORP	20	-	-	-	-
Moffitt Cancer Center	58	-	-	-	-
New Mexico Minority Underserved NCORP	7	-	-	-	-
Northwell Health NCORP	10	-	-	-	-
Northwestern University LAPS	46	-	1	5	-
Ohio State University Comprehensive Cancer Center LAPS	36	-	-	3	-
Regents of the University of Michigan	25	-	1	-	-
Sutter Cancer Research Consortium	-	-	7	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	18	-	4	-	3
USC Norris Comprehensive Cancer Center LAPS	5	1	-	-	-
University of Arkansas for Medical Sciences	7	-	-	1	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	2	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	48	-	3	-	-
University of Kentucky/Markey Cancer Center	13	-	-	-	-
University of Nebraska Medical Center	4	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	1	-	-	-	-
University of Rochester LAPS	7	-	13	-	-
University of Texas Health Science Center at San Antonio	3	-	1	-	-
University of Texas MD Anderson Cancer Center LAPS	23	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	33	-	-	-	-
Western States Cancer Research NCORP	-	-	1	-	-
Wisconsin NCI Community Oncology Research Program	16	-	-	-	-
Yale University - Yale Cancer Center LAPS	29	-	8	-	-
ALLIANCE	132	-	-	-	-
ECOG-ACRIN	228	-	-	-	-
NRG	102	-	-	-	-
Total	1,157	1	78	10	4

Radiation Oncology Committee

Leadership

Chair:..... Chul Ha, MD
 Vice-Chair:..... Lisa Kachnic, MD
 Executive Officer:..... Lisa Kachnic, MD
 Statisticians: Sam Callis, MS

Designates

AI Subcommittee Chair: T.J. FitzGerald, MD
 Breast Committee Liaison:..... Reshma Jagsi, MD, DPhil
 Transplant & Cell Therapies Committee Liaison: Austin Sim, MD
 Cancer Care Delivery Committee Liaison:..... Eileen Connolly, MD
 Prevention, Screening & Surveillance Liaison:..... Eileen Connolly, MD
 CNS Working Group Liaison:..... Tony Wang, MD
 Gastrointestinal Committee Liaison: David Horowitz, MD
 Genitourinary Committee Liaison:..... James Yu, MD
 Immunotherapeutics Committee Liaison: Robert Samstein, MD, PhD
 Leukemia Committee Liaison: Austin Sim, MD
 Lung Committee Liaison:..... Henry Park, MD
 Lymphoma Committee Liaison: Nick Figura, MD
 Melanoma Committee Liaison: Evan Wuthrick, MD
 Myeloma Committee Liaison:..... Chelsea Pinnix, MD, PhD
 Sarcoma Working Group Liaison: Jeremy Harris, MD
 Symptom Management & Survivorship Liaison: .. Erin Gillespie, MD, MPH
 Theranostics Subcommittee Chair..... Jeffrey Wong, MD
 Theranostics Subcommittee Vice-Chairs: Jeremie Calais MD, PhD
 Tanya Dorff, MD
 Data Coordinator: Larry Kaye
 Protocol Project Manager:..... Kali Nicks

3:40 - 4:00 pm SLOW ROLL: SaLvage radiation Or Watchful waiting, Reimaging upOn eLevated Labs with delayed salvage - Martin Ma, MD, PhD

4:00 - 4:20 pm NEO-ROBOT (**NEO**adjuvant immunotherapy with Regional nodes **O**r **B**ladder **O**nly radiation in Trimodality therapy for NOMIBC) and Ai-ROBOT (Adjuvant immunotherapy with Regional nodes **O**r **B**ladder **O**nly radiation in Trimodality therapy for N+ MIBC) for muscle invasive bladder cancer - Sameer Jhavar, MD

4:20 - 4:40 pm Dosimetry guided ¹⁷⁷Lu-PSMA-617 treatment vs SOC ¹⁷⁷Lu-PSMA-617 treatment for mCRPC - Ravi Patel, MD, PhD

4:40 - 5:00 pm Phase III randomized study testing non-inferiority of shorter-course radiation versus standard fractionation for high-risk, resectable sarcoma (S2505) - Jeremy Harris, MD

5:00 pm Closing Remarks - Chul S. Ha, MD

Time/Location

Thursday, April 30, 2026 3:00 p.m. - 5:00 p.m.
 Room: Seacliff AB (Bay Level)

Agenda

3:00 - 3:05 pm Welcome - Chul S. Ha, MD

3:05 - 3:10 pm Report from Executive Officer - Lisa Kachnic, MD

3:10 - 3:15 pm Update from IROC - TJ FitzGerald, MD

3:15 - 3:20 pm Update from NCI - Jacek Capala, PhD, DSc

3:20 - 3:40 pm Phase 3 trial of ARPI+ADT vs. ARPI+SBRT+¹⁷⁷Lu in mHSPC - Adeel Kaiser, MD

Publication List by Committee

The papers listed below from 2025 and 2026 have not appeared in previous Group Meeting publications listings. Accepted and submitted manuscripts are also listed, with the journal names withheld to honor journal embargo policies. Conference abstracts are not included.

ADOLESCENT AND YOUNG ADULT (AYA) COMMITTEE

Published/Accepted Manuscripts

None this cycle

Submitted Manuscripts

None this cycle

BARLOGIE-SALMON MYELOMA COMMITTEE

Published/Accepted Manuscripts

S1702 Isatuximab in Relapsed AL Amyloidosis: Results of a Prospective Phase II Trial (SWOG S1702). T Parker, A Rosenthal, V Sancharawala, H Landau, E Campagnaro, P Kapoor, N Neparidze, S Girnius, P Hagen, E Scott, A Hoering, B Durie, R Orlowski. *Blood* Sep 9;blood.2024027962, 2025. <https://pubmed.ncbi.nlm.nih.gov/40925099/>

Submitted Manuscripts

Interim Analysis in Clinical Trials: Caution Against Premature Conclusions – The SWOG Multiple Myeloma S0777 Case Study. Goren E, Sexton R, Orlowski R, Hoering A. Submitted 2025.

BREAST COMMITTEE

Published/Accepted Manuscripts

S0221 Long-term follow-up of S0221, comparing alternative dose schedules of anthracycline/taxane therapy in early breast cancer. Ali A, Barlow WE, Moore HCF, Hobday TJ, Isaacs C, Salim M, Albain KS, Chew HK, Burton GV, Srkalovic G, McGregor BA, Flaherty LE, Lew DL, Gralow JR, Hortobagyi GN, Sharma P, Puztai L, Budd GT. *JNCI Cancer Spectr*. 2026 Mar 14;pkag024. doi: 10.1093/jncics/pkag024. Online ahead of print. <https://pubmed.ncbi.nlm.nih.gov/41832961/>

S0500 Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis. Wolfgang Janni, Thomas W P Friedl, Tracy C Yab, Francois-Clément Bidard, Massimo Cristofanilli, Daniel F Hayes, Michail Ignatiadis, Meredith M Regan, Catherine Alix-Panabieres, William E Barlow, Carlos Caldas, Lisa A Carey, Luc Dirix, Tanja Fehm, Jose A Garcia-Saenz, Paola Gazzaniga, Daniele Generali, Lorenzo Gerratana, Rafael Gisbert-Criado, William Jacot, Zefei Jiang, Simon A Joosse, Evi Lianidou, Rafael López López, Mark J M Magbanua, Luis Manso, Dimitris Mavroudis, Volkmar Müller, Elisabetta Munzone, Klaus Pantel, Jean-

Yves Pierga, Brigitte Rack, Sabine Riethdorf, Hope S Rugo, Kostandinos Sideras, Stefan Sleijfer, Jeffrey Smerage, Justin Stebbing, Leon W M M Terstappen, Jose Vidal-Martinez, Markus Wallwiener, Karthik V Giridhar, Minetta C Liu. *Clin Cancer Res*. 2025 Jun 3;31(11):2196-2209. doi: 10.1158/1078-0432.CCR-24-3108.

<https://pubmed.ncbi.nlm.nih.gov/40100138/>

S1007 Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial. Irene M Kang, Jamie K Forschmiedt, Michelle M Loch, Danika L Lew, William E Barlow, Julie R Gralow, Funda Meric-Bernstam, Kathy S Albain, Daniel F Hayes, Nancy U Lin, Edith A Perez, Lori J Goldstein, Priya Rastogi, Anne F Schott, Rick Baehner, Priyanka Sharma, Debasish Tripathy, Lajos Pusztai, Gabriel N Hortobagyi, Kevin Kalinsky, N Lynn Henry. *JAMA Oncol*. 2025 Dec 11:e255220. doi: 10.1001/jamaoncol.2025.5220. Online ahead of print. [see also Symptom Management & Survivorship Committee]

<https://pubmed.ncbi.nlm.nih.gov/41379459>

A221405 Breastfeeding after hormone-receptor positive breast cancer: results from the POSITIVE trial. Fedro A Peccatori, Samuel M Niman, Ann H Partridge, Monica Ruggeri, Marco Colleoni, Cristina Saura, Chikako Shimizu, Anna B Satersdal, Judith R Kroep, Karen Gelmon, Frederic Amant, Audrey Mailliez, Halle C F Moore, Manuel Ruiz-Borrego, Janice M Walshe, Virginia F Borges, Andrea Gombos, Akemi Kataoka, Christine Rousset-Jablonski, Simona Borstnar, Junko Takei, Jeong E Lee, Christobel Saunders, Vesna Bjelic-Radicic, Snezana Susnjar, Fatima Cardoso, Natalie J Klar, Teresa Ferreira, Sarra El-Abed, Martine Piccart, Larissa A Korde, Aron Goldhirsch, Richard D Gelber, Olivia Pagani, Hatem A Azim Jr; International Breast Cancer Study Group and the POSITIVE Trial Collaborators. *Journal of Clinical Oncology*. 2025 Aug 20;43(24):2712-2719. doi: 10.1200/JCO-24-02697. Epub 2025 Jul 9. [see also Symptom Management & Survivorship Committee]

<https://pubmed.ncbi.nlm.nih.gov/40632989/>

C40601/Others Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC). A Fernandez-Martinez, M Tanioka, S G Ahn, P Zagami, T Pascual, M Rediti, G Tang, K A Hoadley, D Venet, N U Rashid, P A Spears, S Di Cosimo, E de Azambuja, A Choudhury, P Rastogi, M N Islam, J Cortes, A Llombart-Cussac, S M Swain, C Sotiriou, A Prat, C M Perou, L A Carey. *Ann Oncol*. 2025 Apr;36(4):403-413. doi:

Publication List by Committee

10.1016/j.annonc.2024.12.010. Epub 2024 Dec 18. NIHMS2052322.

<https://pubmed.ncbi.nlm.nih.gov/39706338/>

Submitted Manuscripts

S1007 Recurrence Score Gene Group Components and Outcomes in the RxPONDER Trial (SWOG S1007). Y Abdou, J Hoag, W Barlow, K Albain, J Gralow, J Gralow, F Meric-Bernstam, D Hayes, N Lin, E Perez, L Goldstein, S Chia, S Dhesy-Thind, P Rastogi, A Schott, J Racz, D Tripathy, G Hortobagyi, L Pusztai, P Sharma, K Kalinsky. Submitted 2025.

S1007 Ovarian Reserve as a Measure of Adjuvant Chemotherapy Benefit in Women with Hormone Receptor Positive (HR+), HER2-negative, Node-positive Breast Cancer in SWOG S1007 (RxPONDER). Kalinsky K, Barlow W, Puri R, Mitra A, Home T, Gralow J, Albain K, Hayes D, Delalogue S, Lin N, Perez E, Goldstein L, Chia S, Rastogi P, Schott A, Shak S, Tripathy D, Hortobagyi G, Meric-Bernstein F, Sharma P, Pusztai L, Thompson A, Pathak H, Godwin A. Submitted 2025.

S1706 Toxicity in a Randomized Trial Comparing Radiotherapy +/- Olaparib for Inflammatory Breast Cancer. Reshma Jaggi, Allison Meisner, Pavani Chalasani, William E. Barlow, Jennifer R. Bellon, Norah N. Lynn Henry, Danika Lew, Martha M. Matuszak, Jean M. Moran, Lori J. Pierce, Eileen Rakovitch, Stephanie J. Reyes, Corey Speers, Joseph M. Unger, Julia R. White, Wendy A. Woodward, Richard Cedric Zellars, Lajos Pusztai, Priyanka Sharma. Submitted 2025. [see also Symptom Management & Survivorship Committee]

CANCER CONTROL AND PREVENTION

CANCER CARE DELIVERY COMMITTEE

Published/Accepted Manuscripts

Multiple Studies Screening and Referral for Health-Related Social Needs and Financial Distress: Current Processes Among National Cancer Institute Community Oncology Research Program Practices. Matthew P Banegas, Chandysten L Nightingale, Emily V Dressler, Mary E Cooley, Charles Kamen, Lynne I Wagner, Carol A Kittel, Efen J Flores, Ruth Carlos, Arissa Milton, Elyse Park, Susan K Parsons, Eden Gurganus Wood, Kah Poh Loh, Scott Ramsey; Landscape Committee. *JCO Oncol Pract*. 2025 Oct;21(10):1512-1521. doi: 10.1200/OP-24-00902. Epub 2025 Mar 13. NIHMS2055153. <https://pubmed.ncbi.nlm.nih.gov/40080774/>

Multiple Studies Global perspectives on patient-centered outcomes: advancing patient-centered cancer clinical trials globally. Cecilia Monge; Linsey Eldridge; Paul C Pearlman; Viji Venkatesh; Michelle Tregear; Patrick J Loehrer, Sr; Annette Galassi; Satish Gopal; Ophira Ginsburg. *J Natl Cancer Inst Monogr*. 2025 Mar 1;2025(68):35-41. doi: 10.1093/jncimonographs/lgae043. <https://pubmed.ncbi.nlm.nih.gov/39989041/>

Multiple Studies Composition of Health Care Contact Days and Mortality Prediction Among Older Adult Clinical Trial Participants. Arjun Gupta, Cathee Till, Michael L. LeBlanc, Dawn L. Hershman, Joseph M. Unger. Accepted 2026.

Inclusive Cancer Clinical Trial Participation – A Recipe for New Treatment Advances. Unger JM. *JAMA Network Open*. 2025 Jun 2;8(6):e2515210. <https://pubmed.ncbi.nlm.nih.gov/40504533/>

Financial toxicity: A ubiquitous condition in patients with cancer. Unger JM. *Cancer*. 2025 Feb 15;131(4):e35748. <https://pubmed.ncbi.nlm.nih.gov/39916421/>

The fundamentals of multiplicity adjustment in biostatistics. Grant Izmirlan, Lev A Sirota, Vance W Berger, Victor Kipnis. *J Natl Cancer Inst Monogr*. 2025 Mar 1;2025(68):10-13. doi: 10.1093/jncimonographs/lgae050. <https://pubmed.ncbi.nlm.nih.gov/39989036/>

On the use of external controls in clinical trials. Michelle M Nuño, Stephanie L Pugh, Lingyun Ji, Jin Piao, James J Dignam, Jon A Steingrimsson. *J Natl Cancer Inst Monogr*. 2025 Mar 1;2025(68):30-34. doi: 10.1093/jncimonographs/lgae046. <https://pubmed.ncbi.nlm.nih.gov/39989040/>

The importance of patient-centered research in oncology clinical trials: motivation for the Monograph series. Stephanie L Pugh, Cecilia Lee, Barbara K Dunn, James J Dignam. *J Natl Cancer Inst Monogr*. 2025 Mar 1;2025(68):1-2. doi: 10.1093/jncimonographs/lgae052. <https://pubmed.ncbi.nlm.nih.gov/39989042/>

Submitted Manuscripts

S1415CD Impact of Primary Prophylactic Colony Stimulating Factor Delivery Method on Febrile Neutropenia: Secondary Analysis of a Pragmatic Cluster Randomized Clinical Trial. Lauren Shih, Kathryn B. Arnold, Aasthaa Bansal, Ari Bell-Brown, Kate Watabayashi, Dawn L. Hershman, Scott D Ramsey. Submitted 2026.

PALLIATIVE CARE COMMITTEE

Published/Accepted Manuscripts

S1316 Optimizing Palliative Cancer Surgery Trial Completion: Lessons Learned From Qualitative Content Analysis of S1316 – Comparative Effectiveness Trial for Malignant Bowel Obstruction. M Farooq, N Amini, V Sun, G Deutsch, J Deneve, M Grant, K Arnold, A Secord, G Anderson, R Krouse. *Am J Hosp Palliat Care*. 2025 Oct 29;10499091251391420. doi: 10.1177/10499091251391420. Online ahead of print. <https://pubmed.ncbi.nlm.nih.gov/41159270/>

Publication List by Committee

S2408 KE Goodsell. ASO Author Reflections: Reasonable Doubt: The Case for Somatostatin Analogs in Pancreas Surgery Remains Unsettled. KE Goodsell, JG Sham. *Ann Surg Oncol* 2025 Oct;32(10):7459-7460, 2025. doi: 10.1245/s10434-025-17730-x. Epub 2025 Jun 23. <https://pubmed.ncbi.nlm.nih.gov/40549085/>

Submitted Manuscripts

Integrating Oncology APPs and Clinical Pharmacists into Clinical Cancer Research. C Braun-Inglis, J Myers, B O'Brien, L Kottschade, M Flannery, AT DeTroye, T Elko, A Leatherwood, A Mader, SF Wong, M Foust, M Bakitas, AB Benson III, JL Berenberg, B Primeaux, M Rosenzweig, K Demirhan, T Statler, W Vogel, V Sun. Under review.

PREVENTION, SCREENING AND SURVEILLANCE COMMITTEE

Published/Accepted Manuscripts

S0000/S9217 Genome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves prediction across ancestry groups. Thomas J Hoffmann, Rebecca E Graff, Ravi K Madduri, Alex A Rodriguez, Clinton L Cario, Karen Feng, Yu Jiang, Anqi Wang, Robert J Klein, Brandon L Pierce, Scott Eggener, Lin Tong, William Blot, Jirong Long, Louisa B Goss, Burcu F Darst, Timothy Rebbeck, Joseph Lachance, Caroline Andrews, Akindele O Adebiyi, Ben Adusei, Oseremen I Aisuodionoe-Shadrach, Pedro W Fernandez, Mohamed Jalloh, Rohini Janivara, Wenlong C Chen, James E Mensah, Ilir Agalliu, Sonja I Berndt, John P Shelley, Kerry Schaffer, Mitchell J Machiela, Neal D Freedman, Wen-Yi Huang, Shengchao A Li, Phyllis J Goodman, Cathee Till, Ian Thompson, Hans Lilja, Dilrini K Ranatunga, Joseph Presti, Stephen K Van Den Eeden, Stephen J Chanock, Jonathan D Mosley, David V Conti, Christopher A Haiman, Amy C Justice, Linda Kachuri, John S Witte. *Nat Genet*. 2025 Feb;57(2):334-344. doi: 10.1038/s41588-024-02068-z. Epub 2025 Feb 10. <https://pubmed.ncbi.nlm.nih.gov/39930085/>

S9217 Long-term effect estimation when combining clinical trial and observational follow-up datasets. Gang Cheng, Yen-Chi Chen, Joseph M. Unger, Cathee Till, Ying-Qi Zhao. *J Amer Stat Assoc*. 2025 Jul 15:1-10. 10.1080/01621459.2025.2526703.

S9217 Challenges to and considerations of designing cancer prevention trials. Danielle M Enserro, Heather J Gunn, Mohamed I Elsaid, Fenghai Duan, Stephanie L Pugh. *J Natl Cancer Inst Monogr*. 2025 Mar 1;2025(68):49-55. doi: 10.1093/jncimonographs/lgae044. <https://pubmed.ncbi.nlm.nih.gov/39989045/>

S9217 Emerging strategies for drug-based cancer risk reduction. Maria Daca-Álvarez, Angelo Brunori, Alessio Carbone, Chantelle Carbonell, Catherine M Tangen, Joseph M Unger, M Scott Lucia, Martino Oliva,

Andrea De Censi, Darren R Brenner, Ian M Thompson Jr, Francesc Balaguer. *Am Soc Clin Oncol Educ Book*. 2025 Jun;45(3):e473708. 10.1200/EDBK-25-473708. <https://pubmed.ncbi.nlm.nih.gov/40435434/>

S9217/Others Dietary Fiber Intake and Risk of Advanced and Aggressive Forms of Prostate Cancer: A Pooled Analysis of 15 Prospective Cohort Studies. Sidahmed E, Freedland SJ, Wang M, Wu K, Albanes D, Barnett M, van den Brandt PA, Cook MB, Giles GG, Giovannucci E, Haiman CA, Larsson SC, Key TJ, Loftfield E, Männistö S, McCullough ML, Milne RL, Neuhaus ML, Platz EA, Perez-Cornago A, Sawada N, Schenk JM, Sinha R, Tsugane S, Visvanathan K, Wang Y, White KK, Willett WC, Wolk A, Ziegler RG, Genkinger JM, Smith-Warner SA. *J Acad Nutr Diet*. 2025 Jan;125(1):11-23.e22. doi: 10.1016/j.jand.2024.04.006. Epub 2024 Apr 16. <https://pubmed.ncbi.nlm.nih.gov/38636793/>

EA1151 Design considerations and challenges in the CHinA National CancEr Screening (CHANCES) trial and Tomosynthesis Mammographic Imaging Screening Trial (TMIST). Ping Hu, Jon A Steingrimsson, Elodia Cole, Jean Cormack, Barbara K Dunn, Constantine Gatsonis, Cecilia Lee, Ni Li, Etta D Pisano, Jie He, Barnett S Kramer. *J Natl Cancer Inst Monogr*. 2025 Mar 1;2025(68):42-48. doi: 10.1093/jncimonographs/lgae049. <https://pubmed.ncbi.nlm.nih.gov/39989037/>

Submitted Manuscripts

S1904 Cluster randomized controlled trial of decision support for breast cancer chemoprevention, MiCHOICE. K Crew, GL Anderson, KB Arnold, S Dzingile, A Michel, M DeLucie, CW Law, S Pruthi, AC Sandoval Leon, R Shirley, MT Grosse Perdekamp, SV Colonna, SL Krisher, TA King, LD Yee, TJ Ballinger, C Braun-Inglis, DA Mangino, KB Wisinski, CA DeYoung, MRoss, JD Floyd, AKaster, LH VanderWalde, TJ Saphner, C Zarwan, S Lo, C Graham, AK Conlin, K Yost Butler, DM Agnese, C Jernigan, DL Hershman, ML Neuhaus, JA Zell, B Arun, R Kukafka. Submitted 2026.

SYMPTOM MANAGEMENT AND SURVIVORSHIP COMMITTEE

Published/Accepted Manuscripts

S1007 Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial. Irene M Kang, Jamie K Forschmiedt, Michelle M Loch, Danika L Lew, William E Barlow, Julie R Gralow, Funda Meric-Bernstam, Kathy S Albain, Daniel F Hayes, Nancy U Lin, Edith A Perez, Lori J Goldstein, Priya Rastogi, Anne F Schott, Rick Baehner, Priyanka Sharma, Debasish Tripathy, Lajos Pusztai, Gabriel N Hortobagyi, Kevin Kalinsky, N Lynn Henry. *JAMA Oncol*. 2025 Dec 11:e255220. doi: 10.1001/jamaoncol.2025.5220. Online ahead of print. [see also Breast Committee] <https://pubmed.ncbi.nlm.nih.gov/41379459>

Publication List by Committee

S1714 Risk Prediction Model for Taxane-Induced Peripheral Neuropathy in Early-Stage Cancer: SWOG S1714 . M Trivedi, J Unger, NL Henry, A Darke, D Hertz, T Brannagan, S Reyes, B Schneider, W Irvin, A Hathaway, A Vander Woude, V Gudena, P Cabrera-Galeana, M Orsted, M LeBlanc, M Fisch, D Hershman. Accepted, 2026.

Multiple Studies Baseline Fatigue and Severe Toxic Effects in Patients With Cancer Receiving Systemic Therapy. Joseph M Unger, Michael J Fisch, Salene M W Jones, N Lynn Henry, Dawn L Hershman. *JAMA Oncol.* 2026;12;(2):185-193. 10.1001/jamaoncol.2025.5549. Epub 2025 Dec 26. <https://pubmed.ncbi.nlm.nih.gov/41452615/>

A221405 Breastfeeding after hormone-receptor positive breast cancer: results from the POSITIVE trial. Fedro A Peccatori, Samuel M Niman, Ann H Partridge, Monica Ruggeri, Marco Colleoni, Cristina Saura, Chikako Shimizu, Anna B Satersdal, Judith R Kroep, Karen Gelmon, Frederic Amant, Audrey Mailliez, Halle C F Moore, Manuel Ruiz-Borrego, Janice M Walshe, Virginia F Borges, Andrea Gombos, Akemi Kataoka, Christine Rousset-Jablonski, Simona Borstnar, Junko Takei, Jeong E Lee, Christobel Saunders, Vesna Bjelic-Radisic, Snezana Susnjar, Fatima Cardoso, Natalie J Klar, Teresa Ferreira, Sarra El-Abed, Martine Piccart, Larissa A Korde, Aron Goldhirsch, Richard D Gelber, Olivia Pagani, Hatem A Azim Jr; International Breast Cancer Study Group and the POSITIVE Trial Collaborators. *Journal of Clinical Oncology*, 2025 Aug 20;43(24):2712-2719. doi: 10.1200/JCO-24-02697. Epub 2025 Jul 9. [see also Breast Committee] <https://pubmed.ncbi.nlm.nih.gov/40632989/>

A221405 Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial. Isabelle Demeestere, Samuel M Niman, Ann H Partridge, Daniela S Diego, Roswitha Kammler, Monica Ruggeri, Marco Colleoni, Chikako Shimizu, Cristina Saura, Karen A Gelmon, Anna B Saetersdal, Judith R Kroep, Audrey Mailliez, Frederic Amant, Manuel Ruiz-Borrego, Jeong Eon Lee, Akemi Kataoka, Janice M Walshe, Junko Takei, Simona Borstnar, Virginia F Borges, Christobel Saunders, Snezana Susnjar, Vesna Bjelic-Radisic, Fatima Cardoso, Jane Lowe Meisel, Jennifer F Kawwass, Tanja Spanic, Sarra El-Abed, Martine Piccart, Larissa A Korde, Aron Goldhirsch, Richard D Gelber, Olivia Pagani, Hatem A Azim Jr, Fedro A Peccatori ; International Breast Cancer Study Group and the POSITIVE Trial Collaborators. *Breast*. 2025 Oct;83:104547. doi: 10.1016/j.breast.2025.104547. Epub 2025 Jul 26. <https://pubmed.ncbi.nlm.nih.gov/40743662/>

Submitted Manuscripts

S1600 Effects of Immune-Enhancing Nutrition on Outcomes after Radical Cystectomy: Primary Results from a Randomized Phase III

Double-Blind Clinical Trial (SWOG S1600). Jill M. Hamilton-Reeves, Joseph M. Unger, Jeffrey M. Holzbeierlein, Danika L. Lew, J. Ryan Mark, Siamak Daneshmand, Seth P. Lerner, Janet E.B. Kukreja, Eugene K. Lee, William B. Tabayoyong, Dawn L. Hershman, Michael J. Fisch, N. Lynn Henry. Submitted 2026.

S1600 Flow Cytometry Method To Identify Arginase-1 Expressing MDSCs. Pugazhendhi Srinivasan, Misty Bechtel, Dorota Wyczechowska, Augusto Ochoa, Michael J. Fisch, N. Lynn Henry, Joseph M. Unger, Jill M. Hamilton-Reeves. Submitted 2026.

S1706 Toxicity in a Randomized Trial Comparing Radiotherapy +/- Olaparib for Inflammatory Breast Cancer. Reshma Jagsi, Allison Meisner, Pavani Chalasani, William E. Barlow, Jennifer R. Bellon, Norah N. Lynn Henry, Danika Lew, Martha M. Matuszak, Jean M. Moran, Lori J. Pierce, Eileen Rakovitch, Stephanie J. Reyes, Corey Speers, Joseph M. Unger, Julia R. White, Wendy A. Woodward, Richard Cedric Zellars, Lajos Pusztai, Priyanka Sharma. Submitted 2025. [see also Breast Committee]

NRG-GI004/S1610 Randomized Phase III Study of mFOLFOX/ Bevacizumab/Atezolizumab or Atezolizumab alone as First-line Treatment of Deficient DNA-Mismatch Repair Metastatic Colorectal Cancer. Caio Max Sao Pedro Rocha Lima, Greg Yothers, Thomas J. George, Howard S. Hochster, Hanna K. Sanoff, Deirdre J. Cohen, Katherine A. Guthrie, Samuel A. Jacobs, Anwaar Saeed, Scott Kopetz, Linda H. Colangelo, Tanner J. Freeman, Scott W. Cole, Maged Khalil, Swapna Devanna, Dan S. Zuckerman, Theodore S. Hong, N. Lynn Henry, Patricia A. Ganz, Charles D. Blanke, Norman Wolmark, Michael J. Overman. Submitted 2026. [see also Gastrointestinal Committee]

DIGITAL ENGAGEMENT COMMITTEE

Published/Accepted Manuscripts

Assessing Health Information Seeking Behaviors Among Targeted Social Media Users Using an Infotainment Video About a Cancer Clinical Trial: Population-Based Descriptive Study. Jonathan Sommers, Don S Dizon, Mark A Lewis, Erik Stone, Richard Andreoli, Vida Henderson. *JMIR Cancer*. 2025 Mar 3;11:e56098. doi: 10.2196/56098. <https://pubmed.ncbi.nlm.nih.gov/40029972/>

Submitted Manuscripts

None this cycle

EARLY THERAPEUTICS AND RARE CANCERS COMMITTEE

Published/Accepted Manuscripts

S1609 A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed

Publication List by Committee

pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort . YK Chae, M Othus, S Patel, R Aljumaly, K Win, T Pejovic, S Thomas, W Robinson, H Kim, I Chung, C McLeod, H Chen, E Sharon, H Streicher, C Ryan, C Blanke, R Kurzrock. *Cancer Communications* 2025 Aug;45(8):976-986. <https://pubmed.ncbi.nlm.nih.gov/40402690/>

S1609 Efficacy and CNS Toxicity of Nivolumab and Ipilimumab in Rare Cancer Brain Metastases: A Multi-Center Basket Trial Analysis (NCI/SWOG S1609). Manmeet S Ahluwalia, Sophie Solomon, Sandip P Patel, Zouina Sarfraz, Megan Othus, Young K Chae, Razelle Kurzrock. *Clin Cancer Res*. 2025 Dec 11. doi: 10.1158/1078-0432.CCR-25-2900. Online ahead of print. <https://pubmed.ncbi.nlm.nih.gov/41378983/>

S1609 Outcomes of Patients with Rare Cancers Treated with Combination Immune Checkpoint Inhibitors With and Without Prior anti-PD-1/L1 Exposure (NCI/SWOG S1609). Megan Othus, Sandip P Patel, Young Kwan Chae, Eliana Dietrich, Manmeet S Ahluwalia, Razelle Kurzrock. *JCO Oncol Adv*. 2025 Nov;2(1):10.1200/oa-25-00110. doi: 10.1200/oa-25-00110. Epub 2025 Nov 24. NIHMS2119227. <https://pubmed.ncbi.nlm.nih.gov/41358143/>

S1609 Multicenter phase II trial of ipilimumab and nivolumab in metastatic or unresectable perivascular epithelioid cell tumor (PEComa): a substudy of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609 (Cohort 38). Sandip P Patel, Megan Othus, Young K Chae, Tali Azenkot, Michael J Wagner, Sara Threlkel, John H Farley, Christine M Magner, Helen X Chen, Elad Sharon, Christopher W Ryan, Charles Blanke, Razelle Kurzrock. *J Immunother Cancer*. 2025 Oct 20;13(10):e013147. doi: 10.1136/jitc-2025-013147. <https://pubmed.ncbi.nlm.nih.gov/41120126/>

S1609 Evaluation of mixed response in tumor size and survival in patients with rare cancers treated with dual checkpoint inhibitor therapy (DART SWOG S1609). Young Kwang Chae, Megan Othus, Jiyon Lyu, Seyoung Lee, Seungwon Paik, Eliana Dietrich, Chan Mi Jung, Liam Il-Young Chung, Sandip Patel, Razelle Kurzrock. *Journal for ImmunoTherapy of Cancer* 2026;14:e013260. doi:10.1136/jitc-2025-013260. <https://pubmed.ncbi.nlm.nih.gov/41819545/>

S1609 DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix. Young Kwang Chae, Megan Othus, Sandip P Patel, Floortje J Backes, David M O'Malley, Mihaela Cristea, Aung Naing, Katherine Kurnit, Ramez N Eskander, Scott T Goodrich, William R Robinson, Jennifer Scalici, John Chan, Hussein Ali-Ahmad, John Hays, Colleen McCormick, Edward J Kim, Thanasak Sueblinvong, Amina Ahmed, Jean Siedel, Jessica Thomes Pepin, Justin Neal Bottsford-Miller, Seth Olusegun Fagbemi, Anthony John

Jaslowski, Hye Sung Kim, Liam Il-Young Chung, Carolyn Moloney-Lineen, Christine M McLeod, Helen X Chen, Elad Sharon, Howard Streicher, Christopher W Ryan, Charles D Blanke, Razelle Kurzrock. *Journal for the ImmunoTherapy of Cancer* 2026;14:e012805. doi:10.1136/jitc-2025-012805. <https://pubmed.ncbi.nlm.nih.gov/41672597/>

S1609 Baseline tumor burden and outcomes in patients with rare cancers treated with immunotherapy (Southwest Oncology Group trial S1609). Paul L. Swiecicki, Megan Othus, Sandip P. Patel, Young Kwang-Chae, Razelle Kurzrock. *Cancer*. 2026;e70374. doi:10.1002/cncr.70374. PMC13025072. <https://pubmed.ncbi.nlm.nih.gov/41892875/>

A091802 Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma. Zandberg DP, Allred JB, Rosenberg AJ, Kaczmar JM, Swiecicki P, Julian RA, Poklepovic AS, Bauman JR, Phan MD, Saba NF, Rivera E, Rowland K, Davar D, Cordes J, Ho AL, Zhang M, Berg SA, Munster PN, Schwartz GK. *J Clin Oncol*. 2025 Jul 20;43(21):2398-2408. doi: 10.1200/JCO-25-00759. Epub 2025 May 31. <https://pubmed.ncbi.nlm.nih.gov/40448574/>

EA3163 Neoadjuvant Chemotherapy and Surgery versus Surgery for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma: ECOG-ACRIN EA3163. Saba NF, Flamand Y, Lin DT, Chung CH, McDonald MW, Flampouri S, Khan SA, Snyderman CH, Hanna EY, El-Sayed IH, Solares CA, Le CH, Ghaly M, Hwang PH, Shin DM, Axelrod RS, Ikpeazu CV, Adkins DR, Duan F, Cohen M, Samuels MA, Swiecicki PL, Subramaniam RM, Chakravarthy AB, Burtneess BA. *Clin Cancer Res*. 2025 Jun 13;31(12):2339-2346. doi: 10.1158/1078-0432.CCR-24-4085. <https://pubmed.ncbi.nlm.nih.gov/40227186/>

EAY131 Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H. Mohamed A Gouda, Zihan Wei, Jordi Rodon, Michael A Davies, Filip Janku, Robert J Gray, Victoria Wang, Lisa M McShane, Larry V Rubinstein, David R Patton, P Mickey Williams, Stanley R Hamilton, Raymond Liu, Daniela A Bota, Paul L Swiecicki, Gary L Buchschacher, James V Tricoli, Barbara A Conley, Carlos L Arteaga, Lyndsay N Harris, Peter J O'Dwyer, Alice P Chen, Keith T Flaherty. *JCO Precis Oncol*. 2025 Feb;9:e2400451. doi: 10.1200/PO-24-00451. Epub 2025 Feb 6. NIHMS2058197. <https://pubmed.ncbi.nlm.nih.gov/39913886/>

EAY131 Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131). Mohamed A Gouda, Filip Janku, Ying Yuan, Leylah M Drusbosky, Alice P Chen, Xiaofeng Zheng, Keyur Patel, Stanley R Hamilton, Mark Routbort, James V Tricoli, P Mickey Williams, A John Iafrate, Jeffrey Sklar, Brent Coffey, Richard F Little, Carlos

Publication List by Committee

L Arteaga, Peter J O'Dwyer, Keith T Flaherty, Lyndsay N Harris, Funda Meric-Bernstam. *Clin Cancer Res*. 2025 Oct 15;31(20):4299-4310. doi: 10.1158/1078-0432.CCR-24-3531. NIHMS2084882.

<https://pubmed.ncbi.nlm.nih.gov/40388547/>

Submitted Manuscripts

S1609 Outcomes of Patients with Rare Cancers Treated with Combination Immune Checkpoint Inhibitors With and Without Lung and/or Liver Metastases (NCI/SWOG S1609). Y Wang, M Othus, YK Chae, M Davies, E Dietrich, SP Patel, R Kurzrock. Submitted 2026.

S1609 Outcomes of Patients with Rare Adenocarcinoma versus Squamous Cell Carcinomas Treated with Nivolumab plus Ipilimumab (NCI/SWOG S1609: DART trial). Megan Othus, Nolan Cole, Helen Omega, Young Kwan Chae, Sandip P Patel, Razelle Kurzrock. Submitted 2026.

GASTROINTESTINAL COMMITTEE

Published/Accepted Manuscripts

A021202 Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202). E Bergsland, S Geyer, T Asmis, S Behr, P Kumthekar, M Maitland, D Niedzwiecki, A Nixon, L Schwartz, J Strosberg, A Venook, E O'Reilly, J Meyerhardt. *J Clin Oncol*. 2025 Oct 10;43(29):3170-3183. doi: 10.1200/JCO-24-02644. Epub 2025 Sep 3. NIHMS2099573.

<https://pubmed.ncbi.nlm.nih.gov/40902132/>

A021602 Cabozantinib for advanced grade 3 neuroendocrine tumors: subgroup analysis of the phase 3 CABINET trial (Alliance A021602). Jonathan R Strosberg, Tyler Zemla, Susan Geyer, Sydney Pulsipher, Fang-Shu Ou, Spencer Behr, Nitya Raj, Namrata Vijayvergia, Arvind Dasari, Eileen M O'Reilly, Jeffrey A Meyerhardt, Edward M Wolin, Thorvardur R Halfdanarson, Jennifer A Chan. *Endocr Relat Cancer*. 2026 Jan 24;33(1):e250415. doi: 10.1530/ERC-25-0415. Print 2026 Jan 1.

<https://pubmed.ncbi.nlm.nih.gov/41524552/>

C/S80405 GABAergic signaling contributes to tumor cell invasion and poor overall survival in colorectal cancer. C Strelez, F Battaglin, R Perez, Y Yang, C Cherry, J Millstein, A Yoon, J Chylstek, E Canfield, B Haliday, C Shah, K Ghaffarian, S Soni, H Jiang, R Lau, A Schatz, Y Zhou, D Mulkerin, F Ou, A Venook, F Innocenti, J Neman, J Katz, H-J Lenz, S Mumenthaler. *Oncogene* 2025 Oct 44;3924-3938. doi: 10.1038/s41388-025-03546-2. Epub 2025 Aug 24. <https://pubmed.ncbi.nlm.nih.gov/40851030/>

C/S80405 Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance). F Battaglin, B O'Neil, S Stintzing, F Ou, T Zemla, D Niedzwiecki, F Innocenti, H Hochster,

L von Weikersthal, T Decker, A Kiani, U Vehling-Kaiser, T Heintges, C Lerchenmuller, L Weiss, K Heinrich, R Goldberg, R Mayer, R Schilsky, C Blanke, A Venook, H-J Lenz, V Heinemann. *European Journal of Cancer* Sep 9;227:115694. <https://pubmed.ncbi.nlm.nih.gov/40803104/>

C/S80405/Others Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials. Marco Maria Germani, Beatrice Borelli, Tadayoshi Hashimoto, Yoshiaki Nakamura, Simone Oldani, Francesca Battaglin, Francesca Bergamo, Lisa Salvatore, Arndt Stahler, Carlotta Antoniotti, Kohei Shitara, Alan Venook, Eiji Oki, Kei Muro, Clara Ugolini, Junpei Soeda, Sara Lonardi, Filippo Pietrantonio, Heinz-Josef Lenz, Dominik Paul Modest, Takayuki Yoshino, Chiara Cremolini. *J Clin Oncol*. 2025 Oct 10;43(29):3184-3197. doi: 10.1200/JCO-25-01003. Epub 2025 Sep 4. <https://pubmed.ncbi.nlm.nih.gov/40906970/>

C/S80405 Clinical and molecular characterization of AXL in colorectal cancer, CALGB (Alliance)/SWOG and real-world data. Karam Ashouri, Joshua Millstein, Yan Yang, Joanne Xiu, Shivani Soni, Pooja Mittal, Sandra Algaze, Lesly Torres-Gonzalez, Priya Jayachandran, Wu Zhang, Shannon Mumenthaler, Anthony F Shields, Richard Goldberg, Emil Lou, Benjamin A Weinberg, Thomas G Graeber, John L Marshall, Alan P Venook, Alexander Hoffmann, Stacey D Finley, Aaron S Meyer, Francesca Battaglin, Heinz-Josef Lenz. *J Immunother Cancer*. 2025 Dec 21;13(12):e013186. doi: 10.1136/jitc-2025-013186.

<https://pubmed.ncbi.nlm.nih.gov/41423272/>

C/S80702 Sex differences in chemotherapy completion, toxicities, and survival in colon cancer: an analysis of 2201 patients from CALGB/SWOG 80702 (Alliance). En Cheng, Qian Shi, Anthony F Shields, Xiaonan Xue, Thomas E Rohan, Chaoyuan Kuang, Ardaman P Shergill, Chao Ma, Felix Couture, J Philip Kuebler, Pankaj Kumar, Benjamin Tan, Smitha S Krishnamurthi, Kimmie Ng, Eileen M O'Reilly, Justin C Brown, Jeffrey A Meyerhardt. *J Natl Cancer Inst*. 2025 Dec 1;117(12):2643-2652. doi: 10.1093/jnci/djaf281. NIHMS2114152.

<https://pubmed.ncbi.nlm.nih.gov/40996326/>

C/S80702 Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial. George Q Zhang, Jeffrey A Meyerhardt, Qian Shi, Tyler Twombly, Levi Pederson, Chao Ma, Juha P Väyrynen, Melissa Zhao, Yasutoshi Takashima, Ardaman Shergill, Pankaj Kumar, Felix Couture, Philip Kuebler, Smitha Krishnamurthi, Benjamin Tan, Eileen M O'Reilly, Marios Giannakis, Shuji Ogino, Adham Jurdi, Shruti Sharma, Alexey Aleshin, Anthony F Shields, Jonathan A Nowak. *JAMA Oncol*. 2025 Dec 4:e255144. doi: 10.1001/

Publication List by Committee

jamaoncol.2025.5144. Online ahead of print. NIHMS2113693.

<https://pubmed.ncbi.nlm.nih.gov/41343176/>

E3201 Intergroup randomized phase III study of adjuvant FOLFIRI, FOLFOX, or 5-FU/leucovorin for stage II/III rectal cancer: ECOG-ACRIN E3201. Audrey E Kam, Fengmin Zhao, Neal J Meropol, Bruce J Giantonio, Robert B Diasio, Patrick J Flynn, Paul Catalano, Lee Hartner, Kendrith M Rowland, Wei Song, Mary F Mulcahy, Frank A Sinicrope, Robert P Whitehead, Robert J Mayer, Nicholas Petrelli, Peter J O'Dwyer, Stanley R Hamilton, David Cella, Al B Benson. *Oncologist*. 2025 Dec 27;31(1):oyaf416. doi: 10.1093/oncolo/oyaf416.

<https://pubmed.ncbi.nlm.nih.gov/41397917/>

Submitted Manuscripts

C80702 Prognosis-Informed Phenotype Assignment: A Novel In-Situ Single-Cell Analysis Method for Phenotype Discovery. Lau M, Vayrynen J, Haruki K, Ma C, Vayrynen S, Ugai T, Gu S, Borowsky J, Zhao M, Arima K, Dias Costa A, Shields A, Innocenti F, KitTan W, Shi Q, Giannakis M, Fuchs C, Yu K, Nowak J, Ogino S. Submitted 2025.

NRG-GI004/S1610 Randomized Phase III Study of mFOLFOX/Bevacizumab/Atezolizumab or Atezolizumab alone as First-line Treatment of Deficient DNA-Mismatch Repair Metastatic Colorectal Cancer. Caio Max Sao Pedro Rocha Lima, Greg Yothers, Thomas J. George, Howard S. Hochster, Hanna K. Sanoff, Deirdre J. Cohen, Katherine A. Guthrie, Samuel A. Jacobs, Anwaar Saeed, Scott Kopetz, Linda H. Colangelo, Tanner J. Freeman, Scott W. Cole, Maged Khalil, Swapna Devanna, Dan S. Zuckerman, Theodore S. Hong, N. Lynn Henry, Patricia A. Ganz, Charles D. Blanke, Norman Wolmark, Michael J. Overman. Submitted 2026. [see also Symptom Management & Survivorship Committee]

Multiple Studies Disparities in SWOG GI Clinical Trial Enrollment. Safyan R, Colby S, Figueroa Moseley C, Guthrie K, Pumpalova Y, Hershman D, Chiorean E, Philip P. Submitted, 2025.

GENITOURINARY COMMITTEE

Note: All PCPT and SELECT publications are listed under Cancer Control & Prevention Committees

Published/Accepted Manuscripts

S2210 Clinical Trial in Progress: SWOG S2210, a Phase 2 Study of Neoadjuvant Carboplatin for Localized High-risk Prostate Cancer with Germline BRCA1/2 Mutations. Heather H Cheng, Sam Callis, Evan Y Yu, Scott E Delacroix, Alexandra O Sokolova, Catherine M Tangen, Seth P Lerner, Tanya Barauskas Dorff, Daniel W Lin. *Eur Urol Focus*. 2025 Dec

6:S2405-4569(25)00343-8. doi: 10.1016/j.euf.2025.11.011. Online ahead of print. <https://pubmed.ncbi.nlm.nih.gov/41354605/>

Multiple Studies Summary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancer. Andrea Apolo, Brian C Baumann, Hikmat Al-Ahmadie, Leslie Ballas, Rick Bangs, Kenneth Brothers, Stephanie Cooper Greenberg, Scott Delacroix, James J Dignam, Jason A Efstathiou, Adam S Feldman, Jared C Foster, Noah M Hahn, Emma Hall, Donna E Hansel, Jean Hoffman-Censits, Ashish M Kamat, Sophia C Kamran, Francesca Khani, Seth P Lerner, Robert Lipman, Bhupinder Mann, David McConkey, James McKiernan, Tracy L Rose, Angela B Smith, Catherine Tangen, Abdul Tawab Amiri, Chana Weinstock, Pamela J West, Matthew I Milowsky, Peter C Black. *Bladder Cancer*. 2025 Feb 24;11(1):23523735251319185. doi: 10.1177/23523735251319185. eCollection 2025 Jan-Mar. [S1605, S1806] <https://pubmed.ncbi.nlm.nih.gov/40034245/>

A031501 Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma. A Apolo, K Ballman, G Sonpavde, S Berg, W Kim, R Parikh, M Teo, R Sweis, D Geynisman, P Grivas, G Chatta, J Kim, M Bilen, B McGregor, P Singh, A Tripathi, S Cole, N Simon, S Niglio, L Ley, L Cordes, S Srinivas, J Huang, P Steen, M Odegaard, C Watt, D Petrylak, J Hoffman-Censits, Y Wen, O Hahn, C Mitchell, A Tan, H Streicher, E Sharon, H Moon, M Woods, S Halabi, G Burbano, M Morris, J Rosenberg. *N Engl J Med*. 2025 Jan 2;392(1):45-55. doi: 10.1056/NEJMoa2401726. Epub 2024 Sep 15. NIHMS2021479. <https://pubmed.ncbi.nlm.nih.gov/39282902/>

C90203/S9921 Impact of Testosterone Recovery on Oncologic Outcomes in High-Risk, Localized Prostate Cancer. Trevor C Hunt, Kamil Malshy, Matthew Steidle, Ashley Li, Jason Fairbourn, Zijing Cheng, Jathin Bandari. *Prostate*. 2025 Dec;85(16):1522-1530. doi: 10.1002/pros.70043. Epub 2025 Sep 9. <https://pubmed.ncbi.nlm.nih.gov/40926427/>

Submitted Manuscripts

S1216 Inherited variants in SRD5A genes and response to hormonal therapy in prostate cancer (SWOG S1216). S Ingles, J Pinski, Z Manojlovic, S Xiong, D Weisenberger, A Goldkorn, C Tangen, D McConkey, P Lara, M Hussain, D Quinn, I Thompson, S Lerner, T Dorff, N Agarwal. Submitted 2025.

S9346 Evaluating Survival Post-7-Month PSA Response, Stratified by Response, Disease Extent, and Intermittent vs. Continuous ADT in Metastatic Hormone-Sensitive Prostate Cancer: The S9346 Trial. A Sokolova, C Tangen, M Hussain, C Sweeney, T Dorff, M Ong, U Swami, N Aggarwal, I Thompson, S Lerner. Submitted.

Publication List by Committee

Multiple Studies Practice Patterns in Metastatic Hormone-Sensitive Prostate Cancer: A Survey of North American Cooperative Group Oncologists. P Breen, C Chalker, M Ong, O Anya, R McKay, M Carducci, C Kyriakopoulos, M Schweizer, N Haas, A Mandl, C Tangen, S Gulati, M Keim, S Lerner, C Ryan, R Ng, T Dorff, A Sokolova. Submitted.

S1314 Proliferation- and cytotoxic immune signatures identify chemotherapy-responsive bladder tumors in a molecular subtype dependent manner. A Zadoroznyj, P Eriksson, C Bernardo, L Tran, C-A Mattsson, T Flaig, C Tangen, S Lerner, D McConkey, M Höglund, F Liedberg, G Sjö Dahl. Submitted.

IMMUNOTHERAPEUTICS COMMITTEE

Published/Accepted Manuscripts

None this cycle

Submitted Manuscripts

None this cycle

LEUKEMIA COMMITTEE

Published/Accepted Manuscripts

S1203 Treatment discontinuation due to toxicity for patients with acute myeloid leukemia receiving intensive induction chemotherapy: Secondary analysis of SWOG S1203. S Raychaudhuri, M Othus, M Percival, G Garcia-Manero, F Appelbaum, H Erba, J Appelbaum. *Blood Neoplasia* Jun 14;2(3):100129. <https://pubmed.ncbi.nlm.nih.gov/40792015/>

Multiple Studies Multipotent lineage potential in B cell acute lymphoblastic leukemia is associated with distinct cellular origins and clinical features. Ilaria Iacobucci, Andy G X Zeng, Qingsong Gao, Laura Garcia-Prat, Pradyumna Baviskar, Sayyam Shah, Alex Murison, Veronique Voisin, Michelle Chan-Seng-Yue, Cheng Cheng, Chunxu Qu, Colin Bailey, Matthew Lear, Matthew T Witkowski, Xin Zhou, Airen Zaldivar Peraza, Karishma Gangwani, Anjali S Advani, Selina M Luger, Mark R Litzow, Jacob M Rowe, Elisabeth M Paietta, Wendy Stock, John E Dick, Charles G Mullighan. *Nat Cancer*. 2025 Jul;6(7):1242-1262. doi: 10.1038/s43018-025-00987-2. Epub 2025 Jun 27. NIHMS2100933. <https://pubmed.ncbi.nlm.nih.gov/40579588/>

Submitted Manuscripts

None this cycle

LUNG COMMITTEE

Published/Accepted Manuscripts

S1827 Prophylactic Cranial Irradiation for Patients With SCLC – A New Perspective in the Immunotherapy Era (BRIEF REPORT). Levy A, Rusthoven CG, Brown PD, Le Péchoux C, Faivre-Finn C. *J Thorac Oncol*. 2025 Mar;20(3):395-398. doi: 10.1016/j.jtho.2024.11.011. Epub 2024 Nov 15. <https://pubmed.ncbi.nlm.nih.gov/39551470/>

CTIU2317-A082304-S2402 PROSPECT-LUNG: A National Clinical Trials Network Trial Advancing Pragmatic Innovation in Cancer Clinical Trials. A Booth, S Hillman, K Laumann, YQ Zhao, M LeBlanc, K Chansky, S Giri, J Dill, J Johnson, K Kelley, L Martin. *Journal of Thoracic Oncology*. 2026. p.103650. <https://pubmed.ncbi.nlm.nih.gov/41747891/>

A221504 Naloxegol, an Oral Peripherally Acting Opioid Receptor Antagonist, Administered Concurrently with First-Line Systemic Therapy for Advanced Lung Adenocarcinoma (Alliance A221504): A Feasibility and Safety Study. P Gupta, K Gupta, T Dockter, E Harlos, S Chow, N Subbiah, K Ruddy, L Bazhenova, S Terstrief, C Huang, R Kratzke, E Vokes, C Loprinzi. *Cancers*. 2026 Jan 25;18(3):373. doi: 10.3390/cancers18030373. <https://pubmed.ncbi.nlm.nih.gov/41681846/>

Submitted Manuscripts

S0424 Exposures, Tumor Factors and Survival by Sex and Smoking Status in Non-Small Cell Lung Cancer. A Prospective Case-Series Trial (SWOG S0424, NCI NCTN). K Albain, J Moon, C Ambrosone, A Darke, M Hsieh, R Santella, TYD Cheng, W Holland, A Borczuk, CH Chay, PT Morris, E Vallieres, R Kratzke, JR Molina, JM Kolesar, Y Chen, S Matsumoto, M Reid, G Zirpoli, W Davis, R Ondracek, W Bshara, A Omilian, J Gray, K Kelly, PN Lara, M Redman, D Gandara, P Mack. Submitted 2025.

Lung-MAP Defining Resistance to Immune Checkpoint Inhibitor Therapy in Clinical Trials – A Consensus Statement from Lung-MAP. D Doroshow, et al. Submitted 2025.

LYMPHOMA COMMITTEE

Published/Accepted Manuscripts

S0016 Development and Validation of a Gene Expression Signature to Predict Early Events in Patients with Follicular Lymphoma. C Ramsower, G Wright, H Li, J Cerhan, M Mauer, R Mwangi, A Rosenthal, A Novak, B Link, T Witzig, T Habermann, R Kridel, M LeBlanc, M Shadman, S Smith, J Friedberg, D Scott, C Steidl, L Staudt, L Rimsza. *Blood Advances* 2025 Dec 23;9(24):6443-6454. doi: 10.1182/bloodadvances.2025016827. <https://pubmed.ncbi.nlm.nih.gov/40966421/>

Publication List by Committee

S0016 Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy: 15-Year Follow-Up of the SWOG S0016 Trial. Mazyar Shadman, Michael LeBlanc, Lisa Rimsza, John P Leonard, Sonali M Smith, Hongli Li, Jonathan W Friedberg. *JAMA Oncology*. 2026 Feb 26:e260042. doi: 10.1001/jamaoncol.2026.0042. Online ahead of print. PMC12947078. <https://pubmed.ncbi.nlm.nih.gov/41746629/>

S0816/Other Advanced Stage classical Hodgkin Lymphoma Patients with a Positive Interim-PET (PET-2) Deauville Score 5 After 2 ABVD Cycles: A Pooled Analysis of Three Multicenter Trials. S Viviani, S Pavoni, S Barrington, L Guerra, H Schoder, P Johnson, A Kirkwood, D Stephens, J Friedberg, S Chauvie, M Knopp, S Luminari, D Molin, P Corradini, A Gallamini, A Rambaldi, C Tarella. *Blood Cancer Journal*. 2025 Oct 16;15(1):165. doi: 10.1038/s41408-025-01364-z. <https://pubmed.ncbi.nlm.nih.gov/41102172/>

S1826 Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma. Reply. AF Herrera, M LeBlanc, JW Friedberg. *N Engl J Med*. 2025 Jan 2;392(1):102. doi: 10.1056/NEJMc2414269. <https://pubmed.ncbi.nlm.nih.gov/39752312/>

S1826 Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826. Sharon M Castellino, Hongli Li, Alex F Herrera, Michael LeBlanc, Susan K Parsons, Joseph M Unger, Angela Punnett, David Hodgson, Frank G Keller, Richard A Drachtman, Adam Lamble, Christopher J Forlenza, Andrew Doan, Sarah C Rutherford, Andrew M Evens, Richard F Little, Malcolm A Smith, Bradford S Hoppe, Joo Y Song, Sonali M Smith, Jonathan W Friedberg, Kara M Kelly. *J Clin Oncology*. 2026 Feb 20;44(6):449-454. doi: 10.1200/JCO-25-00203. Epub 2026 Jan 9. <https://pubmed.ncbi.nlm.nih.gov/41512237/>

Submitted Manuscripts

S1001/Others Development and validation of a novel conditional event-free survival tool in diffuse large B-cell lymphoma. Z Chen, D Luan, R Rask, L Jakobsen, M Maurer, T El-Galaly, L Nastoupil, J Cerhan, C Flowers, B Link, I Lossos, D Stephens, J Cohen, J Habermann, G Nowakowski, N Bartlett, J Friedberg, B Kahl, J Leonard, P Brown, K Smedby, M Jerkeman, P Martin. Submitted 2025.

S1826 Impact of EBV Status and Histology on Patient Outcomes with Nivolumab-AVD vs BV-AVD in Advanced Classic Hodgkin Lymphoma (S1826). Sairah Ahmed, Hongli Li, Alex F. Herrera, Anamarija M. Perry, Alexandra E. Kovach, Sarah C. Rutherford, Kelly Davison, Sharon M. Castellino, Andrew M. Evens, Brad Kahl, Nancy L. Bartlett, John P. Leonard, Margaret A. Shipp, Sonali M. Smith, Kara M. Kelly, Michael LeBlanc, Jonathan W. Friedberg, Joo Y. Song. Submitted 2026.

MELANOMA COMMITTEE

Published/Accepted Manuscripts

S1512 Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial. K Kendra, S Bellasea, Z Eroglu, S Hu-Lieskovan, K Campbell, W Carson, D Wada, J Plaza, J Sosman, G In, A Ikeguchi, J Hyngstrom, A Brohl, N Khushalani, J Markowitz, G Negrea, S Kasbari, G Doolittle, U Swami, T Roberts, E Medina, I Baselga Carretero, C Gonzalez, I Perez Garcilazo, A Vega-Crespo, J Ming Chen, N Naser Al Deen, S Patel, E Sharon, J Moon, M Wu, A Ribas. *Nature Medicine*. 2025 Nov;31(11):3668-3674. doi: 10.1038/s41591-025-03875-5. Epub 2025 Aug 14. <https://pubmed.ncbi.nlm.nih.gov/40813711/>

S1512 Neoadjuvant PD-1 blockade in patients with surgically resectable desmoplastic 3 melanoma (SWOG S1512 cohort A). K Kendra, S Bellasea, Z Eroglu, S Hu-Lieskovan, K Campbell, W Carson, D Wada, J Plaza, G In, A Ikeguchi, J Hyngstrom, A Brohl, B Chmielowski, N Khushalani, J Markowitz, M Monroe, C Contreras, E Medina, C Gonzalez, I Baselga Carretero, I Perez Garcilazo, A Vega-Crespo, J Ming Chen, N Naser Al Deen, S Patel, K Grossmann, V Sondak, E Sharon, J Moon, M Wu, A Ribas. *Nature Cancer*. 2026 Feb;7(2):272-282. doi: 10.1038/s43018-025-01113-y. Epub 2026 Jan 29. <https://pubmed.ncbi.nlm.nih.gov/41611998/>

S1616 Cellular neighborhoods govern antitumor T-cell infiltration following anti-CTLA-4 in melanoma with primary resistance to anti-PD-1. Katie M. Campbell, Daniel G. Chen, Zaid E. Bustami, Nataly Naser Al Deen, Egmidio Medina, Cynthia R. Gonzalez, Jessica Maxey, Marshall A. Thompson, Sarah Samorodnitsky, Lawrence F. Kuklinski, Ivan Perez Garcilazo, Ignacio Baselga-Carretero, Agustin Vega-Crespo, Jia Ming Chen, Rangasamy Elumalai, Marc Visitacion, Rob Schiemann, Lacey Padron, Cadence Chang, Alan E. Zelin, Sai S. Chelluri, Silvia Boffo, Kari L. Kendra, Bartosz Chmielowski, Thach-Giao Truong, Nikhil I. Khushalani, Frances Collichio, Alexandra Ikeguchi, Adrienne I. Victor, Kim Margolin, Douglas B. Johnson, Yuanbin Chen, Jeffrey A. Sosman, Sapna P. Patel, Siwen Hu-Lieskovan, James Moon, Daniel K. Wells, Christine N. Spencer, Shay Bellasea, Ari M. Vanderwalde, Michael Wu, Philip O. Scumpia, Antoni Ribas. Accepted 2026.

E1609 Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma. Ahmad A Tarhini, Alyssa Obermayer, Sandra J Lee, William A LaFramboise, F Stephen Hodi, Arivarasan D Karunamurthy, Islam Eljilany, Dung-Tsa Chen, Patrick Hwu, Issam M El Naqa, Howard Streicher, Vernon K Sondak, Walter J Storkus, Lisa H Butterfield, Timothy I Shaw, John M Kirkwood. *Clin Cancer Res*. 2025 Aug 1;31(15):3249-3258. doi: 10.1158/1078-0432.CCR-24-3980. NIHMS2085262. <https://pubmed.ncbi.nlm.nih.gov/40392969>

Publication List by Committee

E1609 Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors. Xuefeng Wang, Tingyi Li, Islam Eljilany, Alex Soupir, Michael Radmacher, Phaedra Agius, Vineeth Sukrithan, Aakrosh Ratan, Martin McCarter, Bodour Salhia, Howard Colman, Abdul R Naqash, Igor Puzanov, Susanne Arnold, Julian A Marin-Acevedo, Shridar Ganesan, Michelle Churchman, Patrick Hwu, Paulo C Rodriguez, William S Dalton, George J Weiner, Ahmad A Tarhini. *Nat Commun*. 2025 Nov 13;16(1):9968. doi: 10.1038/s41467-025-65016-3 <https://pubmed.ncbi.nlm.nih.gov/41233329/>

Submitted Manuscripts

None this cycle

PHARMACEUTICAL SCIENCES COMMITTEE

Published/Accepted Manuscripts

None this cycle

Submitted Manuscripts

None this cycle

RADIATION ONCOLOGY COMMITTEE

Published/Accepted Manuscripts

Incorporating Intensity Modulated Total Body Irradiation (IMRT-TBI) Into Future Cooperative Group Clinical Trials: An NRG Hematologic Malignancies Working Group–Led Report From the National Clinical Trials Network. Nataliya Kovalchuk, Eric A. Simiele, Michael LaRiviere, Susan M. Hiniker, Michael Soike, Chunhui Han, Jeffrey Wong, Savita Dandapani, Kiran Kumar, David Parsons, Jose R. Teruel, Naamit K. Gerber, Bingqi Guo, Sheen Cherian, Tze Y. Lim, Kujtim Latifi, Nicholas B. Figura, Deepak K. Shrestha, John Grecula, Austin J. Sim, Rakesh R. Parikh, Andrea C. Lo, Koren Smith, John P. Plastaras, Ying Xiao, Bradford S. Hoppe, Sarah A. Milgrom. *International Journal of Radiation Oncology, Biology, Physics* 2026 Feb 17:S0360-3016(26)00388-3. doi: 10.1016/j.ijrobp.2026.02.201. Online ahead of print. <https://pubmed.ncbi.nlm.nih.gov/41713515/>

Submitted Manuscripts

Consensus Radiation Therapy Organ at Risk Constraints for NCTN Trials in Hematologic Malignancies. AJ Sim, BS Hoppe, LK Ballas, SA Milgrom, SA Terezakis, CS Ha, NB Figura, RR Parikh, JC Grecula, JP Plastaras, A Lo, J Ryckman, S Flampouri, CC Pinnix, CR Kelsey. Consensus Radiation Therapy Organ at Risk Constraints for NCTN Trials in Hematologic Malignancies. Under review, 2025.

Future Meeting Dates

FALL 2026

October 8-10, 2026
Chicago, IL

SPRING 2027

April 15-17, 2027
San Francisco, CA

FALL 2027

October 14-16, 2027
Chicago, IL

SPRING 2028

March 30-April 1, 2028
San Francisco, CA

FALL 2028

October 5-7, 2028
Chicago, IL

SPRING 2029

April 5-7, 2029
San Francisco, CA

FALL 2029

October 4-6, 2029
Chicago, IL

